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Introduction 
Despite the accelerated global response to the worldwide HIV epidemic, 
progress is still fragile and unevenly distributed. Too many new infections are 
still occurring every day and HIV incidence is therefore still increasing in some 
countries and regions. More than 2 million new infections were reported in 2009, 
contributing to the current global prevalence of 33.3 million [1]. Even though 
prevalence reduced from the peak in 1999, new infections continue to outpace 
the number of people treated with anti-retroviral drugs, a situation also true for 
Indonesia.    
The HIV epidemic in Indonesia is among the fastest growing in Asia. At the end 
of 2009, it was estimated that there were 333,200 people living with HIV (PLHIV) 
in Indonesia. The cumulative number of reported cases has risen sharply from 
2,682 cases in 2004 to 19,973 in 2009. The epidemic now affects almost all 
parts of Indonesia as 32 out of 33 provinces report HIV cases [2]. Outside 
Papua, the HIV epidemic in Indonesia is mostly concentrated within certain risk 
groups. The seroprevalence rate is estimated 0.22% in 2009 in the general 
population but has been estimated 43-56% among injecting drug users (IDU),   
6-16% among commercial sex workers (CSW), 14-34% among transgender and 
5-36% among prisoners [2]. HIV-transmission through IDU has shown a 
dramatic increase in the two last decades, whereby at times  more than 80% of 
new HIV-infections in Indonesia were due to IDU [3]. Needle-sharing  is a very 
efficient way to transmit HIV, but also carries the risk of further spreading the 
infection to the general population as unprotected sex is common among  IDU, 
including having multiple partners (48%) and buying sex from sex workers 
(40%) [4].  
Data from the Indonesian ministry of health reported that HIV-seropostive 
patients that were infected through injecting drug use usually present late in 
health facilities with the Acquired Immune Deficiency Syndrome (AIDS) in 
around 70% of the cases [5]. The late presentation may be due to different 
factors, including socio-psychiatric problems, also causing stigmatization from 
the general public as well as from health providers [6]. Consequence is that 
most of the symptomatic patients have initial low CD4-cell counts and present 
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1 
with wasting syndrome, anemia, candidiasis, neurological problems and 
pulmonary infections [5]. Regarding the latter, HIV-TB co-infections occur 
frequently as Indonesia is among the countries with the highest burden of 
tuberculosis in the world [7]. In addition to that, co-infection with hepatitis C 
(HCV) is also common because HIV and HCV share the same transmission 
mode in IDU.  
HIV can be successfully treated since the introduction of combination anti-
retroviral treatment (ART) at the end of the last century, Many studies from 
industrialized and non-industrialized countries have indeed reported high rates 
of both clinical and virological treatment response. Loss to follow up, lack of 
capacity and high costs of proper ART monitoring challenge however the 
evaluation of treatment programs in various resource limited countries, including 
Indonesia.  While the coverage of ART is estimated 36.8% in Indonesia [2], high 
mortality and loss to follow up are some of the issues challenging the delivery of 
ART in Indonesia. From 17880 patients started 1st line ART in 2008, 20.2% were 
reported dead and 11.2% loss to follow-up [5]. 
Hasan Sadikin Hospital, Bandung is the tertiary referral hospital for HIV care in 
West Java, one of the provinces with highest numbers of HIV-infected patients 
in Indonesia. Increasing numbers of HIV patients were seen in the Hasan 
Sadikin Hospital after the year 2000, whereby injecting drug use counted for 
80% as route of transmission [3]. Because of that, an integrated and 
comprehensive program to prevent, control and treat HIV among IDU in West 
Java (IMPACT) was developed with all stakeholders. The comprehensive 
approach included the following main activities: information, education and 
communication about HIV-related risk behavior in adolescents; scaling-up 
voluntary counseling and testing and improving its accessibility for IDUs in the 
community, improving and scaling-up prison services; harm reduction 
interventions, including methadone maintenance; scaling-up and optimizing care 
for HIV/AIDS, including antiretroviral treatment and laboratory testing; capacity 
building and transfer of knowledge about IDU and HIV/AIDS. All patients that 
entered services for HIV/AIDS in Hasan Sadikin Hospital since 2007 were asked 
to participate in a prospective cohort study. The present thesis reports results 
from studies performed within the IMPACT cohort.   
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The first part of this thesis (chapters 2-4) focuses on various aspects of HIV 
care. Chapter 2 reports the challenges in delivering HIV-care in Indonesia, and 
how quality and quantity of HIV-services are monitored. In chapter 3 the use of 
total lymphocyte counts (TLC) as a surrogate for CD4 cell counts was 
evaluated, and based on these results, an algorithm was designed to predict 
CD4 cell counts <200 and <350 cells/mm3  in order to identify patients eligible for 
ART in resources-limited settings. In chapter 4 TLC and CD4 cell counts were 
compared in order to define optimal cut-off levels of single or repeated 
measurements in different subgroups of patients. This supports the identification 
of patients in need for 1) pneumocystic jirovecii pneumonia (PJP) prophylaxis, or 
2) counseling for treatment adherence.  
Anemia is often found in HIV-infected patients, is relatively simple to diagnose 
and can be used as a marker in patients algorithms as described in chapter 3. 
Disturbances in iron homeostasis may play an important role in development of 
HIV-related anemia and recently new insights into iron homeostasis have been 
developed, among others through development of hepcidin assays. In chapter 5 
the prevalence of anemia and the relation to mortality were studied. 
Furthermore, the relation between anemia, iron parameters and inflammation 
was explored, considering also the influence of severity of HIV, ART and HCV 
infection. Chapter 6 focuses on the role of iron homeostasis as risk factor for 
the development of TB in HIV-infected patients. Baseline iron parameters, 
including the recently discovered iron regulating hormone hepcidin were 
analyzed in patients that did or did not develop TB after entering the cohort 
study.  
Apart from iron status, as a risk factor for the development of TB in HIV-infected 
patients, we also studied in chapter 7 whether injecting drug use increase risk 
of active tuberculosis in HIV patients. Furthermore we explored whether 
injecting drug use accelerates the natural decline of CD4 cells in the IMPACT 
cohort in which HIV-infected patients are followed. Because of the common 
belief among clinicians, also in Indonesia, that IDU is associated with lower 
uptake, retention and success of antiretroviral treatment (ART) in HIV-infected 
patients the study was done described in chapter 8, whereby the clinical 
presentation and response to first-line antiretroviral treatment of HIV-infected 
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1 
patients with and without a history of IDU are presented. Chapter 9 reports the 
virological response to ART in the IMPACT cohort, including and the distribution 
of drug resistance mutations. In addition, it was analyzed whether injecting drug 
use was a risk factor for virological failure and subsequent development of drug 
resistance.  
Finally, chapter 10 summarizes the main findings of the present thesis and 
provides suggestions for future research.  
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Abstract 
Background: 
HIV in Indonesia is strongly associated with injecting drug use (IDU), and 
surrounding stigma and lack of knowledge reduce accessibility of services. 
Uptake of HIV-testing is low and many patients present with advanced AIDS.  
 
Method: 
A comprehensive evaluation was made of HIV-services provided between 2006 
and 2008 in a referral hospital in West-Java, the province with the highest 
burden of HIV in Indonesia.  
 
Result: 
A total of 826 HIV-positive patients, mostly infected through IDU (73.9%), 
presented between 2006 - 2008. Targeted screening and provider-initiated 
testing and counseling (PITC) led to earlier HIV-diagnosis. Operational research 
helped optimize diagnosis and treatment of important disease complications. 
Systematic monitoring of treatment response, and collaboration with other 
providers, methadone maintenance program and prison help improve treatment 
outcome. Over the last three years, the number of individuals tested and treated 
for HIV increased approximately two-fold and six-month mortality decreased 
from 13.6% to 7.5%. Loss to follow-up was 12.2% at six months. 
 
Conclusion: 
Significant progress has been made in delivering HIV-care in West-Java through 
operational research, systematic treatment monitoring, and the use of simple 
indicators to evaluate the quantity and quality of care.   
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2 Introduction 
Indonesia is witnessing one of the most rapidly growing HIV-epidemic in Asia. 
Except for Papua, Indonesia has a concentrated epidemic largely driven by 
intravenous drug use. It is estimated that 270.000 Indonesian people are 
already infected with HIV [1]. Awareness is still low, and many people are 
symptomatic when HIV is diagnosed. Indeed, hospitals are confronted with 
growing numbers of patients who present with advanced HIV-infection or with 
AIDS. According to the Ministry of health, until the end of 2008, a total of 22664 
patients had been diagnosed with HIV in Indonesia, of whom 16110 were 
already in WHO stadium IV. A government program for free first-line treatment 
has been established in 150 hospitals, and many doctors, nurses, laboratory 
staff and counselors have been trained in all aspects of HIV-prevention and 
care. However, utilization of preventive and therapeutic services is still relatively 
low as can be derived from a report from the Indonesian national AIDS 
committee that estimated that 35.9% of the most-at-risk population was tested 
for HIV in the last 12 months and that 24.8% of the AIDS patients is receiving 
anti-retroviral treatment (ART) [2]. Although precise data are lacking, retention to 
treatment, like for any chronic disease, is often difficult. In addition, limited 
laboratory facilities, unavailability of certain drugs, and financial constraints 
hamper proper diagnosis and treatment of opportunistic infections. As a result, 
anecdotal reports indicate that mortality among HIV-infected patients, both 
before and after start of ART, is high. 
West-Java is a densely populated province (42 million people) which has the 
highest burden of HIV in Indonesia. Hasan Sadikin hospital, as top-referral 
hospital for West-Java, is facing the challenges of the growing HIV-epidemic. 
Many activities have been undertaken to respond to the difficulties and improve 
the services. In this paper, we will present the challenges in delivering HIV-care 
in this setting, what has been done to address these issues, and how quality 
and quantity of HIV-services are monitored.  
 
Setting 
Hasan Sadikin General Hospital acts as the top-referral hospital for West-Java, 
and is one of the first 25 hospitals which were appointed by the Indonesian 
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Ministry of Health to provide HIV-care. In 2004, a multidisciplinary AIDS-team 
was established, with involvement from specialists from all departments. The 
services provided include voluntary counseling and testing (VCT), laboratory 
testing, antiretroviral treatment (ART), diagnosis and treatment of opportunistic 
infections, prevention of mother to child transmission (PMTCT), pediatric HIV-
care, and post-exposure prophylaxis for health care workers. Most services are 
provided on an outpatient basis, in a specialized HIV-clinic named ‘Teratai’ 
(Indonesian for lotus). HIV-testing is done by three serial tests according to 
national guidelines. Since 2007, the government has facilitated the analysis of 
CD4-cell counts by providing a FACS count at Hasan Sadikin hospital, as the 
only hospital in West-Java.  
Since December 2004, a government program has been established for ART. 
Patients with AIDS (WHO stadium IV), or patients with a CD4-cell count below 
200 / mm3 are offered PCP-prophylaxis and ART. First-line ART consists of 
nevirapine combined with lamivudine, and zidovudine. Nevirapine is replaced by 
efavirenz if patients are treated for tuberculosis, or in case of hepatotoxicity or 
drug allergy. Zidovudine is replaced by stavudine in case of anemia or side-
effects. There is a limited availability of two second-line drugs, boosted lopinavir 
and tenofovir. Treatment of opportunistic infections is done according to national 
guidelines, but drugs are not provided by the national program. Tuberculosis 
treatment, supported by the Ministry of Health, is not provided by clinic Teratai, 
but by the ‘DOTS’ (directly observed treatment short-course) tuberculosis-
policlinic.  
Since 2007, HIV-prevention and care at Hasan Sadikin hospital are supported 
by ‘IMPACT’ (Integrated Management of Prevention And Control and Treatment 
of HIV/AIDS), a comprehensive program focusing on HIV-AIDS in the context of 
injecting drug use in West-Java [3]. With technical support from several 
European universities, different aspects of HIV prevention, control and care in 
Hasan Sadikin have been addressed in a multidisciplinary team. The 
implementation of HIV services in this program is not only accompanied by 
training and capacity building, but operational research is also applied to 
evaluate the interventions and possibilities for improvement. A patient cohort 
was therefore also established whereby patient data were collected 
Challenges in delivering HIV-care in Indonesia 
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2 retrospectively from medical records, and prospectively since September 2007 
using standardized patient records and laboratory examination.  
 
Challenges in delivering service 
Counseling and testing 
One of the major challenges in delivering HIV-care is the fact that patients 
mostly present with advanced HIV-infection or AIDS (table 1). The majority of 
patients are symptomatic when HIV is diagnose and many present with severe 
wasting, candidiasis, pulmonary infections and neurological problems. 
Illustrative is also the initial CD4 cell-count (median 32/mm3) of the patients for 
whom care was provided in 2006. Earlier testing and treatment will prevent 
disease progression [4], but this is hampered by lack of knowledge (among 
patients and health providers), stigmatization [5] perceived lack of benefit of 
HIV-testing, and logistic or financial barriers [6]. Several initiatives have been 
taken in Hasan Sadikin hospital and collaborating institute to overcome these 
barriers. First, systematic screening of (symptomatic or asymptomatic) high risk 
subjects has been introduced. This includes injecting drug users in the 
methadone maintenance treatment program [7], prisoners [8], and marital 
partners of HIV-patients. In 2006, 80.4% of HIV-patients were male, and 44.3% 
were married or had a stable relationship. Systematic recording of the status of 
patients’ marital partners, and repeated counseling of patients whose partner 
has not been tested, is currently done in Teratai clinic, with reasonable success. 
A second approach is ‘provider initiated testing and counseling’ (PITC), whereby 
the physician suggests the patient to be tested, with consent, and the patient is 
counseled more extensively afterwards. PITC is mostly used for symptomatic in-
patients. Common physical clues, like chronic diarrhea or oral candidiasis can 
be used to identify patients for PTIC, also in the absence of (reported) risk 
behavior [6]. One specific patient category has been meningitis. Among 185 
unselected adults presenting with meningitis in our hospital, 47 (25%) were HIV-
infected [9]. Based on that result, all patients presenting with meningitis now 
undergo PITC, and almost all agree.  
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A two-fold increase in the number of subjects tested for HIV was observed since 
2006 (from 388 to 666) and the number of subjects entering HIV-care also 
doubled (from 199 to 397). However, although more patients are diagnosed at 
an earlier stage, the proportion of tested subjects which are HIV-positive 
remains high at 31.4% in 2008. For these people, primary HIV-prevention 
comes too late. Clearly, more efforts are needed to increase early testing at 
community level, and secure effective referral of those tested positive for 
possible HIV-treatment.   
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2 Antiretroviral treatment 
Advanced disease, loss to follow-up and monitoring of antiretroviral treatment 
are some of the issues challenging effective delivery of antiretroviral treatment 
(ART). Almost half of HIV-patients at Hasan Sadikin hospital present with WHO 
stage IV with severe wasting or opportunistic infection, and in 2006 90% had a 
CD4-cell count below 200/mm3. Although there is an urgent need for ART in 
these patients, they may be too ill to start, or show a paradoxical worsening of 
disease following ART, as part of an ‘immune reconstitution inflammatory 
syndrome’ (IRIS). Detection and treatment of opportunistic infection before 
initiating ART can increase survival of HIV-patients. And of course, earlier 
detection of HIV-infection, with timely start of ART is associated with a better 
outcome. Using CD4-cell counts and mortality data from the patient cohort, it 
was calculated that one-year mortality was 3.94% for patients detected through 
screening (median CD4-cell count 253/mm3) versus 12.10% for regular patients 
(median CD4 59 / mm3) [Hinta Meijerink, unpublished data]. 
A second major obstacle to effective delivery of ART is loss to follow-up. Before 
treatment is started, HIV-infected patients need to be informed about side-
effects, IRIS, and the utmost importance of treatment adherence. Since October 
2007, Teratai Clinic provides systematic adherence counseling before initiating 
ART. Weekly adherence team meetings are held between counselors and 
physician to discuss individual cases and improve patients adherence and 
retention to treatment. Despite these efforts, loss to follow-up remains an 
important problem in our setting. Several factors may contribute to this issue, 
including costs of transportation, fear of disclosure/stigma, side-effects of ART 
and lack of community support. In an effort to improve this situation, Hasan 
Sadikin hospital collaborates with district hospitals in West-Java province and 
community services including prison, NGO clinic and primary health centers to 
try and establish or increase treatment in other health centers and improve 
tracing of patients lost to follow-up [10]. Insecure supply of ART, especially 
efavirenz, has also contributed to loss of follow-up, as patients sometimes had 
to come every two weeks to collect their medication. Finally, the overburdened 
out-patient clinic Teratai may play a role in loss to follow-up. Clearly, like in other 
parts of Indonesia, the rapid growth of the number of patients entering HIV-care 
can only be met by establishing more service, including treatment, outside 
hospital [11].  
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One issue which has been addressed successfully in our setting is the 
monitoring of ART and management of treatment failures. The golden standard 
for monitoring ART is the measurement of a ‘viral load’ (plasma HIV-RNA) by 
real-time PCR. Until recently, like most institutes in Indonesia, we relied on 
immunological criteria for treatment failure, as virological monitoring could only 
be performed at a single institute in Indonesia, and at high cost (not covered by 
the National program). In line with previous reports from other settings [12], 
immunological criteria for treatment failure in our setting have a poor correlation 
with viral load monitoring. The predictive value of CD4-cell numbers to identify 
treatment failure (as defined by an elevated plasma HIV-RNA despite at least 
six months of ART) was only 45% in our cohort [Yovita Hartantri, unpublished 
data]. As a result, based on immunological criteria, many patients would be 
switched unnecessarily. In Hasan Sadikin hospital, HIV-RNA measurement has 
been made accessible for all patients since January 2008. Patients who have a 
detectable plasma HIV-RNA while taking ART are managed according to a 
systematic protocol. So far, 17 patients have switched to second line ART, of 
whom none have dropped out, and all patients evaluated three months after 
switching to second-line treatment showed an undetectable plasma HIV-RNA. 
Tuberculosis and other co-infections 
Co-infections are common in HIV-infected patients present in advanced stage 
whereby Mycobacterium tuberculosis is among the most important micro-
organisms. Indeed, almost half of HIV-infected patients at Teratai clinic have a 
history of TB treatment and 20% received concomitant treatment for HIV and 
TB. Diagnosis and treatment of TB in HIV-infected patients faces additional 
challenges, some of which are specifically addressed in our hospital [13]. 
Sputum microscopy and culture have been improved, and systematic 
radiological screening of HIV-patients has been implemented. However, 
especially among in-patients with severe immunosuppression, diagnosis of 
suspected TB is hampered by absence of sputum and insensitivity of chest      
X-ray examination [13].  Combined treatment of HIV and TB is difficult due to 
pill-load, possible drug interactions, hepatotoxicity and IRIS [14]. Operational 
research as described above, and gradual integration of the TB and HIV 
program in our hospital has helped to identify barriers in effective management 
of TB among our HIV-patients.  
Challenges in delivering HIV-care in Indonesia 
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2 Apart from TB, also the diagnosis and management of other infections, such as 
meningitis and candidiasis, are addressed in HIV-infected patients. Among 185 
unselected adult meningitis cases in our hospital, 47(25%) were HIV-positive [9] 
and the meningitis in these HIV-infected patients was caused by Cryptococcus 
neoformans, (n=18) and Mycobacterium tuberculosis (n= 29). Despite antifungal 
or anti-tuberculous treatment, 66% died within the first month of treatment. 
Possibly due to improved detection and immediate treatment, recent mortality 
seems lower, but clearly more effort is needed to improve outcome among this 
patient group. Besides meningitis, operational research has focused on 
candidiasis. Oropharyngeal candidiasis was found in 25.7% of patients, and 
71.0% of hospitalized patients. Oropharyngeal Candidiasis may aggravate HIV-
associated wasting and it appeared a strong risk factor for anemia and mortality 
among our patients [Rachmat Sumantri, unpublished data]. Earlier detection of 
HIV with timely start of ART, and possibly with fluconazol or INH-prophylaxis 
may prevent disease complications and mortality [15,16].  
Other complications which have been addressed include skin problems [17], 
and cytomegalovirus (CMV) retinitis. Sexually transmitted infections (STI) seem 
relatively rare in this population, only 17 (1.97%) of HIV-positive patients in the 
cohort had positive serology (VDRL), none with symptoms. Viral hepatitis is very 
common, 471 male HIV-patients (83.1%) and 54 female patients (29.7%) are 
HCV-seropositive, but so far no HCV-genotyping has been done and no patient 
has been treated HCV-infection. Research has indicated that for ART may be 
started earlier in HCV-infected patients to delay progression of liver fibrosis [18], 
but this policy have not been implemented yet.  
Injecting drug use 
Of all HIV-patients diagnosed in 2006, 77% had a history of injecting drug use 
(IDU). There is a common belief that IDU is associated with lower uptake, 
retention and success of ART. However, our cohort data do not support this 
common belief. Among HIV-patients with and without a history of IDU, mortality 
(15.7% and 18.8%) loss to follow-up (13.0% and 13.5%), and virological failure 
(12.1% and 15.8%) were similar in the two groups. 
   
Physicians may be reluctant to start ART in IDUs who are still actively injecting 
drugs. However, in our experience, integration of HIV-care with opioid 
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substitution as ‘one-stop care’ is associated with good adherence, retention and 
outcome of ART. Among 35 HIV-patients in daily methadone maintenance in our 
hospital, one-year retention to ART was 100%, one-year survival 93.9% and 
virological failure occurred in 3.7% of patients [7].  Providing HIV-care for HIV-
patients with opioid substitutions is important because it will not only to improve 
IDUs health status and quality of life, but also to reduce risk of HIV-transmission.   
Coverage and coordination with other providers  
Coverage and continuum of care in Bandung (2.5 million people) and West-Java 
(42 million people) is a challenge. Care outside hospital is important to assure 
good access (through referral or first line services), and chronic treatment with 
good retention and at the lowest possible costs. Lack of knowledge and 
experience in HIV-care and stigmatization from health care providers has been 
noted in many institutes [5]. Since 2006, Hasan Sadikin Hospital train and 
supervise 17 district hospitals in West-Java province in delivery of HIV-care. 
Since 2006, Banceuy prison in Bandung, appointed for drug-related offense in 
West-Java province, has been supported in establishing HIV-testing and 
treatment [8]. Preparations are made to establish similar collaboration at the 
level of primary health centers. This networking, coordinated with the city and 
Provincial Health Office and AIDS Commission, should contribute to coverage 
and quality of HIV-care in West-Java.   
 
Measuring quantity and quality of HIV-care 
Measuring the quantity and quality of HIV-service may help to analyze, and 
interpret data that are essential for planning, implementation and evaluation of 
the program. Quantity and quality indicators may also help to rationalize 
allocation of limited health resources. We have selected a number of simple 
indicators to measure quantity and quality of HIV-counseling and testing, 
initiation of ART, and follow-up of patients (table 2). Official statistics often use 
cumulative numbers, but when expressed per month or year, such indicators 
more accurately indicate the current situation and recent change in volume 
(quantity) or quality of services. 
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2 
 
With regard to the volume of care, the data (table 2) show that the number of 
subjects tested in our hospital has doubled in two years. Together with 
increased referral of HIV-positive patients from other hospitals (71 patients in 
2006 – 152 patients in 2008), this has also doubled the number of HIV-positive 
patients entering care. The number of patients checked for CD4 increase tripled 
in two years. The number of HIV-patients receiving ART outside the HIV-clinic 
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also increased in 2008, both in Banceuy prison [8], methadone maintenance 
treatment (MMT) clinic [7], and in district hospitals. In 2006, three district 
hospitals delivered ART to 44 patients, and in 2008 this had grown to eight 
hospitals delivering ART to a total 121 patients.      
The quality of HIV-care also increased over years. The higher average CD4 cell-
count in 2008 indicate that more patients are tested early, possibly through 
screening programs among methadone clients, prisoners and patients partners. 
Adherence counseling is now systematically provided for all patients, and 
measurement of CD4 cell-count in 94% (table 2). Access to free HIV-RNA 
examination, increased adherence counseling and better management of       
co-infections may have contributed to decreased mortality and virological failure 
in 2008 (table 2). The mortality of patients starting in 2006, 2007 respectively 
2008 is shown in figure 1. However, loss to follow-up remains high and 
warrants further investigation to identify the underlying reason as well as the 
current status of those patients. Some may have died, but others may have 
transferred to other health institutes. In summary, the use of these indicators 
and more detailed analysis helps to improve services, to prioritize our research 
agenda, and to inform policy makers in and outside hospital.   
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2 Conclusion 
Significant progress has been made in delivering HIV-care in West-Java through 
operational research, systematic treatment monitoring, and the use of simple 
indicators to evaluate quantity and quality of care. More efforts are needed to 
increase early detection and HIV-treatment outside hospital, to integrate HIV-
care with services related to reproductive health, TB and injecting drug use, and 
to improve retention to treatment. Policy makers, in- and outside hospital, should 
be aware of the challenges lying ahead in terms of the increasing number of 
HIV-patients and demand for services in terms of infrastructure, human 
resources and financial resources [19]. Every effort should be made to secure 
the sustainability of therapeutic services and to strengthen primary and 
secondary HIV-prevention.   
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Abstract 
 
Objectives:  
Total lymphocyte counts (TLC) may be used as an alternative for CD4 cell 
counts during monitoring of HIV infection in resource-limited settings, where 
CD4 cell counts are too expensive or not available.  
 
Methods:  
We used prospectively collected patient data from an urban HIV clinic in 
Indonesia. Predictors of mortality were identified via Cox regression, and the 
relation between TLC and CD4 cell counts was calculated by linear regression. 
Receiver Operating Characteristics (ROC) curves were used to choose cut-off 
values of TLC corresponding with CD4 cell counts <200 and ≤350 cells/µl. 
Based on these analyses we designed TLC-based treatment algorithms.  
 
Results:  
Among 889 ART-naive subjects included, 66% had CD4 cell counts <200 and 
81% ≤ 350 cells/µL at baseline. TLC and CD4 cell count were equally strong 
predictors of mortality in our population, where ART was started based on CD4 
cell count criteria. The correlation coefficient (R) between TLC and √CD4 was 
0.70. Optimal cut-off values for TLC to identify patients with CD4 cell counts 
<200 and ≤350 cells/µL were 1500 cells/µL and 1700 cells/µL.Treatment 
algorithms based on a combination of TLC, gender, oral thrush, anaemia and 
body mass index (BMI) performed better in terms of predictive value than WHO-
staging or TLC alone. In our cohort such an algorithm would on average have 
saved $14.05 per patient. 
 
Conclusion:  
TLC is a good marker for HIV-associated mortality. Simple algorithms including 
TLC can prioritize patients for HIV treatment in a resource-limited setting, until 
affordable CD4 cell counts will be universally available.  
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Introduction 
Ideally, decisions about starting patients infected with human immunodeficiency 
virus (HIV) on antiretroviral treatment (ART) are based on CD4 cell count 
criteria, combined with clinical staging. The latest WHO-guidelines advise to 
start ART at a CD4 count ≤350 cells/µL [1], but the former guidelines which use 
a CD4 cell count of 200 cells/µL as a cut-off are still being used in many 
countries [2]. Unfortunately CD4 cell counts are not available or too expensive in 
many resource-limited settings. Under these circumstances ART is mostly 
initiated based on disease stage according to WHO-criteria [3]. As an 
alternative, decisions may use the total lymphocyte count (TLC), which is more 
widely accessible and cheaper compared to CD4 cell counts. 
 
Several studies have investigated the ability of TLC to predict CD4 cell counts. 
However, the correlation between TLC and CD4 cell counts appears to be only 
moderate [4-10]. Combining the TLC with other simple markers, like 
haemoglobin and body mass index (BMI), can increase its accuracy [11-13].  In 
addition, some studies have compared TLC-based treatment algorithms with 
WHO-staging criteria for starting ART [14]. However, only few studies evaluated 
the prognostic value of TLC for mortality among HIV-infected [15]. We 
investigated the ability of TLC to predict mortality and CD4 cell counts, and 
identified the most important covariates that influence the relation between TLC 
and CD4 in HIV-infected patients in Indonesia, which has one of the most 
rapidly growing HIV-epidemics [16]. The use of TLC as a surrogate for CD4 cell 
counts would be of great value in Indonesia. As there are now only 25 hospitals 
in the whole of Indonesia (240 million people) where CD4 cell measurement is 
available. Based on these results we designed a clinical algorithm to predict 
CD4 cell counts <200 and ≤350 cells/µL in order to identify patients who are 
eligible for ART in resource-limited settings. 
 
 
Methods 
Setting and study population 
This study was embedded in a five-year programme called ‘IMPACT’, aimed at 
better prevention, control and treatment of HIV in the context of injecting drug 
use (IDU) in West-Java, Indonesia [17]. IMPACT is supporting HIV-related 
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patient care, to both people with and without a history of IDU, at Hasan Sadikin 
Hospital in Bandung, the top-referral hospital for West Java (40 million people). 
Subjects who are at risk for HIV infection or who present with signs and 
symptoms suggesting HIV/AIDS are counselled and tested for HIV. All testing is 
voluntary and informed consent is obtained from all individuals. Standard 
questionnaires were used to obtain information about demographic factors such 
as age, gender, IDU and history of ART. A physician scored the stage of 
disease using WHO-criteria and performed a physical examination [3]. Anti-
Hepatitis C antibodies (optic density) were measured by ECLIA (Roche 
diagnostic, Mannheim, Germany), with external quality control showing a 100% 
accuracy (National Serology Reference Laboratory, Australia). CD4 cell 
measurements (cells/µL) were done using FACS-count flow cytometry 
technology (BD Biosciences, Jakarta, Indonesia), TLC (cells/µL) and 
haemoglobin concentrations (gr/dL) were measured using the Cell Dyne 3000 
(Abbott, Jakarta). During follow-up, death was recorded from medical records, 
reports from community organizations, or phone interviews from the clinic. If 
patients were lost to follow-up we used the most recent date at which the status 
of a patient was known as an endpoint. This study was approved by the ethical 
committee of the Faculty of Medicine of the Padjadjaran University in Bandung, 
Indonesia. 
 
Data Analysis 
In this study we included all adult patients (≥16 years) diagnosed with HIV-
infection between August 2007 and February 2010. Patients are seen every 
three months if CD4 cell count ≤350 cells/µL, every six months if CD4 cell count 
>350 cells/µL, and every months when started on ART independent of CD4 cell 
count. All patients were censored at date of last visit before February 2011. We 
excluded all patients who had previously been exposed to ART, or who were 
using ART at time of enrolment. All variables used in the analyses were 
selected based on previous literature [10,18,19], as they either have a relation 
with CD4 cell counts, TLC, or mortality. To identify independent predictors of 
mortality we used Cox proportional hazard models. We performed univariate 
Cox regression analysis for the baseline variables TLC, CD4 cell count, 
haemoglobin, gender, oral thrush, BMI, IDU, Hepatitis C infection (HCV), age, 
and ART initiation. ART initiation was evaluated as a time-dependent covariate. 
Using backward selection based on  p-values <0.05, variables were selected for 
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two different multivariate models, one based on TLC and the other based on 
CD4 cell counts. These multivariate models were compared using the Akaike 
Information Criterion (AIC), and used to calculate hazard ratios (HRs) of 
independent predictors of mortality. To prevent potential bias caused by missing 
data, we included a separate group for missing data in the mortality analysis (for 
example IDU: yes, no or missing).  
 
We used univariate and multivariate linear regression analyses to examine the 
correlation between the independent variable TLC and the dependent variable 
CD4 cell count. Gender, age, haemoglobin, BMI, IDU, HCV and oral thrush 
were evaluated as co-variables. These variables were selected based on 
previous research [20,21] and because they are easy to measure in resource-
limited settings. To prevent systematic error, WHO-staging was not entered in 
the linear model, since oral thrush, haemoglobin, and weight are included in the 
WHO-staging system. The square root of the dependent variable (CD4 cell 
count) was used to meet all criteria for linear regression. 
 
Receiver Operating Characteristics (ROC) were used to determine the 
sensitivity and specificity of different cut-off values of TLC to predict CD4 cell 
counts <200 and ≤350 cells/µL. The area under the curve (AUC) of each cut-off 
point was used to determine the optimum cut-off value of TLC within the study 
population. All variables with a predictive effect on CD4 cell counts, according to 
the multivariate regression analyses, were used to design clinical algorithms, 
predicting CD4 cell counts <200 respectively ≤350 cells/µL. In these algorithms, 
we first included variables that could be used to identify patients who could be 
started on ART without measuring the TLC. We selected those variables based 
on clinical experience in the field, previous studies and the results of our own 
analyses. As a final test in the algorithms we included TLC to determine whether 
ART should be initiated. In addition, we looked if different TLC cut-off point were 
needed for subcategories using ROC and the AUC. Test characteristics of these 
algorithms were compared with test characteristics of TLC alone and with WHO-
staging to predict CD4 cell counts. Sensitivity analysis was done to calculate the 
predictive values of the two algorithms after a hypothetical 50% reduction of the 
prevalence of patients with a CD4 cell counts <200 and ≤350 cells/µL, under the 
assumption that the sensitivity and specificity would not change. SPSS version 
16.0 (SPSS Inc, Chicago, IL) was used for all statistic analyses. 
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Results 
We included 889 HIV-positive ART-naïve patients in this study. The majority of 
patients had advanced disease, 590 subjects (66%) had CD4 cell counts <200 
cells/µL and 723 (81%) had CD4 cell counts ≤350 cells/µL. The median CD4 
cell count in our population was 74 cells/µL.The characteristics of our study 
population are displayed in table 1. The median follow up period was 496 days 
(IQR 108-744 days), 94 patients (10.5%) died during follow-up, and the median 
time to death was 82 days (IQR 16-220 days). 366 patients (41%) dropped out 
of the study, those patients had a higher median CD4 count (165 cells/µL) 
compared to patients who died (13 cells/µL) or did return for follow-up (70 
cells/µL). 
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TLC, CD4 cell count, haemoglobin, oral thrush, gender, BMI, ART and age had 
a significant relationship with mortality (p<0.05) in univariate Cox regression 
analysis (table 2). There were missing values for hepatitis C (n=83), age (n=1), 
oral thrush (n=130), haemoglobin (n=1) or BMI (n=220), 150 subjects had 
missing data on multiple variables. Four factors appeared as significant 
covariates in the multivariate proportional hazard model that was based on TLC, 
namely haemoglobin (p=0.005), gender (p=0.009), ART (p <0.001) and missing 
data on oral thrush (p <0.001). In the multivariate model based on CD4 cell 
count, only haemoglobin (p=0.001), ART (p<0.001) and missing data on oral 
thrush (p <0.001) were significant covariates (table 2). The AIC of the model 
based on TLC was 1022.8, the AIC of the model based on CD4 was 1019.2, 
and this small difference indicates that the predictive value of both models is 
comparable. In addition, TLC and CD4 cell count had comparable hazard ratios 
(HRs) for mortality in these two proportional hazard models (table 2). 
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There was a good correlation between TLC and √CD4  count in univariate linear 
regression (n=889, R=0.700). The test characteristics for different cut-off-values 
of the TLC to predict a CD4 cell count <200 cells/µL and ≤350 cells/µL are 
shown in table 3. Based on the combined sensitivity and specificity, the most 
accurate TLC cut-off value was 1500 cells/µL to predict CD4 cell counts <200 
cells/µL, and 1700 cells/µL to predict CD4 cell counts ≤350 cells/µL. The 
negative predictive value (NPV) of these cut-off values were 0.67 and 0.55; this 
means that 33 patients with a TLC > 1500 would actually have a CD4 cell count 
<200, and 49 patients with a TLC>1700 a CD4 cell count ≤350 cells/µL In 
multivariate regression analysis gender, oral thrush, haemoglobin, BMI and age 
were significant covariates for CD4 cell counts (table 4). Adding these 
covariates to the model resulted in a significant change in R2  from 0.47 to 0.62. 
(p<0.001).  
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The AUC of the ROC-curve of TLC was 0.80 (95%CI:0.76-0.83) to predict CD4 
cell counts <200 cells/µL and 0.83 (95%CI:0.79-0.87) to predict CD4 cell counts 
≤350 cells/µL. Based on the previous analyses, two clinical algorithms were 
designed to predict CD4 cell counts <200 and ≤350 cells/µL. According to these 
algorithms, all patients with oral thrush and all patients with both haemoglobin 
<12 g/dL and a BMI <18,5 kg/m2 should commence ART irrespective of TLC. 
For all other patients TLC should be measured. We calculated TLC cut-off 
values for various subgroups, and found that different cut-off values should be 
used for men and women. To predict a CD4 cell count <200 cells/µL, cut-off 
values for TLC <1500 cells/µL for female patients and <1700 cells/µL for male 
patients should be used (figure 1).  
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All patients with oral thrush and all patients with both Hb <12 g/dL and a         
BMI <18.5 kg/m2 should commence ART. For all other patients TLC is 
measured. To predict a CD4 cell count <200 cut-off values for TLC are ≤1500 
cells/µL for female and ≤1700 cells/µL for male patients. The same algorithm 
can be adjusted to predict CD4 cell counts ≤350 cells/µL, by changing the cut-
off value of TLC to ≤1700 cells/µL for female patients and to ≤1800 cells/µL for 
male patients. 
In this cohort of patients, use of this algorithm would have obviated the need for 
CD4 cell measurements in all patients, and measurement of TLC in 37% of 
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patients (n=332). Assuming a cost of US$16.70 per CD4 cell count, CD4 cell 
measurements in all 889 patients would have cost US$14,846 whereas 
measurement of TLC according to the algorithm in 567 patients would have 
amounted to a cost of US$2,211 (assuming a cost of US$3.90 per TLC). 
Consequently, the use of this algorithm would have saved US$12,635 in our 
cohort, which is US $14.05 per patient. This ignores any costs associated with 
errors of inclusion (over diagnosis) and exclusion (under diagnoses) of the 
algorithm compared to the use of CD4 cell count. A similar algorithm was made 
to predict a CD4 cell count ≤350 cells/µL, using values of <1700 cells/µL for 
female patients and <1800 cells/µL for male patients.  
Algorithms combining TLC with oral thrush, BMI and haemoglobin were 
compared with WHO-staging or TLC alone (table 5). When predicting CD4 cell 
counts ≤350 cells/µL, only 88 out of 889 patients (9.9%, median CD4 cell count: 
254 cells/µL) would be denied ART using the TLC-based algorithm, compared 
with 284 out of 693 patients (41.0%, median CD4 cells: 182 cells/µL) when 
using WHO-staging. ART would be started prematurely in 35 patients (3.9%, 
median CD4 cells: 425 cells/µL) using the TLC-based algorithm, and 5 patients 
(0.7%, median CD4 cells: 422 cells/µL) when using WHO-staging. 
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The previous results were based on the actual proportion of CD4 cell counts 
<200 and ≤350 cells/µL in our study population (66% and 81%). To determine 
the effect of these proportions on the predictive values of the tests, we 
hypothetically reduced these proportions by 50%, assuming that sensitivity and 
specificity of our tests remained the same. If only 33% of patients would have a 
CD4 cell count <200 cells/µL, the positive predictive value (PPV) of the TLC 
algorithm would be 0.58 (95%CI: 0.53-0.62) compared to 0.88 (95%CI: 0.83-
0.92) for WHO-staging. The NPV of the TLC algorithm and WHO-staging would 
be 0.95 (95%CI: 0.92-0.97) and 0.83 (95%CI: 0.80-0.85). When looking at CD4 
cell count ≤350 cells/µL (prevalence 40%), the TLC algorithm would have a PPV 
of 0.71 (95%CI: 0.67-0.75) compared with 0.75 (95%CI: 0.70-0.79) for WHO-
staging. The NPV would be 0.90 (95%CI: 0.88-0.93) for TLC algorithm and 0.86 
(95%CI: 0.83-0.89) for WHO-staging. This shows that even when the average 
CD4 cell counts would be higher in this setting, the TLC-based algorithms would 
still outperform WHO-staging.  
 
 
Discussion 
This study shows that the TLC is a useful tool to monitor HIV infection and to 
decide who is eligible for starting ART in a resource-limited setting. The TLC 
was a strong predictor of mortality and corresponded reasonably well with CD4 
cell counts in this setting.  Optimal cut-off values of the TLC to predict CD4 cell 
counts <200 and ≤350 cells/µL in our population were much higher than 1200 
cell/µL, which is often reported, and higher for men than for women. A clinical 
algorithm that includes TLC, oral thrush, BMI, haemoglobin and gender more 
reliably identified patients qualifying for ART that clinical staging based on 
WHO-criteria. 
 
Optimal cut-off values of TLC to predict CD4 cell counts as described by others 
show great variation, values range from 1000 to 2250 cells/µL for a CD4 cell 
count <200 cells/µL [21-23]. This variation can be explained by the influence of 
certain patient characteristics on the relation between TLC and CD4, and by the 
distribution of CD4 cell counts within a certain population. Our finding that TLC 
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and haemoglobin are strong predictors of mortality in HIV patients is in 
concurrence with previous research [24-26]. 
 
Algorithms that include TLC and simple markers like haemoglobin and BMI have 
been designed before, predicting CD4 cell counts with moderate accuracy 
[11,13,14,20,21]. We improved this approach by adjusting cut-off values of the 
TLC for gender, because gender influenced the correlation between TLC and 
CD4. The use of these algorithms will obviate the need for laboratory testing for 
many and thereby save costs. In this study population, 37% (332 out of 889 
patients) would have been offered ART based on the clinical parameters in the 
algorithm, without use of TLC measurement.  
 
An important limitation of our study is that median CD4 cell counts in our 
population were relatively low. Test characteristics, especially the predictive 
values, are affected by the high proportion of patients with low CD4 cell counts. 
In our study 66% of all subject had CD4 cells <200 cells/µL and 81% had CD4 
cells ≤350 cells/µL. In Indonesia, HIV patients generally present with advanced 
disease, therefore our study-population is representative for this population [27]. 
When we hypothetically increased the average CD4 cell count, the algorithms 
still outperformed WHO-staging. Even though more people would receive ART 
prematurely when using the TLC algorithm, with WHO-staging significantly more 
patients would unintentionally be denied ART, and this might have severe 
consequences for HIV related morbidity and mortality. The TLC algorithm is also 
much more practical than using WHO-staging. In resource-limited settings it is 
often quite difficult to determine whether a patients has WHO stage III or IV, 
whereas the variables used in our algorithm are very easy to collect.  
 
The TLC algorithm could also be a useful tool for screening in settings were a 
CD4 cell count is available but too expensive for routine care. In this case, 
especially the high sensitivity of the algorithm is important. In these settings the 
algorithm would be used to prioritise patients for CD4 cell testing, which would 
be used to initiate ART. When using the algorithm for this purpose, one might 
consider a higher TLC cut-off value in order to increase sensitivity.  
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We did not yet evaluate the usefulness of TLC to monitor treatment success 
after starting ART. Monitoring treatment is ideally performed with HIV viral load 
and CD4 cell counts. HIV viral load measurements are even more expensive to 
perform and less widely available than CD4 cell counts. Therefore a cheaper 
alternative for resource-limited settings would be useful. Some studies have 
already looked at the use of TLC and simple algorithms to monitor HIV 
treatment, with varying results [28,29]. 
 
 In summary, we demonstrated that the TLC is a good marker for HIV-related 
mortality, and that an algorithm based on simple patient characteristics can 
improve its predictive value, outperforming WHO-staging when it comes to 
prioritization of patients for ART.  
 
 
Acknowledgement 
We would like to Dr. Bayu Wahyudi, Director of Hasan Sadikin General Hospital, 
and Prof. Tri Hanggono Achmad, Dean of the Medical Faculty Padjadjaran 
University for encouraging and accommodating research at their institutions. 
Everyone working at the HIV clinic in the hospital is thanked for providing HIV 
care and collecting the data used for this study. This study was supported by 
‘IMPACT’ (Integrated Management of Prevention And Care and Treatment of 
HIV/AIDS), a collaborative research and implementation programme of 
Padjadjaran University, Bandung, Indonesia; Maastricht University and 
Radboud University Nijmegen, the Netherlands; and Antwerpen University, 
Belgium. IMPACT is funded by the European Commission (SANTE/2005/105-
033). 
 
 
 
 
 
 
 
 
 
Total lymphocyte count as a tool for starting ART 
 
47 
 
3 
References 
1. World Health Organization. Rapid advice, antiretroviral therapy for HIV 
infection in adults and adolescents. 2009. 
2. Raizes E, Lindegren M, Ellerbrock T, Ferris R, & Marston B. A Comparison of 
the Adult National Antiretroviral Therapy (ART) Guidelines of 15 PEPFAR 
Focus Countries. 2008. 
3. World Health Organization. WHO case definitions of HIV for surveillance and 
revised clinical staging and immunological classification of HIV-related 
disease in adults and children. 2007. 
4. Akinola NO, Olasode O, Adediran IA, Onayemi O, Murainah A, Irinoye O, et 
al. The search for a predictor of CD4 cell count continues: total lymphocyte 
count is not a substitute for CD4 cell count in the management of HIV-infected 
individuals in a resource-limited setting. Clin Infect Dis. 2004; 39(4): 579-81. 
5. Angelo AL, Angelo CD, Torres AJ, Ramos AM, Lima M, Netto M, et al. 
Evaluating total lymphocyte counts as a substitute for CD4 counts in the 
follow up of AIDS patients. Braz J Infect Dis. 2007;11(5): 466-70. 
6. Daka D, Loha E. Relationship between total lymphocyte count (TLC) and CD4 
count among peoples living with HIV, Southern Ethiopia: a retrospective 
evaluation. AIDS AIDS Res Ther. 2008;5: 26-30. 
7. Gitura B, Joshi MD, Lule GN, Anzala O. Total lymphocyte count as a 
surrogate marker for CD4+ t cell count in initiating antiretroviral therapy at 
Kenyatta National Hospital, Nairobi. East African Medical  Journal. 2007;84: 
466-72. 
8. Kamya MR, Semitala FC, Quinn TC, Ronald A, Njama-Meya D, Mayanja-
Kizza H, et al. Total lymphocyte count of 1200 is not a sensitive predictor of 
CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. 
African Health Sciences. 2004;4, 94-101. 
9. Liotta G, Perno CF, Ceffa S, Gialloreti LE, Coehlo E, Erba F, et al. Is total 
lymphocyte count a reliable predictor of the CD4 lymphocyte cell count in 
resource-limited settings? AIDS. 2004;18(7):1082-3. 
10. Schreibman T, Friedland G. Use of total lymphocyte count for monitoring 
response to antiretroviral therapy. Clin Infect Dis. 2004;38:257-62. 
11. Chen RY, Westfall AO, Hardin JM, Miller-Hardwick C, Stringer JS, Raper JL, 
et al. Complete blood cell count as a surrogate CD4 cell marker for HIV 
monitoring in resource-limited settings. J Acquir Immune Defic Syndr. 
2007;44: 525-30. 
Chapter 3 
48 
 
12. Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, mayer KH, 
Carpenter CC, et al. Total lymphocyte count (TLC) is a useful tool for the 
timing of opportunistic infection prophylaxis in India and other resource-
constrained countries. J Acquir Immune Defic Syndr. 2002;31:378-83. 
13. Spacek LA, Griswold M, Quinn TC, Moore RD. (2003) Total lymphocyte count 
and hemoglobin combined in an algorithm to initiate the use of highly active 
antiretroviral therapy in resource-limited settings. AIDS. 2003;17:1311-7. 
14. Morpeth SC, Crump JA, Shao HJ, Ramadhani HO, Kisenge PR, Moylan CA, 
et al (2007) Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV 
type 1-infected African population. AIDS Res Human Retroviruses. 2007; 
23,1230-6. 
15. May M, Boulle A, Phiri S, Messou E, Myer L, Wood R, et al. Prognosis of 
patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan 
Africa: a collaborative analysis of scale-up programmes. Lancet. 2010; 
376:449-57. 
16. National AIDS Commission. Country report on the follow up to the declaration 
of commitment on HIV/AIDS. UNGASS report 2006-2007. 2008. 
17. Alisjahbana B, Susanto H, Roesli R, Yusuf H, Hinduan Z, Mase JC, et al. 
Prevention, control and treatment of HIV-AIDS among injecting drug use in 
Bandung, Indonesia. Acta Medica Indones. 2009;41 Suppl 1:65-9. 
18. Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick J B. Rapid 
declines in total lymphocyte counts and hemoglobin concentration prior to 
AIDS among HIV-1-infected men. AIDS. 2003;17: 2035-44. 
19. Nowicki MJ, Karim R, Mack WJ, Minkoff H, Anastos K, Cohen M, et al. 
Correlates of CD4+ and CD8+ lymphocyte counts in high-risk 
immunodeficiency virus (HIV)-seronegative women enrolled in the women's 
interagency HIV study (WIHS). Human Immunol.2007;68(5):342-9. 
20. Gautam H, Saini S, Bhalla P, Singh T. Use of total lymphocyte count to 
predict absolute CD4 count in HIV-seropositive cases. J Int Assoc Physicians 
AIDS Care (Chic). 2010;9:292-5. 
21. Moore DM, Awor A, Downing RS, Were W, Solberg P, Tu D, et al. 
Determining eligibility for antiretroviral therapy in resource-limited settings 
using total lymphocyte counts, hemoglobin and body mass index. AIDS Res 
Ther. 2007;4:1. 
22. Liu FR, Guo F, Ye JJ, Xiong CF, Zhou PL, Yin JG, et al. Correlation analysis 
on total lymphocyte count and CD4 count of HIV-infected patients. Int J Clin 
Pract. 2008;62:955-60. 
Total lymphocyte count as a tool for starting ART 
 
49 
 
3 
23. World Health Organization. Antiretroviral therapy for HIV infection in adults 
and adolescents: Recommendations for a public health approach. 2006 
revision. 2006. 
24. Anastos K, Shi Q, French AL, Levine A, Greenbalt RM, Williams C, et al. Total 
lymphocyte count, hemoglobin, and delayed-type hypersensitivity as 
predictors of death and AIDS illness in HIV-1-infected women receiving highly 
active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35:383-92. 
25. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, et al. Prognostic 
importance of anaemia in HIV type-1-infected patients starting antiretroviral 
therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 
2008;13:959-67. 
26. Post FA, Wood R, Maartens G.CD4 and total lymphocyte counts as predictors 
of HIV disease progression. QJM. 1996;89:505-8. 
27. Wisaksana R, Indrati AR, Fibriani A, Rogayah E, Sudjana P, Djajakusumah T, 
et al. Response to first-line antiretroviral treatment among human 
immunodeficiency virus-infected patients with and without a history of 
injecting drug use in Indonesia. Addiction. 2010;105:1055-61. 
28. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly 
active antiretroviral therapy in resource-limited settings. AIDS. 2003;17:541-5. 
29. Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Mehta K, Solomon S, et 
al. Changes in total lymphocyte count as a surrogate for changes in CD4 
count following initiation of HAART: implications for monitoring in resource-
limited settings. J Acquir Immune Defic Syndr. 2004;36:567-75. 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
50 
 
 
 
 
 
 
 
 
 
 
51  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total lymphocyte count is a reliable Surrogate 
marker for CD4 cell counts after the first year 
of antiretroviral therapy;  
data from an Indonesian cohort study 
 
 
Marrigje A. de Jong1, Rudi Wisaksana2, Hinta Meijerink1, Agnes R Indrati3,  
Andre J.A.M. van de Ven1, Bachti Alisjahbana2, Reinout van Crevel1 
 
 
1 Department of Internal Medicine, Radboud University Nijmegen Medical Centre, 
Nijmegen, the Netherlands 
2 Internal Medicine Department at Medical Faculty, Padjadjaran University,  
Hasan Sadikin Hospital, Bandung, Indonesia 
3 Clinical Pathology Department at Medical Faculty, Padjadjaran University, 
Hasan Sadikin Hospital, Bandung, Indonesia 
 
 
Published in Tropical Medicine & International Health 2012;17(5):581-3 
Chapter 4 
Chapter 4 
 
 
52  
Abstract 
Many studies have evaluated the total lymphocyte count (TLC) as a cheap 
surrogate marker for CD4-cells in HIV-infected patients not receiving 
antiretroviral therapy (ART). We assessed if TLC can replace CD4 cell counts in 
evaluating the immunological response to ART. In a cohort of patients in 
Indonesia TLC, if measured after at least 1 year ART, correctly identified 
patients with < 200 CD4-cells, and reliably excluded immunological failure, 
obviating the need for CD4-cell measurement in 43% of patients.  
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The gold standard for monitoring HIV treatment is regular measurement of 
circulating HIV-RNA but in many low- and middle-income countries this is not 
routinely available. Measurement of circulating CD4 cells is an accepted 
alternative strategy and basis for the WHO criteria for immunological failure. 
However, also CD4 cell count measurements are often unavailable and costly in 
countries with a high HIV disease burden. Therefore the role for TLC as a 
relatively cheap surrogate marker has been assessed in ART-naïve patients. 
We ourselves found that a simple algorithms including TLC, anemia and oral 
candidiasis more reliably predicted CD4 cell counts necessitating ART than the 
WHO algorithms, while saving on average $14.05 per patient as a replacement 
of CD4 [1]. TLC as a surrogate for CD4 cell counts during ART would lead to 
even bigger cost savings given the fact that patients on ART require lifelong 
monitoring. However, only a handful of studies have examined TLC in patients 
on ART. Some studies found TLC to be a useful prognostic marker [2,3] with 
satisfactory correlation with CD4 [4,5] while others did not [6]. Most studies were 
conducted in industrialized countries [7] or in Africa [2,4], to our knowledge none 
were done in South-east Asia. We therefore compared TLC and CD4 cell counts 
in a cohort of patients receiving ART in Indonesia over time, aiming to define 
optimal cut-off values of single or repeated measurements in different 
subgroups of patients to identify the need for PJP prophylaxis or expand 
counseling for adherence. 
From a cohort of HIV patients in Indonesia [8] 287 consecutive patients were 
prospectively followed for a minimum of 6 months after starting ART. The mean 
duration for follow up after starting ART was 469 days (IQR: 357-652) and 73% 
of the patients, of whom 76% male, were followed more than 365 days.  The 
TLC was measured using the Cell Dyne 3000 (Abbott, Jakarta) and the CD4 cell 
count using flow cytometry (FACS-count, BD Biosciences, Jakarta). In total 436 
paired TLC and CD4 cell count measurements were available at two 
consecutive time points with a mean interval of 148 (±SD: 27) days between 
measurements. Differences in TLC and CD4 cell count trajectories over time 
were defined using Wilcoxon statistics. Models for regression analysis and 
Receiver Operation Curves were computed to determine TLC cut-off points 
corresponding with a CD4 cell count of 200 cells/µl. Single TLC values and 
changes of TLC over time (∆TLC) were compared with WHO-defined criteria for 
immunological failure during ART as defined as: a persistent CD4 level below 
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100 cells/µl after at least 6 months of ART; a fall to the pretreatment baseline 
CD4 cell count or below; or a 50% drop from the on-treatment peak level [9]. 
Additionally we looked at several co-variables: gender, body mass index, 
intravenous drug use, hemoglobin, tuberculosis and oral candidiasis. 
We included 211 males and 76 females, with a mean age of 29 years (SD 5.3). 
Most patients had advanced disease at baseline with a median CD4 cell count 
of 37 cells/µl (IQR: 11 - 95) and a corresponding median TLC of 1070 cells/µl 
(IQR: 726 - 1465). During the course of ART the TLC and CD4 cell count 
increased gradually with comparable trajectories for both markers and a sharp 
increase in the first 4 months. The CD4 cell count as a percentage of TLC also 
showed a significant increase during treatment from: 3.7% (IQR:  1.6-7.9) during 
the first 3 months, to 9.5% (IQR: 6.6-14.3) after 4-9 months, 11.4% (IQR: 8.9-
15.3) after 10-15 months and 13.3% (IQR: 9.3-17.6) after 16 months of ART 
(p<0.001). This shows that the contribution from the CD4 cell count as part of 
the TLC increases over time during effective ART. The correlation between TLC 
values and CD4 cell counts was poor during the first year of ART (r2=0.08), but 
better afterwards (r2=0.32; p <0.001). 
We first examined if TLC could be used to identify patients with CD4 cell counts 
< 200/µl, who would qualify for Pneumocystis jirovecii pneumonia (PJP) 
prophylaxis. After the first year of ART, a CD4 cell count <200 cells/µl can 
reliably be excluded in male patients with a TLC >2300 cells/µl (sensitivity 0.96 
and specificity 0.54) and in female patients with a TLC >1400 cells/µl (sensitivity 
0.88 and specificity 0.81), both with a negative predictive value (NPV) of 0.69. 
(figure 1) Applying these TLC cut-off points in our population would reduce CD4 
cell measurements with 43% (95% CI 35.6-50.4). Next we examined if a change 
in TLC can be used to identify patients with immunological failure. Thirty-one 
patients (10.8%) met the WHO-definition of immunological failure. An average 
decrease in TLC of > 5% per month was suggestive for immunological failure 
during ART (OR 4.9, 95% CI: 1.8-13.3). Any increase in TLC precluded 
immunological failure. Both for identifying CD4 cell counts <200 cells/µl and 
immunological failure, adding additional variables: body mass index, intravenous 
drug use, hemoglobin, tuberculosis and oral thrush did not improve the 
algorithm. 
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In conclusion, TLC can be used as an alternative to CD4 cell measurements 
during ART, but not during the first year of treatment. TLC can identify patients 
with immunological failure, and help clinicians decide about stopping PJP-
prophylaxis without the need for CD4 cell testing. As such, TLC obviates the 
need for routine measurement of CD4 cell counts in many cases, thereby 
reducing the costs of laboratory monitoring of HIV treatment. We found different 
TLC thresholds for men and women; adding other variables showed no 
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significant benefit. Further studies are needed to examine if combining TLC with 
clinical markers (e.g. pill counts) can more accurately predict immunological or 
virological failure to treatment and we highly encourage continuous research 
with ∆TLC as immunological marker in a larger setting. Some caution is 
warranted in interpreting our research findings given the relatively small study 
population, which came exclusively from Indonesia. 
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Abstract 
Background :  
Anemia is a common clinical finding in HIV-infected patients and iron deficiency 
or redistribution may contribute to the development of low hemoglobin levels. 
Iron overload is associated with a poor prognosis in HIV and Hepatitis C virus 
infections. Iron redistribution may be caused by inflammation but possibly also 
by hepatitis C co-infection. We examined the prevalence of anemia and its 
relation to mortality in a cohort of HIV patients in a setting where injecting drug 
use (IDU) is a main mode of HIV transmission, and measured serum ferritin and 
sTfR, in relation to anemia, inflammation, stage of HIV disease, ART and HCV 
infection. 
 
Methods:  
Patients characteristics, ART history and iron parameters were recorded from 
adult HIV patients presenting between September 2007 and August 2009 in the 
referral hospital for West Java, Indonesia. Kaplan-Meier estimates and Cox’s 
regression were used to assess factors affecting survival.  Logistic  regression  
was  used  to  identity  parameters associated  with  high ferritin concentrations. 
 
Results : 
Anemia was found in 49.6% of 611 ART-naïve patients, with mild (Hb 10.5 - 
12.99 g/dL for men; and 10.5 – 11.99 g/dL for women) anemia in 62.0%, and 
moderate to severe anemia (Hb < 10.5 g/dL)  in  38.0%.  Anemia  remained  an  
independent  factor  associated  with  death,  also  after adjustment for CD4 
count and ART (p=0.008). Seroprevalence of HCV did not differ in patients with 
(56.9%) or without anemia (59.6%). Serum ferritin concentrations were elevated, 
especially in patients with anemia (p=0.07) and/or low CD4 counts (p<0.001), 
and were not related to hsCRP or HCV infection. Soluble TfR concentrations 
were low and not related to Hb, CD4, hsCRP or ART. 
 
Conclusion :  
HIV-associated anemia is common among HIV-infected patients in Indonesia 
and strongly related to mortality. High ferritin with low sTfR levels suggest that 
iron redistribution and low erythropoietic activity, rather than iron deficiency, 
contribute to anemia. Serum ferritin and sTfR should be used cautiously to 
assess iron status in patients with advanced HIV infection. 
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Introduction 
Anemia is a common clinical finding in HIV-infected patients and is associated 
with advanced disease, lower quality of life and higher mortality [1-4]. Many 
factors  may  contribute  to the development of anemia in HIV-infected patients 
including nutritional deficiencies, opportunistic infections, AIDS-related 
malignancies, drug treatment and a direct effect of HIV on the bone marrow [4]. 
Iron deficiency and inflammation-induced iron maldistribution may also 
contribute to HIV-associated anemia [5,6]. Due to the effects of inflammation, 
iron is diverted from the circulation into the reticulo-endothelial system and other 
storage sites. Apart from inflammation, also HCV may possibly contribute to 
redistribution of iron [7]. Hepcidin plays an important role in these processes 
[8,9], by limiting the availability of iron for hematopoiesis [10]. Iron 
maldistribution  may have another unwanted effect; it may increase susceptibility 
to opportunistic infections, and accelerate disease progression [7,11-14], 
Indeed, iron overload is associated with a poor prognosis in HIV and Hepatitis C 
virus infections [7]. 
Serum concentrations of ferritin and soluble transferrin receptor (sTfR) are 
frequently used to assess iron status [15]. Low ferritin is an indicator of iron 
deficiency, but as ferritin is also an acute phase reactant its interpretation is 
difficult in the presence of inflammation. Levels of sTfR are predominantly 
determined by the erythropoietic activity. Iron deficiency leads to increased 
erythroblast numbers and increased TfR expression and thus to considerably 
elevated sTfR levels. 
In contrast, anemia of inflammation is characterized by normal sTfR levels [6,16]. 
So far, limited and sometimes contradictory reports have been published on 
ferritin and sTfR in HIV-infected patients. High plasma ferritin concentrations 
have been found among HIV-infected patients [14,17-19], while other studies 
have reported low ferritin concentrations [20-21]. Co-infection with hepatitis C 
virus (HCV) may further complicate the assessment of iron status, as HCV 
infection is associated with high plasma ferritin concentrations.[22]. With 
respect to sTfR levels in HIV patients, two studies found sTfR within the normal 
range [14-18], suggesting that sTfR is not affected by HIV infection [12]. 
However, this is in contrast with two other studies showing an increase in sTfR 
concentrations after initiation of antiretroviral treatment (ART) [19-21]. 
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In the present study, we examined the prevalence of anemia and its relation to 
mortality in a cohort of HIV patients in a setting where injecting drug use (IDU) is 
the main mode of HIV and HCV transmission [23]. We also measured serum 
ferritin and sTfR, in relation to anemia, inflammation, stage of HIV disease, 
ART and HCV infection. 
 
Methods 
Setting and design 
This cohort study was conducted at Hasan Sadikin hospital as the referral 
hospital for HIV in West Java, Indonesia. As one of the first 25 hospitals 
selected by the Indonesian government to provide HIV-care, Hasan Sadikin 
hospital has delivered free antiretroviral treatment and PCP-prophylaxissince 
December 2004. Following WHO and national guidelines [24-25], ART is 
indicated for patients presenting with WHO clinical stage IV, WHO clinical 
stage III with a CD4 count below 350/mm3, or WHO clinical stage I or II with 
a CD4 count below 200/mm3. The national program provides choice of 
nevirapine (NVP), efavirenz (EFV), zidovudine (ZDV), stavudine (d4T) and 
lamivudine (3TC) as first-line ART. For this study, we included all HIV-
positive patients above 14 years old presenting between September 2007 and 
August 2009. All patients signed informed consent and the study was 
approved by the hospital ethical committee. 
Data collection and laboratory examination 
At time of first presentation at the hospital, all patients (both ART-naïve and 
ART-experienced) have a ‘baseline visit’ for structured interviewed and 
laboratory examination. Afterwards they come or scheduled visits, once-
monthly when on ART, three- to six-monthly when not on ART. ART naïve 
patients were compared with patients with a favorable effect of ART, 
excluding those that with less than three months of ART, those who had ever 
interrupted ART for more than one month, those who had detectable  HIV-RNA  
after six months ART, and those taking 2nd ART. At presentation, data collected 
included gender, age, history of injecting drug use, body mass index (BMI, 
kg/m2), WHO stage, oral candidiasis, and history of ART or tuberculosis (TB) 
treatment. For ART-experienced patients, treatment duration and regimen were 
recorded. During follow-up, death was recorded from medical records. 
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Laboratory examinations included hemoglobin, red cell indices (Cell Dyne 
3000, Abbot) and manual reticulocyte counts. Reticulocyte  index  was  defined  
as the reticulocyte percentage x  (measured hematocrit/normal hematocrit) 
[26].  Anti HCV antibodies were detected by an electrochemiluminescence   
assay, ECLIA (Elecsys 2010, Roche)  and   CD4-cell   count   by flowcytometry 
(BD Biosciences, Jakarta, Indonesia). In our setting, HIV-RNA (real time 
PCR, Abbott, USA) is only measured in patients taking ART, but not in ART 
naïve patients. Between January 2008 and June 2008 we also measured 
plasma ferritin (ECLIA method Elecsys 2010, Roche; reference range 30-
400 ng/mL for men and 35-150 ng/mL for women), soluble Transferin 
Receptor (sTfR) (enzyme Immunoassay method, Diamed, Eurogen; 
reference range 1870-2450 U/mL) and high sensitive C-Reactive Protein 
(hsCRP) (immunoturbidimetry method, Hitachi 912, Roche; reference < 5 
mg/L) in newly diagnosed patients. We defined ferritin as ‘high’ if it was 
above the upper reference value. 
Data analysis and statistics 
WHO/ACTG criteria were used to define mild (Hb 10.5 - 12.99 g/dL for men; 
and 10.5–11.99 g/dL for women), moderate (Hb 8.0–10.49 g/dL) and severe 
(Hb < 8.0 g/dL) anemia [27,28]. As diagnosis of TB is difficult in HIV-positive 
patients in this setting due to its paucibacillary nature and the  fact  that  many 
patients  are  unable  to  expectorate  sputum [29]. we  considered  all  patients 
receiving TB treatment within three months after presentation as having TB 
co-infection. Mortality data were derived from clinical files, reports from 
community organizations or phone interviews from the clinic. Patients not 
returning for more than three months without confirmation of death or transfer 
were considered lost to follow-up. Data are presented as proportions or 
median with inter quartile range if not normally distributed. Categorical and 
continuous data were compared using the Chi-squared and Kruskal-Wallis tests 
respectively. Progression to death was measured by Kaplan - Meier estimates 
with Cox-regression to examine factors in baseline visits that affecting 
survival. Ferritin and sTfR concentration divided based on manufacturers 
reference values. Cox-proportional hazard regression model was used to 
investigate association between iron inflammatory parameters and mortality. 
Clinical parameters were examined as a possible determinant of mortality and 
high ferritin concentrations using logistic regression models. Variables which 
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were significantly associated in univariate analysis (p < 0.05) were used in the 
final backward stepwise multivariate regression model. Proportionality was 
first assessed by generating time dependent covariates of interactions 
between predictors and survival function. Log-transformed ferritin and sTfR 
values were used to examine the relation between ferritin, sTfR, CRP and 
CD4. All statistical analysis was done using SPSS version 16.0.2 and Prism 4 
for Windows. 
 
Results 
Patient characteristics 
A total number of 869 HIV positive patients were enrolled in this study, 70.3% 
(611) of whom were ART naïve, and 258 (29.7%) of whom were on ART (figure 
1).  Table 1 shows the baseline patient characteristics. 
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ART naïve patients 
In this group, mild, moderate and severe anemia was present in 30.4%, 14.1%, 
and  4.6%, respectively, while hemoglobin levels were missing for 7 patients 
(1.1%). Clinical characteristics of ART-naïve patients, stratified according to 
anemia category are presented in table 1. Most ART-naive patients 
presented with advanced HIV infection or AIDS; 66.7% had a CD4-cell count 
below 200 cells/mm3, and 62.8% were in WHO stage III/IV. Malnourishment, 
defined as a body mass index (BMI) below 18.5 kg/m2 was found in 38.0% 
of patients; severe malnourishment (BMI < 16 kg/m2) was found in 12.7% of 
patients. One fifth (21.3%) of patients were already on TB treatment or started 
TB treatment within 3 months of presentation, 58.5% were co-infected with 
HCV, and oral candidiasis was diagnosed in 27.8% of patients. 
 
Anemia in ART-naïve HIV patients was mostly normocytic, normochromic and 
characterized by a normal or low reticulocyte index suggesting ‘anemia of 
chronic disease as the main cause. Anemia was associated with a low CD4-
cell count (p<0.001), and TB treatment (p<0.001) (table 1). Hepatitis C co-
infection prevalence was not different in patients with and without anemia 
(56.9% vs. 59.6%, p=0.54). During follow-up, 314 patients (51.4%) started 
ART after a median of 28 days (IQR:1 9-55). The majority of patients (70.1%), 
none of whom had moderate or severe anemia, were started on a ZDV-
containing regimen. From this group, 13.6% developed anemia during 
follow-up and were subsequently switched from ZDV to d4T. 
 
Mortality in ART-naïve patients 
Anemia was associated with increased mortality during follow-up. When 
611 ART-naïve patients were followed for a median of 4.4 (IQR: 0.0-2.1) 
months (total follow-up: 335 person-years), 45 patients (7.4%, IQR: 5.3%-
9.5%) died and 121 (19.8%, IQR: 16.6%-23.0%) were lost to follow-up    
(figure 1). Mortality (75.6% of the total) and loss to follow-up (92.6% of the 
total) were highest in the first 6 months after presentation. Using Kaplan-Meier 
estimates, the survival rates at 6 months were 98.6% (95% CI: 97.3-99.9%) 
for patients without anemia, 95.1% (92.0-98.5%) for patients with mild 
anemia and 82.5% (75.5-89.4%) for patients with moderate or severe 
anemia (P < 0.001; figure 2). Beside a CD4 cell count below 50/mm3  (HR: 
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5.7, IQR: 1.6-17.8, p=0.003), moderate to severe anemia remained 
independently associated with an increased risk of death in multivariate  
analysis  (HR:  6.5,  IQR:  2.0-21.2,  p = 0.002)  (table  2),  This  association  
remained significant after eliminating subjects with tuberculosis co-infection, 
which is an important risk factor for death. 
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Iron status parameters in ART-naïve patients 
Serum ferritin, sTfR, CRP and reticulocyte index were measured in a 
subgroup of 141 randomly selected patients. ART-naive patients (n=95) with 
available iron parameters had very high plasma ferritin concentrations 
(median 641 ng/mL, IQR: 242-1296), moderately elevated CRP concentrations 
(median 6 mg/mL, IQR: 2-34), low sTfR concentrations (median 1014 U/mL, 
IQR: 736-1322), and normal reticulocyte counts (median 0.8%, IQR: 0.6-1.5%). 
 
Very high ferritin concentrations were found in subjects with CD4 counts below 
or equal to 50 cells/mm3 (median 1078 mg/ml, IQR: 550-1824) compared to 
subjects with CD4 counts above 50 cells/mm3 (median 279 mg/ml, IQR: 41-
465, p<0.001), and in subjects with moderate-severe anemia (median 1223 
mg/ml, IQR: 519–2764) compared to subjects without (median 436 mg/ml, 
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IQR: 245-1296. p=0.07) or with mild anemia (median 532 mg/ml, IQR: 194-1099,  
p=0.01). Moderately elevated hsCRP levels were also found in subjects with 
CD4 counts below or equal to 50 cells/mm3
  (median 12.2 mg/L, IQR: 2.0-63.2) 
compared to subjects with CD4 counts above 50 cells/mm3
  
(median 4.9  
mg/ml,  IQR:  1.5-17.2,  p=0.08),  and in subjects  with moderate-severe anemia 
(median 18.4 mg/ml, IQR 4.5–94.4) compared to subjects without (median 2.0 
mg/ml, IQR: 1.4-5.4, p=0.001) or with mild anemia (median 6.0 mg/ml, IQR: 
1.2-27.8, p=0.03). Subjects with high ferritin, high hsCRP or low sTfR 
concentrations showed a higher mortality during follow-up, although this was 
not statistically significant (table 3). Low ferritin levels (<30 mg/ml) were found 
in 6.3% of patients, all were women with a CD4 cell count above 200 
cells/mm3. There was a significant negative correlation between ferritin 
concentrations and CD4 count (figure 3). 
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Predictors of hyperferritinemia in ART-naïve patients were subsequently 
determined in a univariate and multivariate model (table 4).  CD4 cell count 
below 50/mm3 and hsCRP > 5 mg/L were associated with hyperferritinemia 
after correction for gender, degree of anemia, and HCV co-infection. After 
exclusion of patients with tuberculosis co-infection, low CD4 count was the 
only factor associated with hyperferritinemia. 
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ART experienced patients 
At time of enrollment in the cohort, 258 patients were already taking 1st line 
ART, for a median of 24.0 months (range: 3.3-96.3 months). The majority 
of patients were on a ZDV containing regimens (62.8%), the others on a d4T 
containing regimen. Anemia was less common in patients taking ART: 14.3% 
had mild, 1.9% had moderate, and no patient had severe anemia (p<0.001) 
(table 1). The use of ZDV was associated with anemia: among patients 
taking ZDV, 20.3% had anemia, compared with 7.4% among those who were 
not taking ZDV (p=0.01). During a median 19.8 months (IQR: 9.8-20.0), 2 (0.8%) 
ART experienced patients died and 26 (10.1%) were lost to follow-up. 
 
Patients taking ART seemed to have lower plasma ferritin concentrations 
(median 304.1 ng/mL, IQR; 160.7-574.6) compared to ART-naïve patients, 
although this was not statistically significant (p=0.12). In addition, they had 
lower hsCRP values (median 3.0 mg/mL, IQR: 0.9-6.3, p=0.02), but similarly 
low sTfR concentrations (median 1378.5 U/mL, IQR: 1104.3-1798.5, p=0.95) 
compared to ART-naïve patients. Duration of ART was not associated with 
plasma concentrations of ferritin or sTfR (data not shown). There was a 
significant negative correlation between ferritin concentrations and CD4 count 
in ART-naïve patients, but not in patients taking ART (figure 3). 
 
 
Discussion 
The results from our study indicate that anemia is highly prevalent among HIV 
patients in Indonesia and that moderate to severe anemia is strongly related to 
mortality. This is in line with findings from other studies [2,3,30-32]. We also 
report serum concentrations of ferritin and sTfR, both of which are often used 
for assessment of iron status. High serum ferritin concentrations were found, 
especially in patients with CD4 cell counts below 200 cells/mm3. Iron 
redistribution in the setting of a prolonged acute phase response is most 
likely responsible for this observation and this may explain the reported iron 
excess in the liver, bone marrow and other organs during the advanced 
stages of HIV [33]. Concentrations of CRP were however only moderately 
elevated and did not correlate well with ferritin concentrations. Although CRP 
is the most commonly used indicator of inflammation in daily practice, other 
Chapter 5 
 
74  
acute phase response proteins such as a-1-acid-glycoprotein (AGP) may 
better reflect serum ferritin changes in inflammation because AGP remains 
elevated for a much longer time in sub-clinical chronic infections compared to 
CRP [15-34]. 
 
We found that sTfR concentrations were generally low and not related to CD4 
count. This finding is in contrast to studies that showed that sTfR is not affected 
by HIV infection, even though these studies also report that sTfR alone has 
little value for differentiating anemia in the presence of infmammation. 
[12,35,36]. We hypothesize that low sTfR concentrations more likely reflects 
the presence of some degree of bone marrow suppression by HIV. Together, 
these findings suggest that both serum ferritin and sTfR concentrations may 
not be reliable indicators of iron status in advanced HIV infection. 
 
The prevalence of anemia was more than 40% in our untreated HIV-infected 
patients, more or less similar to studies from outside Indonesia [2,18,30,37]. 
Severe anemia was noticed in nearly 5% of our patients and this was higher 
compared to previous data from Europe [2] or Asia [3] but lower compared to 
a study from Africa [30]. Differences between the levels of immunodeficiency 
in the different studies may account for these differences. Our study also 
demonstrates that anemia is strongly related to increased mortality, as 
reported by others [2,3,30,31]. Interestingly, we found that this was also true 
after correction for CD4 cell count, indicating that anemia is an independent 
factor for HIV disease progression. 
 
Measurement of iron parameters in a sub-group of patients revealed marked 
elevations in plasma ferritin, in line with earlier studies [14,17-19,35]. Our 
study shows that high ferritin levels are strongly (and inversely) related to 
CD4 cell numbers but not to gender, HCV co-infection nor CRP as a marker of 
inflammation, as has been suggested by others [19,37]. Apart from the 
prolonged acute phase response, the inverse relation between ferritin and 
CD4 cell count may also be caused by increased oxidative stress [38]  related 
to depletion of CD4 cells [39]. Furthermore, The HIV virus itself may increase 
ferritin levels as HIV-1 Nef protein directly down-regulates the hemochroma-
tosis  protein HFE and as such causes iron accumulation [40]. However, the 
latter hypothesis was not supported by a study among HIV patients in 
Thailand, which reported no relation between serum ferritin  concentrations  
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and plasma HIV RNA [20]. Finally, the role of inflammation cannot be completely 
excluded since inflammatory pathways that do not include IL-6 and CRP can 
lead to high ferritin concentrations [41]. Interestingly, the inverse relation 
between ferritin levels and CD4 cell numbers disappeared after ART. This could 
be due to the effect of ART on oxidative stress, plasma HIV-RNA and/or 
inflammation. Our results argue against an important role of HCV as no 
relation was found between ferritin and HCV infection, although the number 
of subjects in whom all parameters were measured was limited. 
 
Low ferritin levels (<30 mg/ml) indicating iron deficiency were found in 6.3 % of 
our patients and in 18.5 % of the female patients. In previous studies from 
United States, iron deficiency anemia was found in 20% of HIV infected 
female injecting drug users [42], and iron supplementation was found to 
reduce anemia without adverse effects on HCV co-infection or plasma 
HIV-RNA [43]. However, iron supplementation should be done carefully and only 
in patients with iron deficiency as iron overload is associated with a poor 
prognosis of HIV-1 and hepatitis C virus infections and with growth of 
pathogenic microorganism [7]. Indeed, excess mortality was reported among 
HIV-infected patients   receiving   low-dose   oral   iron   with   dapsone   for   
Pneumocystis   carinii   pneumonia prophylaxis [11]. In our study, we did not 
find a significant relation between plasma ferritin level and mortality, even 
though those who died on average had two-fold higher plasma ferritin levels. 
Unlike ferritin, sTfR levels showed no association with CD4 cell counts, neither 
among ART-naïve nor among ART-experienced patients. Furthermore, sTfR 
levels were not different in anemic versus non-anemic subjects. Our sTfR 
levels seem slightly low, especially in ART-naive patients suggesting that 
reduced erythropoiesis may contribute to the development of anemia, although 
no relation was found between sTfR levels and the presence or degree of 
anemia. Plasma sTfR concentrations were not associated with mortality 
during follow-up. This was also found in other studies which showed an 
increase of sTfR following ART [19,21], and no relation between sTfR levels  
and disease progression [19]. 
 
Our study has several limitations as it was observational, and as iron 
parameters were only measured in a subset of patients. Furthermore, no 
data are available on food or micronutrient intake which might affect iron 
status, and on occurrence of other opportunistic infections causing anemia. 
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Tuberculosis could be important cause of anemia and could confound the 
results, although sensitivity analysis showed this was not the case. Furthermore 
we did not adjust ferritin concentrations for circulating HIV-RNA which are not 
measured routinely in ART naïve patients. To be able to see the effects of ART 
on iron parameters, we excluded non-adherent patients. Loss to follow-up may 
have affected the estimated mortality, although we believe this did not affect 
our conclusions, since there was no significant difference in clinical 
characteristics including degree of anemia and CD4 cell count between 
patients with and without follow-up (data not shown). Still, we can conclude 
that anemia, although usually mild, is highly prevalent in this setting and 
strongly related to immune-deficiency and mortality. Iron maldistribution and 
not iron deficiency seems to underlie the development of anemia while the 
role of compromised erythropoiesis and HCV co-infection seems limited. 
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Abstract 
Background: 
Distortion of iron homeostasis may contribute to the pathogenesis of human 
immunodeficiency virus (HIV) infection and tuberculosis (TB). We studied the 
association of the central iron-regulatory hormone hepcidin with the severity of 
HIV and the association between hepcidin and other markers of iron 
homeostasis with development of TB.  
 
Methods: 
Three groups of patients were selected from a prospective cohort of HIV-
infected subjects in Bandung Indonesia where injecting drug use is a common 
route of transmission. We included HIV patients starting TB treatment more than 
30 days after cohort enrollment and they were compared with matched (age, 
gender and CD4 cell count) and unmatched controls (CD4 cell counts above 
200 cells/mm3) without TB during follow-up. Iron parameters including hepcidin 
were compared using samples collected at cohort enrollment, and compared 
with recently published reference values for serum hepcidin.  
 
Results: 
A total of 127 HIV-infected patients were included, 42 developed TB, together 
with 42 matched controls and 43 unmatched controls. Patients with advanced 
HIV infection had elevated serum hepcidin and ferritin levels. Hepcidin levels 
correlated inversely with CD4 cells and hemoglobin. Cases who started TB 
treatment had significantly higher hepcidin and ferritin concentrations at cohort 
enrollment compared to matched controls, but this differences was fully 
accounted for by those starting treatment between day 31 and 60 after 
enrollment. Hepcidin levels were not different in those with or without hepatitis C 
infection. 
 
Conclusion: 
Iron metabolism is distorted in advanced HIV infection with CD4 cell counts 
correlating inversely with serum hepcidin levels. High serum hepcidin levels and 
hyperferritinemia were found in patients starting TB treatment shortly after 
cohort enrollment, suggesting that these markers may be useful predictors of 
manifest TB. 
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Introduction 
Alterations in iron distribution are common in infectious diseases and many of 
these alterations may be attributable to actions of hepcidin [1]. This hormone 
inhibits iron absorption in the intestine and locks iron into monocyte/ 
macrophages and the spleen, through degradation of the sole cellular iron 
exporter ferroportin [2]. 
 
Changes in iron homeostasis have been described in HIV-infected patients and 
several epidemiological studies have found an association between elevated 
iron status in advanced HIV disease and the risk for opportunistic infections and 
HIV progression [3,4]. HIV replication involves several iron-dependent steps [5], 
and as a central determinant of macrophage iron contents, hepcidin may play a 
distinct role in HIV pathogenesis. Indeed, hepcidin was recently shown to 
increase HIV-1 transcription in cultured monocytes and T-cells by degradation of 
ferroportin with a secondary increase in intracellular iron [6]. Hepcidin may also 
be involved in two important complications of human immunodeficiency virus 
infection/ acquired immune deficiency syndrome (HIV/AIDS). First, elevated 
hepcidin levels limit iron supply to the bone marrow and may thus contribute to 
HIV-associated anemia - a common complication of advanced HIV infection with 
significant impact on clinical outcome and quality of life [7-10]. Second, 
hepcidin-mediated iron accumulation in macrophages may increase the risk for 
outgrowth of intracellular pathogens like Mycobacterium tuberculosis. 
Worldwide, tuberculosis (TB) is the most important infectious disease 
complication among HIV-infected patients, and several lines of evidence 
suggest that macrophage iron content is related to the risk for developing active 
TB [11,12]. Interestingly, hepcidin itself has antibacterial activity and hepcidin 
was shown to inhibit M. tuberculosis growth in vitro [13].   
 
To our knowledge, no studies have reported levels of hepcidin in HIV-infected 
patients. The pro-inflammatory cytokine interleukin (IL)-6 is a dominant regulator 
of hepatic hepcidin production in bacterial infections and other inflammatory 
conditions, but IL-6 concentrations are often not or only mildly elevated in viral 
infections. Indeed, recent studies have shown that hepcidin levels are reduced 
in hepatitis C virus (HCV) infection, which may be related to pathological liver 
iron storage in patients with such chronic infection [14,15].  
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The present study was performed in Indonesia, which has one of the fastest 
growing HIV epidemics in Asia with a high rate of TB and hepatitis C co-
infection. Our primary aim was to study the effect HIV infection on serum 
hepcidin levels and other markers of iron homeostasis and to compare hepcidin 
levels with recently determined reference levels for hepcidin in healthy Dutch 
volunteers [16]. The secondary aim was to identify whether hepcidin and other 
markers of iron homeostasis were associated with development of TB more than 
30 days after inclusion in the study. Finally, we studied whether iron parameters 
were influenced by factors such as gender, anemia, the use and kind of 
antiretroviral treatment (ART) and HCV co-infection. 
 
 
Methods 
Patients and setting 
This study was conducted in a cohort of HIV-infected patients in Hasan Sadikin 
Hospital in Bandung, the referral hospital for HIV care in West-Java, as 
previously described [10]. Injecting drug use is an important route of HIV 
transmission in West Java and hepatitis C serostatus was therefore determined 
in all patients. Free anti-retroviral treatment (ART) is delivered since December 
2004. Following the 2006 World Health Organization (WHO) guidelines [17], 
indications for start of ART during the study period were: HIV stage IV 
irrespective of CD4 cell count; HIV stage III with a CD4 cell count of less than 
350 cells/mm3; and HIV stage I or II with a CD4 cell count less than 200 
cells/mm3. First-line ART includes the nucleoside reverse transcriptase inhibitors 
(NRTI’s) zidovudine, stavudine and lamivudine, and the non-nucleoside reverse 
transcriptase inhibitors (NNRTI’s) efavirenz and nevirapine.  
 
Since September 2007, all patients, aged 14 years and above presenting with a 
HIV infection were included in a prospective cohort study. Baseline enrollment 
consists of a structured interview, physical examination, chest X-ray and blood 
examination (with storage of serum at -800 C), the latter being performed within 
one week from initial presentation and enrollment. A number of patients were 
already under treatment in Hasan Sadikin hospital and other hospitals before 
cohort enrollment in 2007. After cohort enrollment, patients were scheduled for 
monthly follow up visits. 
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TB diagnosis followed national and WHO guidelines based on a combination of 
clinical features, imaging studies and sputum acid-fast bacilli (AFB) smear 
microscopy using Ziehl Neelsen (ZN) staining. Screening for active TB is 
conducted among all HIV-infected subjects at time of enrollment through 
screening for symptoms, chest X-ray, and, sputum microscopy if indicated. For 
research purposes, M. tuberculosis genotyping has been done in this setting 
using spoligotyping as previously described, revealing nontuberculous 
mycobacteria in < 1% of patients [18]. For this study, sputum smear-positive 
pulmonary TB was defined as at least one sputum smear positive for acid fast 
bacilli (AFB). Sputum smear-negative pulmonary TB as a chest radiography 
finding consistent with tuberculosis together with a lack of response to a trial of 
broad-spectrum antibiotics and at least 2 negative AFB sputum smears, 
including early morning samples. Finally, extra pulmonary TB was defined as a 
positive AFB smear or culture from appropriate biopsy material, 
histopathological findings consistent with tuberculosis, or clinical signs and 
symptoms consistent with extra-pulmonary tuberculosis [19].  
 
From September 2007 until August 2010, 1323 HIV-infected patients aged 14 
years old and above entered the cohort. Patients with signs or symptoms of an 
opportunistic infection or abnormalities at chest radiography at cohort enrollment 
(n=516) and patients who were started on anti-TB treatment within one month 
after cohort enrollment (n=9) were excluded from the present study. From the 
remaining 798 patients, 45 developed TB > 1 month after cohort enrollment and 
42 were included as cases in this study. From the remaining three, no serum 
samples were available. This one-month interval was deliberately chosen to 
avoid delayed diagnosis of co-existing subclinical tuberculosis already present 
at time of cohort enrollment. Two control groups of HIV-infected patients without 
a previous diagnosis of TB and without TB during follow were selected from the 
remaining 753 patients of our prospective HIV cohort: one group matched for 
age, gender and CD4 cell count (‘matched controls’; n=42), and one control 
group consisting of only moderately immunocompromised HIV-patients with a 
CD4 cell count > 200 cells/mm3 (‘unmatched controls’; n=43). From all included 
patients, a total number of 38 out of 127 (30%) were already on ART with a 
median duration of 455 days (IQR 75-1008 days). All participants provide written 
informed consent to participate in this study. This study was approved by the 
Hasan Sadikin Hospital ethical committee. 
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Laboratory methods 
Serum hepcidin and iron parameters were measured in archived serum 
collected at time of cohort enrollment in the Department of Laboratory Medicine 
of the Radboud University Medical Centre using a combination of weak cation 
exchange chromatography and time-of-flight mass spectrometry (TOF MS). This 
technique allows discrimination between the three naturally occurring isoforms 
of hepcidin (hepcidin-20, -22, and -25), of which only the 25 amino acid form can 
block the iron transporter ferroportin and is referred to as “bioactive” hepcidin. 
An internal standard (synthetic hepcidin-24; Peptide International Inc.) was used 
for quantification [20,21]. Peptide spectra were generated on a Microflex LT 
matrix-enhanced laser desorption/ionization TOF MS platform (Bruker 
Daltonics). Serum hepcidin-25 (further referred to as hepcidin) concentrations 
were expressed in nanomoles. The lower limit of detection of this method was 
0.5 nM; average coefficients of variation were 2.7% (intra-run) and 6.5% (inter-
run). The median level of serum hepcidin-25 concentrations in healthy Dutch 
male adults is 4.5nM, while the reference range (P2.5-P97.5) is < 0.5-14.7 nM; 
for premenopausal women these values are 2.0 nM (<0.5-12.3) [16,22].  
 
Serum concentrations of total iron, total iron binding capacity (TIBC), transferrin 
saturation (TS), ferritin, sTfR and C-reactive protein (CRP) were determined as 
described previously [23]. Reference ranges for concentrations of serum iron:   
10 – 25 μmol/L; transferrin saturation (TS): 30 – 60%; total iron binding capacity 
(TIBC): 45 – 80μmol/L: serum ferritin: 15 – 280 μg/L for males and 6 – 80 μg/L 
for premenopausal females; soluble transferrin receptor (sTfR): 0.76 – 1.76 
mg/L. For statistical analyses, the lower limit of detection for CRP (5 mg/L) was 
used in samples with values below this detection limit. A full blood count was 
measured on a Cell Dyne 3000 (Abbot) hematology analyzer. Anemia was 
defined according to World Health Organization/AIDS Clinical Trial Group 
(WHO/ACTG) criteria as a hemoglobin level below 13.0 g/dL for men and below 
12.0 g/dL for women. Anti-hepatitis C antibodies were tested by an 
electrochemiluminescence assay (ECLIA; Elecsys, Roche Diagnostics); CD4 
cell counts were determined by flow cytometry (BD Biosciences, Jakarta, 
Indonesia). Due to limited volume of archived samples, serum levels of ferritin 
and sTfR were available in only 107 patients and serum iron, TIBC, TS and CRP 
in 38 patients. 
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Data analysis and statistics 
Serum concentrations of hepcidin and other markers iron homeostasis were 
compared between cases and the two control groups. Subsequently, the effect 
of HIV infection on iron homeostasis was analyzed by comparing iron 
parameters in matched and unmatched controls with recently determined 
reference levels of serum hepcidin and by determination of the correlation of 
serum hepcidin levels with CD4 cell count. Finally, in the whole group of HIV-
infected patients, associations were examined between iron parameters and 
gender, anemia, ART and the presence of HCV antibodies. Data are presented 
as medians with interquartile range (IQR) unless otherwise stated. Paired 
analysis for cases and the matched control group was performed using the 
Wilcoxon signed-rank test for continuous variables and the Mc Nemar test for 
categorical variables.  Unpaired comparisons between cases and unmatched 
controls and between matched and unmatched controls were performed using 
the Mann-Whitney test and Chi-squared used. Comparison of median hepcidin 
levels in our study population with reference values was performed using the 
Wilcoxon signed-rank sum test. A two-sided P value of less than 0.05 was 
considered statistically significant. All statistical analyses were done by software 
SPSS version 17.0. 
 
 
Results 
Patient characteristics 
A total number of 127 HIV-infected patients were included in our study: 42 cases  
who developed TB during follow-up and two control groups, consisting of 42 
controls matched to cases for age, sex and CD4 cell count (‘matched controls’), 
and 43 unmatched controls with a CD4 cell count of more than 200 cells/ mm3 
(‘unmatched controls’). The majority of cases and matched controls had an 
advanced HIV infection with a median CD4 cell count of 30 and 70 cells/mm3, 
respectively; the unmatched controls were moderately immunocompromised 
with a median CD4 cell count of 365 cells/ mm3. Matched analysis did not found 
any difference between cases and matched control group for age, sex and CD4. 
Table 1 summarizes clinical and routine laboratory characteristics in study 
subjects at the time of cohort enrollment. In the cases, TB treatment was started 
a median of 125 days (IQR 44 – 238 days) after cohort enrollment. Thirty-three 
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patients (78%) of the cases had pulmonary TB; including 12 patients with AFB 
smear positive TB. Nine patients were diagnosed with extra-pulmonary TB of 
whom seven with lymphadenitis. The diagnosis of extra-pulmonary TB was 
made by histopathology examination in three cases and by a combination of 
clinical and radiological features, combined with a good response to anti-TB 
treatment in the remaining six. Ten of the cases had a history of TB-treatment, a 
median of 512 days (IQR 357-587 days) before enrollment which only case did 
not finished 6 months TB treatment due to side effect. By definition, the patients 
in the control groups had neither a history of TB, nor any signs or symptoms 
suggesting development of active TB. After cohort enrollment, 27 out of 31 
cases and 20 out of 31 matched controls initiated ART. CRP levels were only 
moderately elevated and mostly limited to the severely immunocompromised 
patients in the cases and matched controls group.  
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Iron parameters in relation to HIV status and CD4 cell count.  
Median serum hepcidin levels in the whole group of HIV-infected patients were 
above reference values for healthy Dutch adult males (7.3 vs. 4.5 nM; p<0.001) 
and premenopausal females (3.1 vs. 2.0 nM; p=0.028) [15,21]. However, these 
higher hepcidin were largely restricted to cases and matched controls, i.e. those 
with advanced HIV infection (table 2). The unmatched male controls had a 
similar median hepcidin level value as healthy Dutch adults (4.4 [2.1 - 8.1] nM), 
but female unmatched controls had a higher median hepcidin level (4.4 [1.5 - 
8.2] nM). The higher hepcidin levels in cases compared to unmatched controls 
were associated with higher serum levels of the iron storage protein ferritin and 
lower serum iron, TIBC and mean corpuscular volume (MCV) values (table 2). 
Serum hepcidin levels also correlated inversely with CD4 cell counts, 
hemoglobin levels and MCV, and positively with serum ferritin levels (figure. 
1B-D).  
 
 
 
 
 
 
 
 
 
 
 
 
Hepcidin in HIV –TB patients  
91 
 
6 
 
Chapter 6 
 
92 
 
 
Iron parameters and development of TB  
Compared to matched controls, cases starting TB treatment (‘cases’) more than 
30 days after enrollment had significantly higher serum hepcidin (p=0.035) and 
ferritin levels (p=0.006) (table 2). However, this difference was fully accounted 
for by the cases starting TB treatment between day 31 and 60. Compared to 
those starting TB treatment more than 60 days after cohort enrollment, the 
cases had significantly higher serum hepcidin and ferritin levels at cohort 
enrollment with median (IQR) serum levels for hepcidin of 16.1 nM (8.4 – 20.6 
nM) vs. 5.8 nM (4.1 – 14.1 nM; p=0.01) and for ferritin of 1206 µg/l (591 – 1799 
µg/l) vs. 310 µg/l (190 – 887 µg/l; p=0.004), despite the fact that clinical and 
radiological examination showed no signs for TB at cohort enrollment. There 
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were no significant differences in either hepcidin or other iron indicators between 
cases starting TB treatment more than 60 days after cohort enrollment and their 
matched controls. Combining all cases of pulmonary TB, smear positive 
pulmonary tuberculosis was associated with a significantly higher serum 
hepcidin level at cohort enrollment than smear negative tuberculosis (15.9 nM 
[13.1 - 21.9 nM] vs. 5.3 nM [4.1 - 5.5 nM] nM; p=0.003). In addition, cases 
developing extrapulmonary TB had significantly higher ferritin levels at cohort 
enrollment than cases with pulmonary TB (1351 μg/L [725 - 1800 μg/L] vs. 491 
μg/L [193 - 1250 μg/L]; p=0.03), but similar hepcidin levels (9.4 nM [6.0 - 11.8 
nM] vs. 11.5 nM [4.9 - 17.0 nM]; p=0.47).  
 
 
Other factors affecting iron parameters.  
Apart from HIV and/or TB infection, iron parameters may be influenced by other 
factors such as gender, anemia, the use and kind of ART and HCV co-infection. 
As shown in table 3, women had significantly lower serum hepcidin and ferritin 
levels than men (p<0.01) owing to their lower total iron stores. Second, anemic 
patients had higher ferritin and hepcidin levels (p<0.001 and p=0.05, 
respectively) together with a lower value of TIBC (p<0.001), which is consistent 
with anemia of chronic disease. Third, patients taking stavudine had somewhat 
higher hepcidin concentrations than those taking zidovudine, although this 
difference was not statistically significant (p=0.24) and might have been caused 
by bias by indication as anemic patients are usually prescribed stavudine. 
Finally, HCV-infected patients had slightly higher serum hepcidin, ferritin and 
transferrin saturation levels, although these differences were not statistically 
significant.  
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Discussion 
Different studies have shown that disturbances in iron homeostasis and anemia 
are associated with advanced HIV infection and an adverse outcome [3,4,8,24]. 
To our knowledge, this study is the first to report values for the central iron 
regulator hepcidin in patients with HIV. Our data show that serum hepcidin 
levels were increased in Indonesian patients with advanced HIV infection. In 
contrast, HIV-infected patients without TB and with CD4 cell counts above 200 
cells/mm3 (unmatched controls) had similar serum hepcidin levels as healthy 
Dutch adults. Inflammatory cytokines, especially IL-6, are important inducers of 
hepatic hepcidin expression. Our observation of an inverse relation of CD4 cell 
counts with serum hepcidin levels and the fact that elevated CRP levels were 
more common in those with advanced HIV-infection support the notion that 
elevated hepcidin levels in advanced HIV are predominantly caused by HIV-
associated inflammation. Moreover, only few of the unmatched controls with 
CD4 cell counts above 200 cells/mm3 had an elevated CRP level (6.7%), and 
this may explain why this group had similar hepcidin levels as healthy Dutch 
individuals. Other HIV-specific mechanisms, apart from inflammation, may also 
contribute to higher hepcidin levels. HIV can directly infect bone marrow 
progenitor cells leading to bone marrow suppression, which is associated with 
upregulated hepcidin expression [25,26]. Zidovudine is also known for its 
suppressive effect on the bone marrow, but use of zidovudine was not 
associated with higher hepcidin levels in our study.  
 
Our finding of increased hepcidin expression with secondary iron dysregulation 
in advanced HIV infection may have several clinical consequences. First, 
increased hepcidin expression leads to macrophage iron loading and this may 
be associated with a higher risk for intracellular infections. This also applies to 
M. tuberculosis, which needs iron for its multiplication, and macrophage iron 
loading might thus stimulate development of TB. In our present study, we indeed 
found higher serum hepcidin and ferritin levels at cohort enrollment in those who 
subsequently started TB treatment, but these higher levels were restricted to 
those starting treatment from day 31 to 60 after enrollment. Recent studies have 
shown that M. tuberculosis and mycobacterial components may also induce 
hepcidin and we speculate that the presence of subclinical TB at cohort 
enrollment may have explained these higher hepcidin and ferritin levels [13,27]. 
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Alternatively, higher hepcidin and ferritin levels may put HIV-infected patients at 
an increased risk for TB reactivation of TB immune reconstitution inflammatory 
syndrome (IRIS). The latter seems less likely, however, especially because 
hepcidin not only functions as an iron regulator, but also possesses antibacterial 
effects. Indeed, other authors have suggested increased hepcidin production in 
response to M. tuberculosis infection to represent a host defense mechanism 
[13,27]. A second possible clinical consequence of the high hepcidin levels is its 
effect on HIV progression. Several lines of evidence suggest that iron 
accumulation in macrophages promotes HIV progression (reviewed in 
Drakesmith et al, [5]). Hepcidin regulates macrophage iron content by binding to 
and degrading the sole iron exporter ferroportin [2], and a recent ex vivo study 
showed that hepcidin increases HIV transcription [6]. Chronic inflammation with 
prolonged hepcidin over-expression may thus explain earlier findings of a 
positive correlation between the degree of iron loading in macrophages and 
mortality [3]. Third, hepcidin has turned out to be a central mediator of the 
anemia of inflammation by reducing iron absorption from the intestine and iron 
recycling by macrophages of the spleen and the reticulo-endothelial system. 
Over-expression of hepcidin in transgenic mice indeed led to typical features of 
anemia of inflammation [28]. Hepcidin can also directly inhibit red blood cell 
production during inflammation [29]. Anemic patients in our study had 
significantly higher hepcidin levels and there was a negative correlation of 
hepcidin levels with hemoglobin levels. Thus, prolonged HIV-associated 
changes in absorption and distribution of iron through the actions of hepcidin are 
likely to contribute to the still insufficiently understood anemia of advanced HIV 
infection. 
 
Serum ferritin levels were strongly elevated in patients who developed 
tuberculosis 31-60 days after enrollment. Several mechanisms may explain the 
high ferritin level in these patients. First of all, ferritin is an acute phase protein 
and inflammation can independently increase ferritin expression. Unfortunately, 
sufficient data to analyze this further were not available. Other factors that may 
contribute to high ferritin levels include HIV [30], chronic liver disease [31], 
metabolic syndrome or iron loading anemia. Some of these factors do not seem 
relevant: increased ferritin levels were not noticed in control patients with an 
untreated HIV infection nor in those with HCV infection. Alcoholic liver diseases 
is also very rare in our Muslim population while none of the patients was known 
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with an iron loading anemia or a history of recent blood transfusion. Although 
obesity and hypertension are rare in our population, a trend for higher 
triglyceride and random blood glucose levels was noticed in the cases, 
suggesting some metabolic disturbance. A fatty liver with hyperferritinemia can 
also be seen in other conditions such as rapid weight loss, starvation, and use 
of illicit drugs [32]. Interestingly, a large autopsy study from India revealed that 
tuberculosis was the second commonest cause of steatohepatitis [33] and 
severe hyperferritinemia in Mycobacterium tuberculosis infection has recently 
been reported, especially among HIV-infected patients [34]. Our results were 
however not obtained from patients with active TB but an average of 125 days 
earlier when no signs of an active (opportunistic) infection were present.  
Possibly, serum ferritin may thus be a useful and low-cost marker to predict the 
change for development of TB in near future. Hepcidin seems less useful for this 
purpose because of its high cost and limited availability of assays.    
 
As injecting drug use is the main route of HIV transmission in this study, many 
patients are also infected with hepatitis C. Chronic hepatitis C has been 
associated with disturbances in iron homeostasis, most prominently iron 
accumulation in hepatocytes [35]. Two recent studies found relatively low 
hepcidin levels in patients with HCV, suggesting that HCV impairs hepcidin 
production, which may in turn contribute to high iron contents of the liver [14,15]. 
These findings could not be confirmed in our study, which is the first study to 
report data in HCV/HIV co-infected patients.  
 
Our study has several limitations. First, in more than 50% in all cases there was 
no culture confirmation of TB. Unfortunately, it is well known that sputum 
microscopy and culture both suffer from decreased sensitivity in HIV-infected 
individuals [36,37]. Second, as also mentioned above, we cannot exclude with 
certainty that TB was already present in some of the cases during cohort 
enrollment, even though clinical and radiological examination failed to show any 
signs of active TB. The fact that as much as 85% of cases and matched controls 
had a CD4 count below 200 cells/mm3 at cohort enrollment enhances the risk for 
subclinical TB.  Third, development of an IRIS against TB following the start of 
ART is common in this setting [38], and some of the patients starting TB 
treatment may in fact have suffered from TB IRIS. Fourth, data on serum iron, 
transferrin saturation and CRP were only available in a subset of patients due to 
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limited volume of some of the archived samples, although no difference in 
clinical characteristics were found between patients with and without available 
samples (data not shown). Finally, we acknowledge that the number of patients 
developing TB was rather small despite the fact that 798 patients were 
prospectively followed for a median follow-up time of 836 days (table 1). 
 
In conclusion, our study shows that advanced HIV infection is associated with 
increased hepcidin expression and characteristic features of iron maldistribution 
and this may, among others, stimulate HIV progression and contribute to HIV-
associated anemia. Patients starting TB shortly after cohort enrollment had 
significantly higher serum hepcidin and ferritin level at cohort enrollment, but this 
effect was not present in those starting TB treatment after at least 2 months.  
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Abstract 
Objective: 
It remains unclear whether injecting drug use (IDU) affects the natural course of 
HIV and M. tuberculosis infection. We examined the effects of IDU on CD4 cell 
decline and susceptibility to tuberculosis among HIV-infected patients in 
Indonesia. 
 
Design: 
A cohort of 1411 unselected HIV-infected patients was followed prospectively to 
determine CD4 cell decline and tuberculosis incidence. 
 
Methods: 
Factors associated with CD4 cell decline and tuberculosis incidence were 
examined using a linear mixed model respectively Cox proportional hazard 
regression analyses. 
 
Results: 
IDU, reported in 65.2% of patients, was associated with a more rapid decline of 
CD4 cell counts (p=0.009). According to the model, which accurately predicted 
subsequent CD4 cell counts (R2=0.77), a decline of CD4 cells from 350 to 200 
cells/µl would take an average of 18 months less for patients with a history of 
IDU. During follow-up, patients with a history of IDU had a higher incidence of 
active tuberculosis (19.5% versus 8% for patients without IDU, adjusted hazard 
ratio: 2.38, p<0.001).  
 
Conclusions: 
IDU among HIV-infected patients in this low-income setting is associated with a 
more rapid CD4 cell decline and a higher risk of active tuberculosis. Our findings 
have implications for patient monitoring and starting ART, and for tuberculosis 
prophylaxis, both among HIV-infected and non-infected injecting drug users.  
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Introduction 
Injecting drug use (IDU) accounts for more than 10% of new human 
immunodeficiency virus (HIV) infections worldwide [1,2]. IDU is not only a risk 
factor for HIV transmission, but it may also change the natural course of HIV 
infection, for instance because of co-infections and/or nutritional deficiencies. In 
addition, heroin and other opioids have immune-modulating effects, which may 
alter progression of HIV infection and susceptibility to infections, such as 
tuberculosis [3-7].  
Epidemiological studies looking at the association between IDU and the natural 
course of HIV infection have shown contradictory results [4,8-13]. Most studies 
used clinical endpoints, such as mortality and AIDS free survival, and were 
conducted in high-income countries, mostly among Caucasian subjects [8-12]. 
Factors unrelated to HIV infection may however skew the relation between IDU 
and AIDS-free survival. One such factor is mortality not related to HIV, which is 
higher among HIV-infected injecting drug users (IDUs) than among HIV-infected 
patients who are no IDUs [14-16]. Differences in the occurrence of AIDS 
defining illnesses, for example Kaposi sarcoma, may also affect the association 
between risk group and AIDS-free survival [9].  
In this study we determined the effect of IDU on the natural decline of CD4+ T-
lymphocytes (CD4 cells), as the primary and most precise marker for 
immunodeficiency in HIV-infected patients. In addition, we examined the effect 
of IDU on tuberculosis incidence among HIV-infected patients. These effects 
were based on data derived from a patient cohort in Indonesia, which has a 
rapidly growing HIV epidemic, largely driven by IDU [17], and the fifth highest 
number of tuberculosis patients worldwide.  
 
Methods 
Setting and study population 
This study was embedded in a five-year programme called ‘IMPACT’, aimed at 
better prevention, control and treatment of HIV in the context of IDU in West-
Java, Indonesia [17]. IMPACT is supporting patient care in three clinics in 
Bandung, the capital of West Java (40 million people): a teaching hospital, a 
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methadone clinic, and a prison clinic. In these clinics, people with and without a 
history of IDU, who are at risk for HIV infection or who present with signs and 
symptoms suggesting HIV/AIDS are counselled and tested for HIV. All testing is 
voluntary and informed consent is obtained from all study participants. HIV-
infected patients are characterised and followed prospectively in a cohort study, 
which has been approved by the Health Research Ethics Committee at the 
Faculty of Medicine of Padjadjaran University/Dr. Hasan Sadikin General 
Hospital in Bandung, Indonesia. Data on demographic factors, history of IDU, 
co-morbidity, self-reported tuberculosis treatment and history of antiretroviral 
treatment (ART) are collected through interview with standard questionnaires. 
Laboratory examinations include CD4 cell measurement at baseline and fixed 
time points afterwards. Patients are seen by a doctor every 3-6 months if not on 
ART, and more frequently when ART is initiated. Sputum microscopy and 
culture, and chest X-ray examination are performed to diagnose acute 
tuberculosis. At the time of this study, ART was indicated in Indonesia for 
patients presenting with WHO clinical stage IV or a CD4 count less than 200 
cells/µl in accordance with WHO guidelines from 2006. Since 2004, ART can be 
accessed free of charge in Indonesia. 
 
Data analysis and statistics 
In this study, we selected all adults (≥16 years) presenting with HIV infection 
between August 2007 and August 2010, who had not yet been exposed to ART 
(figure 1). Hepatitis C (HCV) infected patients without a history of IDU were 
excluded, as HIV-HCV co-infection is very unlikely in the absence of IDU in this 
setting. All statistical analyses were done using SPSS statistical software 
(version 17.0). 
 
Natural decline of CD4 cells 
To determine the effect of IDU on the natural decline of CD4 cells over time we 
included all ART-naïve patients who had two or more CD4 cell counts measured 
at least one month apart, with all measurements done before start of ART 
(figure 1). We used a linear mixed model to describe the decline of CD4 cell 
over time, to meet all criteria we transformed all CD4 cell counts to the square 
root scale. The effect of IDU on the decline of CD4 cells was determined with an 
interaction-term between IDU and time in days (IDU*t). A constant variable was 
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added to the model to account for the variability in CD4 cell decline, which is 
independent of other variables. Information on body mass index (BMI) was not 
available for all study subjects. Therefore, BMI was combined with a dummy for 
missing BMI value in the model describing the natural decline of CD4 cells. The 
correlation between CD4 cell counts as measured and predicted by the final 
model was determined and expressed as the coefficient of determination (R2).  
 
 
Tuberculosis incidence 
The effect of IDU on the incidence of tuberculosis was examined using 
univariate and multivariate Cox proportional hazard regression analyses. In 
these analyses the diagnosis of tuberculosis was the dependent variable. Time 
was recorded as days until diagnosis of tuberculosis or days until last visit 
before the first of August 2010. In the multivariate analyses we used the 
variables IDU, CD4 cell count, gender, age, haemoglobin concentration, and 
ART initiation. ART initiation was taken into account as a time-dependent 
covariate in extended Cox proportional hazard model. Variables that were not 
statistically significant (p>0.05) were removed from the Cox proportional hazard 
model.  
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Results 
The total cohort consisted of 1411 HIV-infected patients, the majority was male 
(69.9%) and had a history of IDU (65.2%) (table 1). The median CD4 cell count 
at the first visit was 227 cells/µl for HIV-infected patients currently or previously 
exposed to ART, and 65 cells/µl for ART-naive patients. Almost two thirds of all 
patients were infected with Hepatitis C virus (HCV), and this was 92.1% among 
those with a history of IDU. Many patients had been treated for tuberculosis 
(33.2%), or received tuberculosis treatment (9.5%) during follow-up. In ART-
naive patients, tuberculosis was strongly associated with low CD4 cell counts; 
45.9% of those with CD4 cell counts below 200 cells/µl were or had ever been 
treated for tuberculosis, compared with 10.8% of patients with CD4 cell counts 
above 200 cells/µl (χ2=93.9, p<0·001). Most patients in this cohort had a high 
education, 84.7% had finished senior high or university. Patients with a history 
of IDU more often had finished senior high school or university (92.6% versus 
70.4%, p<0.001). Among male patients the majority had a job, both among 
patients with and without a history of IDU (78% and 77% respectively, p=0.967). 
Among women, those with a history of IDU were more likely to have a job than 
those without a history of IDU (56% and 36% respectively, p<0.001). 
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Natural decline of CD4 cells 
We excluded 494 patients who were already taking ART and 692 ART-naïve 
patients who only had a single CD4 cell count measured, mostly because they 
had an immediate indication to start ART. A total of 225 patients fulfilled the 
selection criteria for inclusion in the model to examine the natural decline of CD4 
cells (figure 1). Selection of people with at least two CD4 cell counts without 
ART resulted in a study population with higher CD4 cell counts (median 329 
cells/µl, table 1). Similar to the total cohort the majority of people with a history 
of IDU were infected with HCV (89.4%). Tuberculosis and oral candidiasis 
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infections were less prevalent in the study population compared to the total 
cohort. Patients with and without a history of IDU had a similar average time 
between subsequent CD4 cell count measurements (182 respectively 184 days, 
p=0.999), and an equal first CD4 cell count (312 respectively 334 cells/µl, 
p=0.169). In addition, the occurrence of active tuberculosis, both prospective 
and retrospective, was comparable between people with and without a history of 
IDU (p-value 0.50 and 0.67 respectively). Most patients (53.3%) had two serial 
CD4 cell counts, 21.3% had three CD4 cell counts, and the rest (25.3%) had 
more than four CD4 cell counts, with a maximum of nine CD4 cell counts. The 
median CD4 cell count at baseline was independent of the number of serial CD4 
cell counts available (p=0.226). 
 
The multivariate model with a follow-up CD4 cell count as dependent variable 
included a constant (p=0.023) and three independent variables: previous CD4 
cell count (p<0.001), days between CD4 cell counts (p=0.007), and the 
interaction term of IDU and time in days (p=0.009). Follow-up CD4 cell counts 
as predicted by the model correlated well with CD4 cell counts as measured 
(R2=0.77). No statistically significant relation was found for haemoglobin 
(p=0.149), age (p=0.114), gender (p=0.294), BMI (p=0.356), dummy for missing 
BMI (p=0.637) and IDU (p=0.536) in multivariate analyses, therefore these 
variables were excluded from the final model. Figure 2 shows the difference in 
decline of CD4 cells between HIV-infected patients with (black) and without 
(grey) a history of IDU, as seen with the interaction term IDU and time. This 
model predicts that a decline from 350 to 200 CD4 cells/µl would take an 
average of 20 months in patients with a history of IDU, compared with 38 
months in patients without a history of IDU, a difference of 18 months. This 
indicates that people with a history of IDU progress 1.9 times faster from 350 to 
200 CD4 cells/µl.  
 
Tuberculosis incidence 
A history of IDU was also associated with a higher risk of developing 
tuberculosis. A total of 914 HIV-infected patients were ART-naive and had 
information about tuberculosis treatment during a median follow-up of 231 days 
(IQR: 36-533 days). During the follow-up period, 139 of these patients (15.2%) 
were diagnosed with tuberculosis and received treatment. Tuberculosis 
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incidence was higher in patients with a history of IDU than among those with no 
history of IDU (19.5% versus 8.0%, p<0.001). In univariate Cox regression 
analyses a history of IDU had a significant relation with tuberculosis incidence 
(table 2). This relation remained statistically significant after adjustment for the 
baseline CD4 cell count, haemoglobin concentration, and ART during follow-up 
(time-dependent). The adjusted hazard ratio for a history of IDU was 2.38 
(95%CI 1.5 – 3.8) (figure 2). ART was kept in model despite non-significance, 
since the protective effect of ART on tuberculosis incidence is widely accepted. 
Gender, age, BMI and HCV did not affect the relation between IDU and 
tuberculosis incidence (table 2).  
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Discussion 
In this study we show that IDU is associated with a more rapid decline of CD4 
cells and a higher risk of tuberculosis among ART naïve HIV-infected patients in 
Indonesia. Our findings indicate that HIV disease progression should be 
monitored carefully in IDUs, and support the use of tuberculosis prophylaxis 
(isoniazid preventive therapy) in this patient category.  
 
We used the decline of CD4 cell numbers, as it is a very accurate and 
meaningful parameter to monitor the natural course of HIV infection. Based on 
previous studies, we chose to transform the CD4 cell counts to the square root 
scale before generating a linear mixed model [8,12]. Our model showed a faster 
CD4 cell decline than other studies using the square root of CD4 cells. This 
difference may be explained by differences in study population and study 
design, such as using Gibbs sampling, and Student-t distribution to model the 
decline of CD4 cells [8,12]. 
 
Our study is the first to show that IDU accelerates CD4 cell decline in a low-
income setting. Our results are supported by a study from McNeil et al. who 
used similar models of HIV progression with a square root transformation of 
CD4 cell counts in a high-income setting (Scotland) [12]. Similar to our cohort, 
70% of patients in that study had a history of IDU and 70% were male. Based on 
this study population, two models were created which both showed that 
individuals infected through IDU tended to have a faster CD4 cell decline than 
those infected through heterosexual contact (p=0.13 and p=0.05) [12]. Other 
epidemiological studies on HIV progression in drug users found contradictory 
results [8,9,11,14]. For instance, individuals infected through sex between men 
had a higher AIDS incidence than other exposure categories in a study using 
data from several cohorts. However, this effect could be explained by the high 
incidence of Kaposi sarcoma, which occurs at relative higher CD4 cell counts, in 
those infected through sex between men [9]. Others found that the drug use, 
especially heroin, was associated with disease progression [11]. However, most 
studies were conducted in high-income settings, which have a different 
distribution of opportunistic infections, such as tuberculosis. In addition, many 
studies uses clinical endpoints instead of CD4 cell counts, and other statistical 
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methods, such as Markov models and hazard ratio’s. Consequently, the 
outcomes of these studies are somewhat difficult to compare to our results.  
 
Older age has been associated with faster disease progression in several 
studies [9,18,19]. However, in this patient cohort the age range was small (IQR 
26-31 years), which could explain why age had no effect on the natural CD4 cell 
decline (p=0.114) in this study. Another variable that may influence the natural 
decline of CD4 cells is HIV replication [8,20,21]. Measurement of plasma HIV 
RNA was only introduced recently in West Java, and therefore this variable 
could not be taken into account. Our study is limited by the fact that half of our 
patients only had two CD4 counts measured. Despite these limitations, we can 
still conclude that IDU accelerates the natural decline of CD4 cells in HIV-
infected patients.  
 
A possible explanation for the more rapid CD4 cell decline among IDUs might lie 
in the high rate of co-infection with HCV. Recent studies have shown that HCV 
replication might indeed effect CD4 cell decline [22]. However, this effect seems 
to be more pronounced among patients receiving ART [22, 23]. Alternatively, 
immunomodulating effects of heroin and other opioids could affect the CD4 cell 
decline. In vitro studies have shown that opioids increase the expression of the 
chemokine receptors CXCR4 and CCR5, which are co-receptors for HIV and 
mandatory for cellular invasion, and consequently increase viral replication of 
HIV [3-7]. 
 
The risk of developing active tuberculosis was almost two-and-a-half times 
higher for HIV-infected patients with a history of IDU than among those without a 
history of IDU, even after adjusting for CD4 cell count, haemoglobin 
concentration and ART during follow-up. This is a very intriguing finding, which 
asks for an explanation. Some earlier studies also found that tuberculosis 
incidence was higher in IDUs. This was usually attributed to poverty and higher 
exposure of IDUs to tuberculosis or to poor uptake of ART among HIV-infected 
IDUs [24-28]. However, in Indonesia, the burden of tuberculosis is already very 
high in the general population while the IDUs from our cohort are generally not 
poor and mostly well educated, as shown in our results [17,29]. In addition, we 
have shown that uptake and effectiveness of ART is comparable in patients with 
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a history or IDU [17]. In line with our findings, a recent study examining 
tuberculosis screening among HIV-infected patients in several Asian low-income 
countries found a strong association between IDU and tuberculosis (OR 3.4) 
[30]. We speculate therefore that the higher incidence of tuberculosis among 
IDUs has a biological explanation. Experimental studies have shown that 
opioids induce an anti-inflammatory response, decrease phagocytosis and 
chemotaxis, and impair proliferation of immune cells [5]. Also in vivo studies 
showed that animals exposed to opiates have higher morbidity and mortality 
after infection with microbial pathogens, such as Salmonella enterica, Herpes 
simplex virus and Candida albicans [5]. The immuno-modulating effects of 
opiates could result in an impaired immune response to tuberculosis, and thus 
explain the increased risk of developing tuberculosis among IDUs. More 
research is needed to elucidate how opioids exert its immunomodulating 
properties. 
 
In conclusion, IDU accelerates the natural decline of CD4 cells and increases 
the risk of active tuberculosis in HIV-infected patients in Indonesia. These 
findings indicate that HIV disease progression should be monitored carefully in 
IDUs and that earlier initiating of ART should be considered for this risk group. 
We have recently shown that a history of IDU in HIV-infected patients does not 
have a negative effect on virological or immunological response to ART, nor on 
retention to treatment and mortality [17]. As a second finding we report that 
IDUs in this high endemic setting also have an increased risk of developing 
tuberculosis, which may be explained by the immunomodulating effects of 
opioids. Isoniazid preventive therapy effectively reduces tuberculosis incidence 
rates, also in IDUs [31,32]. Our data support scaling up of isoniazid preventive 
therapy, especially among IDUs, with monitoring for hepatotoxicity which might 
be higher due to HCV co-infection.  
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Abstract 
 
Background: 
There is a common belief that injecting drug use (IDU) is associated with lower 
uptake, retention and success of antiretroviral treatment (ART) in HIV-infected 
patients. We examined this in an Indonesian setting, where IDU is the main risk 
factor for HIV-infection. 
 
Method: 
Patient characteristics and response to ART were recorded for all patients 
diagnosed with HIV-infection in the referral hospital for West-Java (40 million 
people). Kaplan-Meier estimates and Cox’s regression were used to compare 
mortality, loss to follow-up and virological failure between patients with and 
without a history of IDU.  
 
Result: 
773 adult HIV patients (81.9% IDUs) presented between January 1996 and April 
2008. IDUs had a median CD4 cell count of 33 (IQR,12-111) cells/mm3 
compared to 84 (IQR, 28-224) cells/mm3 in non IDUs. Among patients with a 
history of IDU, 87.7% were co-infected with hepatitis C (HCV). Mortality was 
strongly associated with CD4 count; after six months of ART, 18.3, 20.3, 7.1, 
and 0.7% of patients with CD4 cell counts < 25, 25-99, 100-199 respectively > 
200/mm3  had died  (P < 0.0001). Mortality (adjusted for CD4; HR=0.65; 95% CI 
0.35-1.23) loss to follow-up (HR=0.85, 95% CI 0.51-1.41), and virological failure 
(HR=0.47, 95% CI 0.19-1.13) were not significantly different in IDUs and non-
IDUs.  
 
Conclusion: 
Intravenous drug users (IDUs) in Indonesia with HIV-AIDS tend to have more 
advanced disease but respond similarly to non IDUs to antiretroviral therapy. 
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Introduction 
Indonesia is facing one of the most rapidly growing HIV-epidemics in Asia, 
which, except for Papua, is mostly driven by injecting drug use (IDU) [1]. 
Currently, the HIV-prevalence is still low (0.2%) in the general population, but 
among intravenous drug users (IDUs), HIV-prevalence rates above 50% have 
been found [2]. Unprotected sex, also with commercial sex workers, is common 
among IDUs and it seems a matter of time before Indonesia, which has the 
fourth biggest population in the world, will have a more generalized HIV-
epidemic [1]. Until now however, the majority of HIV-infected Indonesians that 
are in need of antiretroviral treatment (outside Papua) are IDUs.  
 
A number of factors may hamper treatment of HIV-infected IDUs in Indonesia. 
First of all, access to care is limited because drug use is illegal and therefore 
patients may be reluctant to look for medical care [3]. Stigmatization from the 
site of the health care worker may also contribute to this [4,5]. Secondly, HIV-
treatment itself may be more difficult in IDUs because of non-compliance [6-8], 
psychiatric conditions [3], concurrent infections like hepatitis C and late 
presentation [9-11]. Harm reduction, especially opioid substitution, not only 
reduces HIV transmission, but may also increase access and retention to highly 
active antiretroviral therapy (ART) [3,6,8]. In Indonesia, harm reduction has 
however only recently become available and only on a limited scale. 
 
Physicians may be reluctant to start ART in HIV-infected IDUs, although a 
number of studies have shown that IDU is not associated with increased 
mortality during HIV-treatment [12-14], nor with development of drug resistance 
[15]. However, these studies were mostly conducted in western countries. To 
the best of our knowledge, no studies from Asia have described the response to 
ART among HIV-infected IDUs. We have examined clinical presentation and 
response to first-line antiretroviral treatment in a cohort of Indonesian HIV-
infected patients with and without a history of IDU.  
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Methods 
Setting and patients 
All HIV-positive patients above 14 years of age presenting between 1996 and 
April 2008 at Hasan Sadikin hospital as the referral hospital for HIV in West 
Java (population 40 million) were included in this cohort study. As one of the first 
25 hospitals selected by the government to provide HIV-care, Hasan Sadikin 
hospital has delivered free antiretroviral treatment and PCP-prophylaxis since 
December 2004. Following WHO guidelines, ART is indicated for patients 
presenting with WHO clinical stage IV and/or a CD4 count less than 200/mm3. 
For patients who cannot afford CD4-cell measurement, total lymphocyte count 
(TLC) is used as a surrogate. After 2006, HIV patients with WHO clinical stage 
III and CD4-cell counts between 200-350/mm3 are also offered ART. The 
national program provides a choice of nevirapine (NVP), efavirenz (EFV), 
zidovudine (ZDV), stavudine (d4T) and lamivudine (3TC) for first-line ART. 
Laboratory testing is not supported by the program and CD4-testing was not 
available in this hospital until September 2007. Measurement of HIV-RNA has 
only become available in this hospital since January 2008. 
 
Data collection and analysis 
Patient data were retrieved retrospectively from medical records. In addition, all 
patients presenting between September 2007 and April 2008 were 
characterized prospectively using a standard questionnaire, physical 
examination and laboratory examination. For all patients, data collected included 
age, sex, history of injecting drug use, body mass index (BMI, kg/m2), CD4-
count at first presentation, Hepatitis B and C status and history of TB-treatment. 
For patients starting ART, drug regimens and CD4-counts before and after ART 
were recorded. After September 2007, HIV-RNA was measured for patients with 
more than six months ART and adherence (correct intake of medication) was 
evaluated by three-day, one-week and one-month self-report [16]. CD4-cell 
measurements were done using Facscount flow cytometry technology (BD 
Biosciences, Jakarta, Indonesia). HIV-RNA was quantified by real-time PCR 
(Abbott, USA) with a detection limit of 150 copies HIV-RNA/mm3. External 
quality assurance for HIV, HBV and HCV serology was done (National Serology 
Reference Laboratory, Australia) showing a 100% accuracy.  
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The primary endpoints during follow-up were survival, retention to treatment and 
virological response. Death was recorded from medical records. In addition, 
patients were classified as dead if reported by family or community 
organizations or confirmed by telephone calls from the clinic. Patients not 
returning for more than three months without confirmation of death or transfer 
were considered lost to follow-up. Virological failure was defined as a plasma 
HIV-RNA concentration above 400 copies/mm3, at two different time points, after 
at least six months of ART. 
 
Data are presented as mean (SD) if normally distributed, median (interquartile 
range) if not normally distributed, or as proportion. Comparisons between 
groups were done using chi-square and parametric and non-parametric tests as 
appropriate. Progression to death, loss to follow-up and virological failure was 
measured by Kaplan-Meier estimates. Differences between groups in retention, 
mortality and virological failure were calculated by Cox’s regression and 
expressed as hazard ratio’s (HR) with 95% confidence intervals (CI). All 
statistical analyses were done using SPSS version 13.00. 
  
 
Results 
Patient’s characteristics 
Between January 1996 and April 2008, a total of 888 patients were referred or 
newly diagnosed with HIV-infection at Hasan Sadikin Hospital. One hundred and 
six patients were excluded because of unknown age, age less than 14 years old 
or absence of information on IDU. Nine patients who denied having a history of 
IDU but who were positive for anti-HCV antibodies were also excluded. A total 
number of 773 patients were included for further analysis.  
 
Most patients were young, 59.7% were or had been married, and 77.3% had 
completed higher education. Most patients (81.9%) had a history of IDU. IDUs 
reported to have started IDU at a median age of 19 years (n=295; IQR, 17-22), 
and to have engaged in IDU for a median duration of five years (n=393; IQR,    
3-7). Patients with a history of IDU were more often male, single and younger 
than patients without a history of IDU (table 1). The median CD4-cell count 
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(available for 514 patients) at presentation was 39 cells/mm3 (interquartile range 
[IQR] 13-126), and significantly lower among IDUs. IDUs also had a lower BMI. 
Almost 90% of patients with a history of IDU were co-infected with hepatitis C. A 
history of TB treatment at any time was found in 42% of patients, significantly 
more often among patients with a history of IDU (table 1). 
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Treatment response 
From 773 patients, 626 (81.0%) were started on ART. A history of IDU did not 
appear to have a negative effect on access to ART; 83.6% of patients with a 
history of IDU compared to 69.3% of patients without a history of IDU were 
started on ART (p<0.001). One fourth of patients (24.4%) were started on ART 
the same day they entered the clinic and 22.2% without measurement of CD4 
cell-count. The median CD4-cell count before start of ART was 99 (IQR 24-227) 
cells/mm3 (table 2). From 616 patients (98.4%) whose ART regimen could be 
established, the most common combination used was NVP/ZDV/3TC (59.6%), 
followed by EFV/ZDV/3TC (15.0%), NVP/d4T/3TC (12.6%) and EFV/d4T/3TC 
(10.9%). Only two patients (0.3%) were started on a protease-inhibitor based 
regimen. Patients with a history of IDU were less often prescribed NVP 
containing regimens compared to patients without a history of IDU, probably due 
to (anticipated) liver dysfunction or combined TB treatment at time of initiating 
ART.  
 
The median duration of follow-up under ART was 348 days (IQR 65 – 867) for 
patients with a history of IDU, and 251 days (IQR 46 - 477) for non-IDUs. 
Treatment substitutions were recorded in 162 patients (25.9%), mostly because 
of ZDV-related anemia, or NVP-related allergy or liver dysfunction. Patients with 
a history of IDU experienced significantly more NVP-related toxicity compared to 
patients without a history of IDU, but not more ZDV-related anemia (table 2). 
The median time to treatment substitutions was 48 days (IQR 23-163). Patients 
with a history of IDU had significantly more substitutions than patients without a 
history of IDU (table 2). Missed clinic visit and adherence (self-reported 
medication intake) were not significantly different between groups. 
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Both mortality and loss of follow-up were high, with 82.8% of mortality and 
71.9% of loss to follow-up occurring in the first six months. Using Kaplan-Meier 
estimates from all 626 ART patients complete data, mortality at six months was 
18.3% (95% CI 11.5-25.0%) for patients with CD4-cell counts below 25 
cells/mm3 before start of ART, 20.3% (13.1-27.6%) for patients with CD4-cell 
counts of 25 - 99 cells/mm3, 7.1% (0.2-12.2%) for patients with CD4-cell counts 
of 100 - 199 cells/mm3, and 0.7% (0.0-2.0%) for patients with CD4 cell counts 
same or above 200 cells/mm3 (p<0.0001).  
 
A history of IDU appeared not to have a negative effect on patient’s survival and 
retention to treatment. Mortality following start of ART among patients with a 
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history of IDU and among patients without a history of IDU was not significantly 
different (HR=0.90; 95% CI 0.55-1.47) (figure 1a, table 3), even if adjusted for 
CD4 (HR=0.65; 95% CI 0.35-1.23). Since 2007, mortality following ART has 
decreased significantly in this cohort. For patients who started ART after 
September 2007, the six-month mortality was 5.1% for IDUs and 8.1% for non-
IDUs (HR=0.56; 95% CI 0.09-3.61). Similar to mortality, loss to follow-up was 
not different between patients with and without a history of IDU (HR=0.85; 95% 
CI 0.51-1.41) (figure 1b, table 3). 
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IDU did not show a negative effect on immunological or virological response to 
treatment either. CD4-cell counts were available for 377 patients on ART 
(median duration 615 days, IQR 294-964). Among patients with history of IDU, 
66.2% had a CD4-cell count > 200 cells/mm3, compared with 67.3% of patients 
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without a history of IDU (p=0.870). HIV-RNA measurements were available for 
310 patients. After a median duration of ART of 606 days (IQR 291-965), HIV-
RNA was below 400 copies/mL in 87.9% of patients with a history of IDU 
compared to 84.2% of patients without a history of IDU (figure 2). Using Cox 
regression, the risk of virological failure appeared to be lower among patients 
with a history of IDU, but this was not statistically significant (HR=0.47, 95% CI 
0.19-1.13).   
 
 
Discussion 
We have compared clinical presentation and outcome between HIV-patients 
with and without a history of injecting drug use (IDU) in Indonesia. HIV-patients 
with a history of IDU in this setting were mostly young males, presenting with 
HCV co-infection, and more severe immunosuppression than HIV-patients 
without a history of IDU. IDU did not have a negative effect on mortality, 
retention to treatment, and virological or immunological response to ART.  
 
Our cohort reflects the specific nature of the HIV-epidemic in Indonesia which, 
except for Papua, is mostly driven by IDU. Not less than 80% of patients in our 
cohort had a history of IDU. This is different from many neighboring countries 
where unprotected sex is the main route of HIV-transmission [1,17,18]. Our data 
show that young people, often highly educated, engage in IDU at a young age. 
Needle sharing is common [1], leading to a high prevalence of hepatitis C co-
infection, even higher than previously reported among IDUs in other countries 
[19]. Also typical for the HIV-epidemic in Indonesia is the fact that patients 
mostly present with advanced HIV disease or AIDS, as reflected by their median 
CD4-count of 39 cells/mm3, lower than in many other resource limited settings 
[17,18,20-22].  As shown by our data, IDUs presented with more advanced and 
more symptomatic disease than patients without a history of IDU. Similar to 
many other settings, several factors may be involved  [3]. National policy leads 
to marginalization of IDUs in Indonesia and stigmatization in the medical system 
[4]. In addition, drug use and associated socio-financial and psychiatric 
problems may create barriers to enter HIV-care. Finally, health providers may be 
reluctant to treat patients with a history of IDU. Our data do not support this last 
Chapter 8 
 
 
132 
 
possibility however; the proportion of patients that was started on ART was not 
lower among those with a history of IDU.  
 
A systemic review has shown that IDU is associated with increased mortality 
and a poor response to treatment, largely due to differences in treatment 
adherence [23], but individual cohort studies from western countries [14], have 
found no negative effect of IDU. Mortality among HIV patients starting ART in 
our cohort was high, in line with national data [24], and comparable to data from 
Africa [25]. The early and high mortality is probably related to late presentation, 
extensive co-morbidity and lack of diagnostic facilities and adequate treatment 
of opportunistic infections. Immune reconstitution to Mycobacterium tuberculosis 
or other pathogens may also have contributed but further study is needed to 
confirm this. Our study, as far as we know, is the first to compare HIV-patients 
with and without a history of IDU from a low-income or transitional setting. 
Similar to the recent cohort in Canada [14], we found no difference in mortality, 
despite the fact that patients with IDU had more advanced disease. In addition, 
in contrast with common belief and results from most studies in western 
countries [3] patients with a history of IDU had a similar (good) immunological 
and virological response to treatment.  
 
Retention to treatment was lower than reported in other studies from Asia 
[21,22], but higher compared to data from Africa [26]. There was no clear 
association between IDU and retention to treatment. We should be cautious 
interpreting this finding, as the true outcome of patients lost to follow-up is 
unknown; many might have died or transferred to other clinics for treatment [27]. 
Most probably, costs for transportation and medical services contribute to loss to 
follow-up in both groups. This and other factors like disclosure of HIV-status to 
family, patient’s trust and relationship with the doctor need further investigation.  
 
Our study was observational and partly retrospective, which limits the 
conclusions that can be made. Furthermore, no urine testing or other 
investigations were done to identify patients with active drug use, and patients 
may have falsely denied drug use out of fear of negative influences of illicit drug 
policies [3]. However, although the HCV-prevalence was close to 90% in those 
who admitted IDU, only 6% of patients who denied IDU were HCV-positive, 
compared with estimates of 2-3% in the general population [28]. Loss to follow-
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up may have affected the estimated mortality, and mortality decreased 
dramatically in recent years, although this did not affect our results. There may 
also have been selection at time of enrolment in HIV-care. Approximately 15% 
of those who need ART in Indonesia actually receive this treatment [24], and 
IDUs in this cohort, although they came late, might be a selected group with a 
fewer drug-related problems, a better health status or better treatment 
adherence. Treatment adherence also affected by severity of HIV infection, 
presence or absence of HIV symptoms can be either incentive or a restraint to 
treatment adherence. 
  
Despite these limitations, our study clearly demonstrates that HIV patients with a 
history of IDU in Indonesia have a similar response to ART compared to those 
without a history of IDU, despite the fact that they present with more co-
infections and more advanced immunosuppression. Our data also confirm the 
urgent need for effective control of HIV in Indonesia among IDUs whereby 
sharing of needles and unsafe sex needs to be addressed. 
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Abstract 
Objectives: 
We studied virological response and development of drug resistance during first-
line anti-retroviral treatment (ART) in Indonesia where the majority of HIV-
infected patients have a history of injecting drug use (IDU), which is often linked 
with lower treatment adherence and development of drug-resistance.  
 
Design: 
We prospectively followed 575 patients starting ART between September 2007 
and March 2010 in Hasan Sadikin Hospital Bandung. Clinical and laboratory 
monitoring was performed every 6 months. Plasma samples with HIV-RNA >400 
copies /ml were examined for drug resistance mutations. 
 
Result: 
Most patients were male (72.3%), 59.7% had a history of injecting drug use, and 
the median CD4 cell count before start of ART was 35 cells/mm3 (IQR 10-104). 
From 438 HIV patients with HIV-RNA measurements, 40 (9.1%) subjects had 
HIV-RNA >400 copies/ml after 24 weeks (median follow-up 16 (IQR 8-25) 
months). Of these failing patients 16 (47%) subjects had drug resistance 
mutations, predominantly M184V (35.3%), Y181C (23.5%), K103N (11.7%) and 
TAMs (11.7%). A history of treatment discontinuation >1 month, reported by 
5.3% (23) of patients, was strongly associated with virological failure (adjusted 
OR 12.64, 95% CI 4.51-35.41); and a history of IDU was not (OR 0.75, 95% CI 
0.38-1.46).  
 
Conclusion: 
This is the largest and most systematic evaluation of virological response to first 
line ART in Indonesia. Patients in this cohort responded well to first line ART, 
with low rates of virological failure and drug resistance. A history of injecting 
drug use should not be a reason to withhold ART in this setting. 
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Introduction 
The development of antiretroviral treatment has dramatically reduced morbidity 
and mortality among HIV-infected individuals, and has turned HIV infection into 
a chronic condition for many patients. The success of HIV treatment depends on 
maintaining long-term viral suppression, which also avoids development of HIV 
resistance to anti-retroviral drugs. Unfortunately, HIV-RNA plasma 
measurements and drug resistance testing are often not generally available in 
low- or medium income countries. As a result, reliable data about effectiveness 
of first and second line ART in those settings are often lacking. This is also true 
for Indonesia, which has one of the most rapidly growing HIV epidemics in Asia. 
HIV-RNA measurements can only be performed in a limited number of institutes, 
mostly in the capital Jakarta and not routinely for all patients. As a result, viral 
resistance may accumulate and spread, but so far this has not been analyzed 
systematically. 
The Indonesian epidemic is different from many other epidemics, as it is a 
concentrated epidemic largely driven by injecting drug use, except for Papua 
which has a more generalized epidemic. The HIV prevalence in the general 
population is around 0.2%, but among injecting drug users (IDUs) 50% or more 
are found HIV-seropositive [1, 2]. Many IDUs have not been tested and for those 
who are HIV-infected, as few as 6% are currently getting HIV-treatment [1]. 
Health providers tend to think that IDUs have a low adherence to treatment [3], 
and thus are at risk to develop and spread drug resistant HIV.  
We therefore conducted a prospective cohort study in an urban setting in West-
Java to examine the rate of virological failure, possible risk factors for failure and 
the development of drug resistance. Almost two-thirds of patients of our cohort 
are infected through injecting drug use allowing us to examine injecting drug use 
as a risk factor for failure of ART and development of drug resistant viruses. 
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Methods 
Setting and study population 
This study was embedded in a five-year program called ‘IMPACT’, aiming to 
prevent, control and treat HIV among injecting drug users (IDUs) in West-Java, 
Indonesia [4]. At the time of the study, IMPACT was supporting patient care in 
three clinics in Bandung, the capital of West Java (40 million people): a teaching 
hospital, a methadone clinic, and a prison clinic. In these clinics, people with and 
without a history of injecting drug use, who are at risk for HIV infection or who 
present with signs and symptoms suggesting HIV/AIDS are counseled and 
tested for HIV infection. All testing is voluntary and informed consent is obtained 
from all study participants. From all patients baseline data are collected 
including: socio-demographics, medical history, injecting and sexual risk 
behavior, physical examination and plasma HIV RNA and CD4 cell counts. HIV-
infected patients are characterized and followed prospectively in a cohort study, 
which has been approved by the Health Research Ethics Committee at the 
Faculty of Medicine of Padjadjaran University/Dr. Hasan Sadikin General 
Hospital in Bandung, Indonesia. 
First-line ART, consisting of efavirenz (EFV) or nevirapine (NVP) in combination 
with lamivudine (3TC), and stavudine (d4T) or zidovudine (ZDV), is provided 
free of charge. Since 2007, tenofovir (TDF) and ritonavir-boosted lopinavir 
(LPV/r) are available as second line ART for a limited number of HIV-infected 
patients failing first-line ART. At the time of the study, following 2006 World 
Health Organization (WHO) guidelines, ART was indicated for HIV-infected 
patients presenting with CD4 < 200 cells/mm3 or with WHO clinical stage III or 
IV. All patients receive adherence counseling before starting ART.  
After initiation of ART, patients return to the clinic monthly for medication, with 
CD4 and HIV-RNA testing done usually every six months. CD4 cell counts are 
examined using Facscount flow cytometry technology (BD Biosciences, Jakarta 
Indonesia), and HIV-RNA is quantified by real-time polymerase chain reaction 
(RT-PCR) (Abbot, IL, USA) with a detection limit of 150 copies HIV-RNA/mm3. 
Virological failure for this analysis was defined as HIV RNA more than 400 
copies/ml after at least 24 weeks therapy. However, patients were switched to 
second-line ART if HIV-RNA >104 copies/ml were detected after at least six 
months ART despite reporting sufficient treatment adherence [5]. 
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Treatment adherence is evaluated each visit and every six months, using a 
systematic assessment of self-reported treatment discontinuations > 1 month 
and missed ART doses in the last three days, last week and last month. Patients 
considered having suboptimal adherence or possible treatment failure receive 
more intensive counseling. For this study, the level of adherence (or average 
adherence for patients with multiple assessments) was calculated, and good 
adherence was defined as > 95% reported medication intake. Factors that can 
affect adherence and response to ART, e.g. disclosure of HIV-status to the 
spouse or close relatives, living conditions, concurrent TB treatment and other 
issues, were explored using standardized interviews during baseline and follow-
up. For this study blood samples from virological failure patients were sent to the 
Erasmus Medical Center in Rotterdam, The Netherlands, for genotypic drug 
resistance testing. The reverse transcriptase and protease genes from failure 
patients were amplified using in-house primers [6] and analyzed by Sanger 
sequencing method.  
Data analysis and statistics 
We retrieved data from all adult patients who started ART between September 
2007 and March 2010. The primary end-point during follow-up was HIV-RNA > 
400 copies/ml after a minimum of six months of ART, measured at one or more 
time points. Data are presented as mean [standard deviation (SD)] if distributed 
normally, median [interquartile range (IQR)] if not distributed normally, or as a 
proportions. Differences between groups were examined using chi-square test 
for proportions and Mann-Whitney test for continuous variables. Predictors of 
virological failure were examined using logistic regression and expressed as 
odds ratios (OR) with 95% confidence interval (CI), factors with p<0.25 in 
univariate analysis were included in multivariate analysis [7]. All statistical 
analysis was performed using SPSS version 16.0.1. The genes sequences were 
processed using DNASTAR Lasergene 8 USA, bioinformatics software. HIV sub 
typing was determined using REGA HIV-1 subtyping tool Version 2.0 (HIVdb, 
Stanford University). Drug resistance mutations were determined using HIVdb 
program, genotypic resistance interpretation algorithm (Stanford University). 
Potential second line drugs options were defined based on drug resistance 
interpretations and mutations scores (HIVdb, Stanford University). 
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Results 
Patient characteristics 
A total of 595 consecutive HIV patients who started their ART between 
September 2007 and March 2010 were included. The majority were young men 
with a history of injecting drug use and advanced HIV infection with very low 
CD4 cell counts before start of ART (table 1). Female patients, many diagnosed 
as a result of partner notification, had higher CD4 cell counts (median 76 
cells/mm3, IQR 23-183) compared to men (median 27 cells/mm3, IQR 9-73) 
(p=0.001). Compared to men, women less frequently reported a history of 
injecting drug use (18.4% vs. 80.5%, p<0.001), as also seen in a lower 
prevalence of HCV infection (27.6% vs. 79.6%, p<0.001). Both male and female 
patients were well educated, 87.5% had completed secondary school, probably 
because in the ‘90s drug use typically started among the higher socioeconomic 
class in Indonesia. The large majority (93.9%, 559) of HIV infections was 
diagnosed in the hospital, while 3.5% (21) of patients were diagnosed in the 
methadone clinic (MMT) [8] and 2.5% (15) in prison [9] as part of targeted 
testing among high-risk groups. HIV patients who started ART in MMT and 
prison had slightly higher CD4 cell counts (median 95 cells /mm3, IQR 20-165) 
compared to HIV patients in hospital (median 33 cells /mm3, IQR 10-95) 
(p=0.01).    
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Treatment response 
During follow-up of a median 16 (IQR 8-25) months, 66 patients (11.1%) died, 
the large majority (48; 73%) within the first six months. In addition, 60 patients 
(10.1%) were lost to follow-up, most (42; 70%) within six months. Patients who 
died had a lower CD4 cell count (median 23 cells /mm3, IQR 6-49) compared to 
those lost to follow-up (median 37 /mm3, IQR 5-104). Another 21 patients (3.5%) 
were transferred, while in 10 patients (1.6%) no HIV-RNA measurement was 
done (figure 1). HIV-RNA was examined in 438 patients who had taken >6 
months ART, with a median of 1.7 measurements per patient. Virological failure 
(HIV RNA range 2.7 – 6.2 log10 copies/ml) was found in 40 patients (9.1 %). The 
median time from start of first line ART until detection of failure was 11 (range 6-
31) months, and within this group 25% (10) had undetectable plasma HIV-RNA 
before being diagnosed with virological failure. These patients showed low-level 
HIV-RNA plasma concentrations  (< 3 log10 copies/ml) during ART in 12.5% (5), 
while 30.0% (12) had 3-4 log10 copies/ml, 22.5% (9) had 4-5 log10 copies/ml and 
35.0% (14) had > 5 log10 copies HIV-RNA/ml. Viral load measurements were 
repeated in 24 patients after a median of 7 (range 4-19) months; in 15 (62.5%) 
patients virological failure was observed. Adherence counseling revealed that 
nine patients were not taking their ART at the time of HIV-RNA measurement, 
four of them had >5 log10 copies HIV-RNA/ml. 
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CD4 cell measurements following start of ART, available for 78.0 % (464) of HIV 
patients, showed a favorable immunological response in most patients. The 
median CD4 cell count increased from 35 (10-104) cells/mm3 before start of ART 
to 163 (IQR 103-224) cells/mm3 after 6 months of therapy, 211 (IQR 151-279) 
cells/mm3 after 12 months, 254 (IQR 197-382) cells/mm3 after 18 months, and 
340 (IQR 245-369) cells/mm3 after 24 months ART. In line with previous studies, 
WHO immunological failure criteria [5] had a low positive predictive value (PPV) 
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of 25.8% for virological failure, and a reasonable negative predictive value 
(PPV) (92.5%), the latter because of the low occurrence of virological failure.  
 
Risk factors for virological failure 
The single most important factor associated with detectable plasma HIV RNA 
was a history of treatment discontinuation > 1 month (table 2). Among 23 
patients who reported an interruption of ART, 11 (47.8%) were diagnosed with 
detectable HIV, compared with 29 of 415 patients (7%) who had had no 
treatment interruption. Reasons for treatment discontinuation could be specified 
for 17 out of 23 patients, with side effects in six patients and inability to collect 
medication because of travel out of town as the main reasons for five patients. 
Four patients mentioned relapse of drug use as the main reason, one patient 
mentioned he “forgot” his medication, and another patient felt he had to take too 
many drugs. 
 
In univariate analysis, patients who were young, unmarried or living alone, and 
those who had used NVP instead of EFV also seemed at higher risk for 
virological failure, but these associations lost statistical significance in 
multivariate regression analysis. Interestingly, injecting drug use, present in 
almost two thirds in this population, was not associated with virological failure. 
Similarly, low CD4 cell count, male gender, low education, unemployment, lack 
of disclosure of HIV status to spouse or family, distance from the hospital, nor 
concurrent TB treatment during start of ART showed an association with failure 
(table 2).  
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Drug resistance mutations  
Genotypic analysis was performed on samples obtained from 34 out of 40 
failure patients (For six patients not enough material was available). Based on 
REGA HIV-1 subtyping approach, all analyzed samples were HIV CRF01_AE 
except two of them. One sample was HIV-1 subtype A1, and the other one was 
unidentified. Drug resistances mutations were found in 16 (47%) patients (table 
3). The M184V mutation (confining resistance to lamivudine) was seen in 12 out 
of 16 patients, additional NRTI mutations were present in 7 out of 16 patients. 
Thymidine Associated Mutations (TAMs), associated with resistance to 
stavudine and zidovudine, were found in four patients. The K65R mutation 
(resistance to tenofovir) occurred in two patients, both together with M184V and 
NNRTI mutations. The most common NNRTI mutation was Y181C (n=8) 
followed by K103N (n=4). Four patients had resistance to all three antiretroviral 
drugs they were taken, whereas 8 patients showed resistance to two drugs in 
their regimens. Protease resistance associated mutations were not found.  
 
For all patients (n=16) with drug resistance mutations the sensitivity to drugs 
available in Indonesia was evaluated using the Stanford scoring system. Twelve 
patients harbored virus that showed resistance to 3TC, four to zidovudine, 
seven for stavudine and three to tenofovir.  In fourteen out of 16 patients, HIV 
isolates were resistant to the first generation NNRTI (efavirenz and nevirapine).   
 
A comparison between failing patients with and without drug resistance 
mutations revealed that patients in whom no HIV drug resistance mutations 
were detected had higher HIV RNA plasma levels (median 5.1 (3.5-5.7) log10 
copies/ml vs. 4.0 (3.8-5) log10 copies/ml p= 0.11) and lower CD4 counts (median 
63 (20-197) cells/mm3 vs. 199 (125-299) cells/mm3p= 0.05).This suggests that 
resistance associated mutations may not have been detected because the 
patients were not adherent. There was no relevant association between NVP 
failure and development of drug resistance mutations (p= 0.68). 
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Discussion 
To our best knowledge, this is the first study from Indonesia reporting combined 
data of HIV plasma RNA measurements and drug resistance testing in patients 
starting first line ART. Based on intention to treat analysis, the occurrence of 
virological failure was lower compared to those obtained in a multicenter cohort 
study in the Asia-Pacific region [10] and to results from a systematic review 
including 89 cohort studies in Africa [11]. The low occurrence of failure might 
suggest that all patients starting ART in Indonesia have a good prognosis. 
Unfortunately, early mortality in our patients was very high and in line with 
earlier studies from India and Indonesia [12,13].  Early loss to follow-up was also 
high, and as most patients in this group presented with advanced disease 
(average CD4: 37 cells/mm3) it is likely that many have died as well. This has 
been reported in other low-resource settings: in a study performed in Malawi, 
50% of patients registered as ‘lost to follow-up  were actually found to have died 
during home visits [14]. Clearly, earlier detection of HIV infection is a high 
priority for Indonesia, like for many other low-resource settings.  
 
It is well-known that non-adherence to ART leads to virological failure [15-18].  
In our study, long periods of ART discontinuation (for more than one month) 
constituted the single most important risk factor for virological failure. Similar 
findings have been reported from studies in Africa, Europe and America [19-21]. 
Interestingly, incomplete drug intake (suboptimal adherence) was not associated 
with virological failure in our setting. The adherence threshold of 95% that we 
used was based on early studies using the first generation NNRTI and more 
complex protease inhibitor (PI)-based regimens. However, currently used 
regimens may be more ‘forgiving’ [22-23]. The use of NVP as opposed to EFV 
seemed a risk factor for virological failure, although this association was not 
significant in multivariate analysis (OR 2.02, p=0.06). This difference has also 
been reported by studies from India and Africa [24,25], but caution is warranted 
as the prescribed regimens may have been subject to indication bias.  
 
Injecting drug use was not a risk factor for virological failure during ART. In 
contrast to what is often stated, treatment adherence did not significantly differ 
between IDUs and non-IDUs, and treatment discontinuations (4.5% respectively 
4.4%) were similar. A systematic review about injecting drug use and adherence 
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to ART found that IDUs on average display lower adherence to treatment, but 
that similar adherence levels can be achieved compared to non-IDUs by 
comprehensive care, management of co-morbidities, psychosocial support and 
particularly by opioid substitution [26]. 
 
Monitoring response to ART in resources limited setting is challenging. In line 
with previous studies we found that WHO immunological failure criteria lack 
sensitivity and specificity when compared to virological criteria [27,28]. 
Unfortunately, measurement of plasma HIV-RNA is costly, and routine HIV-RNA 
monitoring is generally beyond the financial capacity of low-resource settings. 
Mathematical modeling using data from Africa has shown that viral load testing 
did not have an impact on long-term survival [29], and this was recently 
confirmed in a large clinical trial [28]. Plasma HIV-RNA measurement might 
however impact drug resistance development; a meta-analysis has shown that 
patients treated in settings without viral load monitoring had significantly more 
resistance mutations, compared to patients in settings where plasma HIV-RNA 
is measured every three months [30]. In our study, the M184V mutation and 
NNRTI resistance mutations were most common. The availability of virological 
monitoring in our setting probably limited the development of TAMs (present in 
only 4 out of 34 patients), since the development of these mutations take longer 
periods of virological failure. This finding is in agreement with other reports from 
low-income countries where virological monitoring is part of routine care [31]. 
 
In our study, no drug resistance mutations were found in more than half of the 
patients with virological failure. Most likely this is a result of very low compliance, 
with low drug exposure and a low risk of development of drug resistance 
mutations as a result. However, in the absence of longitudinal resistance data 
and given the fact that our genotyping was performed using population 
sequencing, we cannot rule out that resistant viruses were selected in these 
patients but were not detected in plasma at the time of failure [32]. This may be 
a particular problem for low genetic barrier drugs such as the first generation 
NNRTI [33]. In that case continuing / restarting patients on their first line regimen 
poses a risk of further selection of more resistant viruses.  
 
We observed that the absolute value of their HIV-RNA concentration could help 
to select those who needed switching to second-line ART. Patients with very 
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high plasma HIV-RNA levels (> 5log10 copies/ml) and very low CD4 counts 
(<100 cells/mm3) during ART (probably as a result of prolonged treatment 
interruptions) were less likely to harbor drug resistant virus compared to those 
with viral ‘blips’ or low HIV-RNA concentrations (< 3log10 copies/ml) who were 
probably taking ART, but not with full adherence. 
 
Our data indicate that the currently available second line antiretroviral drugs in 
Indonesia, tenofovir and ritonavir-boosted lopinavir, are probably effective, 
supporting the current WHO recommendation for second-line ART [34]. Thirteen 
out of 16 patients who developed resistance during first line therapy were still 
considered to be sensitive to tenofovir, based on population sequencing. 
Furthermore, no resistance was found against protease inhibitors. However, no 
clinical trial has evaluated the effectiveness of different second line regimens in 
resource limited settings. Potential options for second line are either to recycle 
drugs from the first line, or to use second line options. Whereas recycling first 
line drugs is attractive given the lower costs, it also has the potential risk of 
reduced drug activity due to selection of resistant viruses [35]. Genotyping may 
help to minimize this problem, although the absence of mutations does not 
exclude the possibility of clinically relevant minority species. Constituting a new 
regimen based on boosted protease inhibitors (PI) seems attractive given the 
high genetic barrier of these drugs. Further studies are required to determine 
whether additional drugs are needed and which additional drugs should be 
added. Particularly the role of 3TC/FTC in a setting where the M184V is 
selected has not been resolved. A previous report has shown however that 
continuation of lamivudine is beneficial regarding immunological response and 
clinical progression in patients with limited second lines options [36]. Of interest, 
In the absence of PI-mutations, ritonavir boosted lopinavir monotherapy proved 
effective for patients with extensive resistance to NRTIs and NNRTI in a cohort 
study in Thailand with three year follow-up [37]. 
 
Our study had several limitations. Plasma HIV-RNA measurements were not 
available for all patients, injecting drug use and adherence data were derived 
from self-reporting, and adherence evaluation was limited to  the last month of 
therapy. Despite these limitations, our study clearly demonstrates that patients 
in our setting in Indonesia have a good virological response to first line ART 
consisting of a NNRTI combined with 3TC and an additional nucleoside inhibitor. 
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Importantly injecting drug use, often considered a risk factor for non-adherence 
and treatment failure, although very common in this setting was not associated 
with poor outcome. This indicates that a history of injecting drug use should not 
be a reason to withhold ART. Identifying HIV patients at risk of non-adherence is 
important, as they may be target for intensive adherence interventions [38,39]. 
At present, regular viral load measurements cannot be done in Indonesia. 
Future studies should help design cost-effective monitoring strategies, as was 
done in other settings [40,41]. In addition, efforts are underway to implement 
cheaper ‘in-house’ viral load assays. 
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Summary 
In Eastern Europe and Asia, injecting drug use (IDU) is the biggest factor 
contributing to the HIV epidemic [1]. In recent years the HIV prevalence in Asian 
countries like Thailand, Cambodia and Myanmar has declined, however, 
Indonesia has still one of the fastest growing HIV epidemics in Asia [2]. The 
prevalence rates of HIV among IDU in major Indonesian cities like Jakarta and 
Bandung range from 18% to over 50% and unsafe injecting practices has 
accounted for over 72% of all new HIV infections in 2011 even when the 
numbers of people injecting drugs are relatively small, their contribution to the 
overall epidemic in a country can be considerable, because of further spreading 
sexually, creating a critical mass in sexual networks. IDUs in Indonesia are 
mostly males and unprotected sex was indeed reported to be common, 
including having multiple partners (48%) and buying sex from sex workers 
(40%) [3]. In the most recent years a change is however noticed as more and 
more females are diagnosed with HIV with sexual contact as risk factor.  
A comprehensive and integrated program was therefore developed and funded 
by the European Union (EU) in 2006 for the prevention, control and treatment of 
HIV among drug users in West Java (IMPACT program). Among others, a 
prospective cohort was developed of all patients entering services for HIV/AIDS 
in the Teratai HIV clinic of the Hasan Sadikin Hospital since 2007. Hasan 
Sadikin Hospital, Bandung is the tertiary referral hospital for HIV care in West 
Java, one of the provinces with highest numbers of HIV-infected patients in 
Indonesia. The present thesis reports results from studies performed within the 
IMPACT cohort.   
In chapter 2, an overview of the challenges in delivering HIV care in Indonesia 
is given. Advanced disease, loss to follow-up and monitoring of antiretroviral 
treatment are some of the issues challenging effective delivery of antiretroviral 
treatment (ART). Co-infections are common in HIV-infected patients presenting 
in an advanced stage whereby Mycobacterium tuberculosis is among the most 
important microorganisms. Indeed, almost half of HIV-infected patients at the 
Hasan Sadikin Hospital HIV clinic (Teratai clinic) had a history of TB treatment 
and 20% received concomitant treatment for HIV and TB. Diagnosis and 
treatment of TB in HIV-infected patients faces additional challenges. 
Antiretroviral treatment HIV in Indonesia is strongly associated with injecting 
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drug use (IDU), and surrounding stigma and lack of knowledge reduce 
accessibility of services. Uptake of HIV-testing is low and many patients present 
with advanced AIDS. Through the IMPACT program, significant progress has 
however been made in delivering HIV-care in West-Java through operational 
research, systematic treatment monitoring, and the use of simple indicators to 
evaluate the quantity and quality of care. 
In chapter 3, the value of the total lymphocyte counts (TLC) as an alternative for 
CD4 cell count measurements to monitor HIV infection in resource-limited 
settings is described. Using prospectively collected patient data from the Teratai 
HIV clinic, predictors of mortality were identified and the relation between TLC 
and CD4 cell counts was calculated. ROC curves were used to choose the cut-
off values of TLC corresponding with CD4 cell counts <200 and <350 cells/mm3. 
Based on these analyses, TLC-based treatment algorithms were made. We 
found that TLC and CD4 cell counts were equally strong predictors of mortality 
in our population, where ART was started based on CD4 cell count criteria. The 
correlation coefficient (R) between TLC and CD4 was 0.70. Optimal cut-off 
values for TLC to identify patients with CD4 cell counts <200 and <350 
cells/mm3 were 1500 and 1700 cells/mm3, respectively. Treatment algorithms 
based on a combination of TLC, gender, oral thrush, anemia and body mass 
index performed better in terms of predictive value than WHO staging or TLC 
alone. In our cohort, such an algorithm would on average have saved $14.05 
per patient. We concluded that the total lymphocyte count is a good marker for 
HIV-associated mortality. Simple algorithms including TLC can prioritize patients 
for HIV treatment in a resource-limited setting,  
In chapter 4, further studies were done to explore whether TLC can be used an 
alternative for CD4 cell measurements, focusing on monitoring during ART. It 
was found that TLC cannot be used during first year of ART treatment but 
thereafter can identify patients with immunological failure and help clinicians 
decide about stopping PJP-prophylaxis. As such, TLC obviates the need for 
routine measurement of CD4 cell counts in many cases, thereby reducing the 
costs of laboratory monitoring of HIV treatment. Different TLC thresholds were 
found for for men and women. Further studies are needed to examine if 
combining TLC with clinical markers (e.g. pill counts) can more accurately 
predict immunological or virological failure to treatment. Some caution is 
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warranted in interpreting our research findings given the relatively small study 
population, which came exclusively from Indonesia. 
Anemia appeared to be an important factor in the TLC-based treatment 
algorithms. Indeed anemia is a common clinical finding in HIV-infected patients 
and iron deficiency or redistribution may contribute to the development of low 
hemoglobin levels. Iron overload is associated with a poor prognosis in HIV and 
Hepatitis C virus infections while iron redistribution may be caused by 
inflammation but possibly also by hepatitis C co-infection. In chapter 5, the 
prevalence of anemia and its relation to mortality in the IMPACT cohort was 
examined. Furthermore, the relation between anemia, iron parameters (sTfR, 
ferritin) and inflammation (hsCRP) was explored, considering also the influence 
of severity of HIV, ART and HCV infection. Anemia was found in 49.6% of  ART-
naive patients, with mild (Hb 10.5 - 12.99 g/dL for men; and 10.5 - 11.99 g/dL for 
women) anemia in 62.0%, and moderate to severe anemia (Hb < 10.5 g/dL) in 
38.0%. Anemia remained an independent factor associated with death, also 
after adjustment for CD4 count and ART (p = 0.008). Seroprevalence of HCV 
did not differ in patients with (56.9%) or without anemia (59.6%). Serum ferritin 
concentrations were elevated, especially in patients with anemia (p = 0.07) 
and/or low CD4 counts (p < 0.001), and were not related to hsCRP or HCV 
infection. Soluble TfR concentrations were low and not related to Hb, CD4, 
hsCRP or ART. We concluded that HIV-associated anemia is common among 
HIV-infected patients in Indonesia and strongly related to mortality. High ferritin 
with low sTfR levels suggests that iron redistribution and low erythropoietic 
activity, rather than iron deficiency, contribute to anemia. Serum ferritin and 
sTfR should therefore be used cautiously to assess iron status in patients with 
advanced HIV infection. 
Alterations in the distribution of iron are common in infectious diseases and 
many of these alterations may be attributable to the actions of the central iron-
regulator hepcidin. This hormone inhibits the absorption of iron in the intestine 
and locks iron into monocyte/macrophages and the spleen, through degradation 
of the sole cellular iron exporter ferroportin. Hepcidin-mediated iron 
accumulation in macrophages may increase the risk for outgrowth of 
intracellular pathogens like Mycobacterium tuberculosis. Worldwide, 
tuberculosis is the most important infectious disease complication among HIV-
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infected patients, and several lines of evidence suggest that macrophage iron 
content is related to the risk for developing active TB. In chapter 6, we studied 
the association of hepcidin with HIV-status as well as the association between 
hepcidin and other markers of iron homeostasis with development of TB. HIV 
patients developing TB 1 month after entering the IMPACT cohort (‘cases’) were 
compared with two groups of HIV patients who did not develop TB during follow-
up, one matching for age, gender and CD4 cell count (‘matched controls’), and 
one without matching for CD4 cell count (‘unmatched controls’). Iron parameters 
including hepcidin were measured from samples collected at initial presentation. 
We found that advanced HIV infection is associated with increased hepcidin 
expression and characteristic features of iron maldistribution and this may, 
among others, stimulate HIV progression and contribute to HIV-associated 
anemia. Patients starting TB shortly after cohort enrollment had significantly 
higher serum hepcidin and ferritin level at cohort enrollment, but this effect was 
not present in those starting TB treatment after at least 2 months. 
Apart from iron status, as a risk factor for the development of TB in HIV-infected 
patients, we also studied in chapter 7 whether injecting drug use increase risk 
of active tuberculosis in HIV patients. Furthermore we explored whether 
injecting drug use accelerates the natural decline of CD4 cells in the IMPACT 
cohort in which HIV-infected patients are followed. It was found that IDU was 
associated with a more rapid decline of CD4 cell counts (p=0.009), compared to 
non-IDU. According to the model, which accurately predicted subsequent CD4 
cell counts (R2=0.77), a decline of CD4 cells from 350 to 200 cells/mm3 would 
take an average of 18 months less for patients with a history of IDU. During 
follow-up, patients with a history of IDU had a higher incidence of active 
tuberculosis (19.5% versus 8% for patients without IDU, adjusted hazard ratio: 
2.38, p<0.001).  It was concluded that IDU among HIV-infected patients in West 
Java is associated with a more rapid CD4 cell decline and a higher risk of active 
tuberculosis. These findings may have implications for patient monitoring and 
starting ART, and for tuberculosis prophylaxis, both among HIV-infected and 
non-infected injecting drug users.  
There is a common belief among clinicians, also in Indonesia, that IDU is 
associated with lower uptake, retention and success of antiretroviral treatment 
(ART) in HIV-infected patients. The response to ART in the IMPACT cohort was 
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studied in those with and without a history of injecting drug use (chapter 8).      
A total of 773 adult HIV patients (81.9% IDUs) were included in the IMPACT 
cohort between January 1996 and April 2008. IDUs had a median CD4 cell 
count of 33 [IQR, 12–111] cells/mm3 compared to 84 (IQR, 28–224) cells/mm3 in 
non-IDUs. Among patients with a history of IDU, 87.7% were co-infected with 
hepatitis C (HCV). Mortality was associated strongly with CD4 count; after 6 
months of ART, 18.3, 20.3, 7.1 and 0.7% of patients with CD4 cell counts < 25, 
25–99, 100–199, respectively, 200/mm3 had died (P < 0.0001). Mortality, loss to 
follow-up and virological failure was not significantly different in IDUs and non-
IDUs. It was concluded that HIV-infected IDUs in Indonesia tend to have more 
advanced disease, compared to non-IDUs but respond similarly to non-IDUs to 
antiretroviral therapy.  
Despite the rapid scale-up of ART in Indonesia in recent years, virological 
response of first-line ART is largely unknown. This is of particular interest since 
the majority of HIV-infected patients have a history of injecting drug use (IDU), 
which is often linked with lower treatment adherence and development of drug-
resistance. In chapter 9 the occurrence of virological failure, possible risk 
factors for failure, and the distribution of drug resistance mutations during 
NNRTI-based first line ART were assessed in the IMPACT cohort. Between 
September 2007 and March 2010, 595 HIV patients started ART. Most HIV 
patients were male (72.3%), 59.7% had a history of IDU, and the median CD4 
cell count before start of ART was 35 cells/mm3 (IQR 10-104). From 438 HIV 
patients with HIV-RNA measurements, 40 (9.1%) subjects had HIV-RNA > 400 
copies/ml during a median follow-up 16 of (IQR 8-25) months. Of HIV viremia 
patients 18 (52.9%) subjects had drug resistance mutations, predominantly 
M184V (35.3%), Y181C (23.5%), K103N (11.7%) and TAMs (11.7%). A history 
of treatment discontinuation > 1 month, reported by 3.9% of patients, was 
strongly associated with treatment failure (adjusted OR 12.64, 95% CI 4.51-
35.41). A history of injecting drug use was not linked with HIV viremia. Overall it 
was concluded that patients responded well to first line ART treatment, with low 
levels of HIV-viremia and drug resistance. Efforts should be made to reduce 
treatment discontinuation as it was found to be a strong risk factor for treatment 
failure. A history of injecting drug use should not be a reason to withhold ART in 
this setting. 
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Future perspectives 
As country with the fifth largest burden of TB in the world, TB-HIV causes a 
‘double trouble’ in Indonesia. TB is the main co-infection in HIV and responsible 
for almost 25% of all HIV deaths [4]. Our cohort data show that more than 30% 
of HIV-infected patients have been or are treated for tuberculosis. 
Implementation of the three I’s for TB-HIV – 1. Intensified TB case findings 
among HIV patients, 2. Isoniazid preventive therapy and 3. TB Infection control  
is however insufficient [4]. As such there are still great challenges to improve the 
prevention, control and treatment of HIV-TB co-infections. In any case, there is a 
clear need for high quality care integrating services for HIV and tuberculosis.  
Injecting drug use (IDU) has been one of the main engines driving the HIV 
epidemic in Indonesia. IDU is not only a risk factor for HIV transmission, but it 
may also change the natural course of HIV infection, increase the risk of co-
infections and /or nutritional deficiencies. In addition, drug use could influence 
impulse control, health seeking behaviour and as such could influence treatment 
outcome. In the IMPACT program, continuous efforts were done to secure 
adherence to treatment for all those taking ART. More studies are however 
needed to understand risk behaviour in IDUs and how this interferes with HIV 
and other co-infections. In addition, better access to care is needed for IDU, 
including HIV-infected IDUs.  
Over time, a substantial increase in the number of HIV-seropositive women was 
noticed in the IMPACT cohort in Bandung, including female partners of known 
HIV-positive males. At the end of 2009, women made up 25.8% of people living 
with HIV (PLHIV) in Indonesia as reported by ministry of health [5]. Data from 
our cohort revealed that women had a better health status compared to men, 
9.1% was pregnant at the time of HIV testing and 72.2% had already children. 
HIV-infected women need specialized health services which are currently not 
generally available in Indonesia. A better understanding is needed of how the 
“mostly by male IDU driven HIV epidemic” slowly changes into an epidemic 
were also a substantial number of women are at increased risk.   
A strong multidisciplinary team has been established in the past few years 
concentrating on various issues related to HIV care in Indonesia. I hope that this 
team will continue to work together so that our collaborative research will carry 
on to evolve, increasing our understanding of HIV, and improving the 
comprehensive care for HIV-infected patients in Indonesia and elsewhere.  
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Ringkasan 
Di Eropa Timur dan Asia, pengguna napza suntik (penasun) adalah kelompok 
faktor risiko terbesar yang menyebabkan epidemi HIV [1]. walaupun dalam 
tahun-tahun terakhir prevalensi HIV di negara-negara Asia seperti Thailand, 
Kamboja dan Myannmar mulai menurun, tidak demikian halnya dengan 
Indonesia. Indonesia tetap merupakan salah satu negara dengan pertumbuhan 
HIV tercepat di Asia [2]. Prevalensi HIV pada kelompok penasun di berbagai 
kota besar di Indonesia seperti Jakarta dan Bandung bervariasi antara 18% 
hingga 50%; dan penggunaan alat suntik yang tidak aman menyebabkan 72% 
infeksi HIV baru pada tahun 2011. Walaupun jumlah penasun relatif sedikit, 
tetapi perannya dalam menyebarkan infeksi HIV sangat penting karena dapat 
menularkan lebih lanjut kepada pasangan seksualnya dan menjadi ‘bridging 
population’ kepada kelompok transmisi seksual. Penasun di Indonesia 
kebanyakan bergender pria dan mempunyai perilaku seksual berisiko tinggi, 
diantaranya memiliki pasangan seksual lebih dari 1 (48%) serta kerap membeli 
seks pada pekerja seks komersial (40%) [3]. Akhir-akhir ini mulai terlihat 
pergeseran faktor risiko utama tertular HIV melalui hubungan seksual karena 
terjadi peningkatan proporsi wanita yang terinfeksi HIV melalui hubungan 
seksual.  
 
Pada tahun 2006, Uni Eropa membiayai pengembangan program komprehensif 
dan terintegrasi untuk pencegahan, kontrol dan pengobatan HIV pada penasun 
di Propinsi Jawa Barat (IMPACT: Integrated Management of Prevention and 
control and Treatment of HIV/AIDS). Dalam program ini kohort prospektif dibuat 
dengan mengikutsertakan semua penderita HIV/AIDS yang berkunjung sejak 
tahun 2007 ke Klinik Teratai di Rumah Sakit (RS) Dr. Hasan Sadikin. RS Dr. 
Hasan Sadikin Bandung adalah RS rujukan tersier untuk perawatan HIV di Jawa 
Barat, salah satu propinsi dengan jumlah penderita HIV terbanyak di Indonesia. 
Thesis ini merupakan kumpulan laporan dari beberapa penelitian yang 
dilakukan pada kohort IMPACT ini.   
 
Tinjauan umum mengenai tantangan pelayanan HIV di Indonesia dipaparkan 
pada Bab 2. Datang terlambat dengan penyakit pada tahap lanjut, gagal follow-
up dan monitoring pengobatan Anti Retroviral (ARV) merupakan sebagian dari 
masalah-masalah  pelayanan HIV di Indonesia. Ko-infeksi sering terjadi pada 
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penderita yang datang terlambat pada tahap lanjut penyakit AIDS. Diantaranya 
yang terpenting adalah ko-infeksi dengan Mycobacterium tuberculosis (TB), 
bahkan hampir separuh penderita HIV yang masuk ke Klinik HIV (Teratai) RS 
Dr. Hasan Sadikin memiliki riwayat pengobatan TB dan 20% menjalani 
sekaligus pengobatan untuk HIV dan TB secara bersamaan.  
 
Diagnosis dan pengobatan TB pada penderita HIV memiliki tantangan 
tersendiri. Pengobatan ARV di Indonesia bagi penasun sering berhubungan 
dengan stigma dan rendahnya tingkat pengetahuan, hingga menyulitkan akses 
layanan. Cakupan tes HIV masih rendah dan banyak penderita baru menerima 
tes HIV pada tahap AIDS lanjut. Melalui program IMPACT, berbagai kemajuan 
dalam peningkatan pelayanan HIV di Jawa Barat telah dilakukan melalui 
pendekatan penelitian operasional, monitoring pengobatan secara sistematis 
dan penggunaan indikator-indikator sederhana untuk mengevaluasi kuantitas 
dan kualitas pelayanan kesehatan. 
 
Bab 3 memperlihatkan bahwa nilai total lymphocyte count (TLC) dapat 
menggantikan pemeriksaan CD4 yang lebih mahal untuk memonitor perjalanan 
infeksi HIV di tempat layanan dengan sarana terbatas. Menggunakan data dari 
kohort prospektif Klinik Teratai, prediktor kematian selama pengobatan diteliti 
dan hubungan antara TLC dan jumlah sel CD4 diperiksa. Kurva ROC digunakan 
untuk memilih nilai cut-off TLC yang setara dengan jumlah sel CD4 <200 dan 
<350/mm3. Berdasarkan penelitian ini, algoritma pengobatan dengan 
menggunakan TLC dibuat. Kami menemukan bahwa TLC dan CD4 merupakan 
prediktor kuat kematian yang setara pada populasi yang menggunakan CD4 
sebagai standar pengobatan. Koefisien korelasi (R) antara TLC dan CD4 
ditemukan sebesar 0.70. Nilai cut-off TLC yang optimal untuk mengenali 
penderita HIV dengan jumlah sel CD4 < 200 dan < 350/mm3 adalah < 1500 dan 
< 1700 sel/mm3. Algoritma pengobatan yang menggunakan kombinasi antara 
nilai TLC, oral thrush, anemia dan indeks massa tubuh (IMT) mempunyai 
kemampuan diagnostik yang lebih baik daripada staging menurut WHO atau 
penggunaan nilai TLC saja. Pada kohort kami, penggunaan algoritma ini dapat 
menghemat hingga sejumlah Rp.135.000,- per pasien. Kami berkesimpulan 
bahwa total lymphocyte count adalah faktor prediktor yang baik untuk kematian 
yang berhubungan dengan HIV. Algoritma sederhana yang menggunakan TLC 
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dapat membantu pasien yang memerlukan pengobatan HIV pada tempat 
layanan dengan sarana terbatas. 
 
Peran TLC sebagai alat monitoring pengobatan ARV diteliti lebih lanjut pada 
Bab 4. Kami menemukan bahwa TLC tidak dapat digunakan pada tahun 
pertama setelah pemberian ARV, tetapi dapat mengenali pasien yang 
mengalami kegagalan imunologis dan membantu klinisi untuk memutuskan 
penghentian obat profilaksis PCP (Pneumocystis jiroveci Pneumonia), bila 
digunakan sesudah 1 tahun ARV.  
 
TLC dapat menggantikan pemeriksaan rutin CD4 pada berbagai keadaan, dan 
menurunkan biaya pemeriksaan laboratorium untuk monitoring ARV. Terdapat 
nilai TLC yang berbeda untuk pria dan wanita. Masih diperlukan penelitian 
lanjutan untuk melihat manfaat kombinasi TLC dengan marka-marka klinis 
lainnya (misalnya hitung pil) untuk memprediksi kegagalan imunologis atau 
virologis pada penderita HIV dengan ARV secara lebih akurat. Penelitian kami 
harus diintepretasi secara hati-hati, mengingat jumlah subyek penelitian yang 
relatif sedikit, dan hanya berasal dari Indonesia.  
 
Anemia adalah faktor penting dalam algoritma TLC dan merupakan temuan 
klinis yang sering dijumpai pada penderita HIV. Anemia pada penderita HIV 
dapat disebabkan oleh keadaan defisiensi atau redistribusi zat besi. Telah 
diketahui infeksi virus Hepatitis C (HCV) berpengaruh pada redistribusi zat besi. 
Kelebihan zat besi merupakan faktor prognosis yang buruk pada penderita HIV 
dan infeksi virus Hepatitis C (HCV); dan redistribusi zat besi dapat disebabkan 
oleh proses inflamasi dan infeksi HCV. Pada Bab 5 prevalensi anemia dan 
pengaruhnya pada kematian pada kohort IMPACT diteliti. Lebih jauh lagi, 
hubungan antara anemia, marka-marka homeostasis zat besi (sTfR, ferritin) dan 
inflamasi (hsCRP) dieksplorasi, dengan memperhitungkan pula pengaruh 
beratnya infeksi HIV, pemberian ARV dan infeksi HCV. Penelitian ini 
menemukan bahwa anemia pada penderita tanpa ARV ditemukan hingga 
49.6%, sebagian besar anemia ringan (Hb 10.5 - 12.99 g/dL untuk pria; dan 
10.5 - 11.99 g/dL untuk wanita) sebanyak 62.0%, dan anemia sedang hingga 
berat (Hb < 10.5 g/dL) sebanyak 38.0%. Anemia merupakan faktor risiko 
kematian independen setelah dikoreksi (adjusted) dengan jumlah sel CD4 dan 
ARV (p = 0.008). Seroprevalensi HCV tidak berbeda antara kelompok penderita 
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anemia (56.9%) dan tidak (59.6%). Kadar ferritin serum ditemukan meningkat, 
terutama pada penderita anemia (p = 0.07) dan/atau penderita dengan jumlah 
sel CD4 yang rendah (p < 0.001), tetapi tidak berhubungan dengan hsCRP atau 
infeksi HCV. 
 
Kadar sTfR penderita HIV rendah dan tidak berhubungan dengan Hb, CD4, 
hsCRP atau ARV. Kami berkesimpulan bahwa anemia sering ditemukan pada 
penderita HIV di Indonesia dan berhubungan erat dengan kematian. Kadar 
ferritin yang tinggi dan sTfR yang rendah memperlihatkan adanya redistribusi 
zat besi dan aktifitas eritropoetik yang rendah sebagai penyebab anemia yang 
lebih dominan daripada anemia yang disebabkan defisiensi zat besi. Kadar 
ferritin dan sTfR harus diintepretasi secara hati-hati pada penderita dengan 
infeksi HCV.  
 
Gangguan pada distribusi zat besi sering ditemukan pada berbagai penyakit 
infeksi dan banyak diakibatkan oleh kadar hepcidin sebagai hormon pengatur 
zat besi. Hormon hepcidin menghambat penyerapan zat besi dari saluran 
intestinal dan menimbun zat besi dalam sel-sel monosit/makrofag melalui 
degradasi ferroportin yang merupakan eksporter zat besi pada sel. Akumulasi 
zat besi dalam makrofag meningkatkan risiko pertumbuhan patogen intraselular 
seperti Mycobacterium tuberculosis. Di seluruh dunia, tuberkulosis adalah 
penyakit infeksi terpenting yang menyertai HIV, dan terdapat bukti-bukti bahwa 
kadar zat besi dalam makrofag berkaitan dengan risiko kejadian TB aktif. Pada 
Bab 6 kami mempelajari asosiasi antara hepcidin dan marka-marka 
homeostasis zat besi dalam tubuh dengan kejadian TB. Penderita HIV yang 
mengalami infeksi TB setelah 1 bulan memasuki kohort IMPACT (kelompok 
kasus) dibandingkan dengan 2 kelompok kontrol yang tidak mengalami infeksi 
TB selama follow-up, satu kelompok matched controls setara untuk umur, 
gender dan jumlah CD4, dan satu kelompok lagi diambil dari kelompok 
penderita HIV dengan CD4 yang lebih tinggi (unmatched controls). Pemeriksaan 
hepcidin dan marka-marka zat besi dilakukan pada sampel serum yang 
dikumpulkan pada saat penderita masuk kohort. Kami menemukan bahwa 
tahap lanjut infeksi HIV berhubungan dengan peningkatan kadar hepcidin dan 
redistribusi zat besi; yang juga dapat menstimulasi progresivitas infeksi HIV dan 
menyebabkan anemia. Penderita HIV yang mengalami infeksi TB segera 
setelah memasuki kohort memiliki kadar serum hepcidin dan ferritin yang lebih 
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tinggi daripada penderita HIV yang tidak mengalami infeksi TB selama follow-
up, tetapi hal ini tidak ditemukan pada penderita HIV yang mengalami infeksi TB 
2 bulan setelah memasuki kohort. 
 
Selain status zat besi sebagai faktor risiko kejadian infeksi TB pada penderita 
HIV, kami juga mempelajari pada Bab 7 peran penggunaan napza suntik 
(penasun) sebagai faktor risiko TB aktif pada penderita HIV. Kami meneliti lebih 
lanjut kemungkinan status penasun mempercepat laju alamiah penurunan CD4 
pada penderita HIV dalam kohort IMPACT. Kami menemukan bahwa penderita 
HIV yang memiliki riwayat penasun berhubungan dengan laju penurunan CD4 
yang lebih cepat dibandingkan dengan penderita HIV yang tidak mempunyai 
riwayat penasun (p=0.009). Menurut model, yang secara akurat dapat 
memprediksi nilai CD4 (R2=0.77), penurunan jumlah sel CD4 dari 350 ke 200 
sel/mm3 memerlukan waktu rata-rata 18 bulan atau kurang pada penderita HIV 
yang mempunyai riwayat penasun. Selama follow-up penderita HIV dengan 
riwayat penasun mempunyai angka insidensi TB aktif yang lebih tinggi 
dibandingkan penderita HIV tanpa riwayat penasun (19.5% versus 8%, adjusted 
hazard ratio: 2.38, p<0.001).  Kami berkesimpulan bahwa penderita HIV di Jawa 
Barat dengan riwayat penasun mempunyai laju penurunan CD4 yang lebih 
cepat dan risiko yang lebih tinggi untuk menderita TB aktif. Penemuan ini 
berimplikasi pada perlunya monitoring dan start ARV yang lebih cepat, serta 
perlunya pemberian profilaksis TB pada kelompok penasun dengan atau tanpa 
infeksi HIV.  
 
Masih banyak pendapat para klinisi, termasuk di Indonesia, bahwa penasun 
memiliki uptake pengobatan dan kepatuhan yang rendah, sehingga 
keberhasilan ARV pada penasun dengan infeksi HIV juga terbatas. Untuk 
menjawab masalah itu kami meneliti respon pengobatan ARV pada kohort 
IMPACT, yang meliputi kelompok penderita HIV dengan atau tanpa riwayat 
penasun Bab 8. Sejumlah total 773 (penasun: 81.9%) ikut serta dalam kohort 
IMPACT antara Januari 2006 dan April 2008. Penderita HIV dengan riwayat 
penasun memiliki median jumlah sel CD4 lebih rendah yaitu 33 [IQR, 12–111] 
sel/mm3 dibandingkan dengan 84 (IQR, 28–224) sel/mm3 pada penderita HIV 
tanpa riwayat penasun. Pada penderita dengan riwayat penasun, 87.7% 
mempunyai koinfeksi dengan hepatitis C (HCV). Mortalitas berhubungan erat 
dengan jumlah sel CD4; setelah 6 bulan ARV, kematian terjadi pada 18.3, 20.3, 
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7.1 and 0.7% pada penderita dengan jumlah CD4 sel < 25, 25–99, 100–199, 
200/mm3 (P < 0.0001). Mortalitas, gagal follow-up dan gagal virologis tidak 
berbeda bermakna antara kelompok penderita HIV dengan atau tanpa riwayat 
penasun. Disimpulkan bahwa penasun yang terinfeksi HIV di Indonesia 
mempunyai manifestasi penyakit yang lebih berat dibanding penderita HIV 
tanpa riwayat penasun tetapi memiliki respon yang sama baiknya terhadap 
pengobatan ARV.  
 
Walaupun terjadi intensifikasi (scaling up) pemberian ARV di Indonesia dalam 
tahun-tahun terakhir ini, respon virologis terhadap ARV lini pertama tidak 
banyak diketahui. Hal ini menarik untuk diteliti, mengingat mayoritas penderita 
HIV yang memiliki riwayat penasun sering dihubungkan dengan kepatuhan 
berobat yang rendah dan ketakutan terjadinya mutasi virus yang menyebabkan 
resistensi obat. Pada Bab 9 kejadian kegagalan virologis, faktor-faktor yang 
berhubungan dengan kegagalan virologis dan kejadian resistensi obat pada 
ARV lini pertama berbasis NNRTI dianalisa pada kohort IMPACT. Sebanyak 
595 penderita HIV yang memulai ARV antara bulan september 2007 dan Maret 
2010 diikutkan dalam penelitian ini. Kebanyakan penderita HIV adalah pria 
(72,3%), 59,7% mempunyai riwayat penasun dan memiliki median CD4 35 (IQR 
10-104) sel/mm3 sebelum start ARV. Dari 438 penderita HIV yang diperiksa 
HIV-RNA, 40 (9.1%) memliki HIV-RNA > 400 copies/ml dalam median follow-up 
16 (IQR 8-25) bulan. Pada penderita yang mengalami viremia, 18 (52.9%) 
pasien memperlihatkan adanya mutasi resistensi obat, terbanyak adalah M184V 
(35.3%), Y181C (23.5%), K103N (11.7%) dan TAMs (11.7%). Riwayat 
penghentian obat > 1 bulan yang dilaporkan oleh 3.9% pasien,  berhubungan 
erat dengan kegagalan pengobatan ARV (adjusted OR 12.64, 95% CI 4.51-
35.41). Riwayat penasun tidak berhubungan dengan kejadian viremia HIV. Kami 
mengambil kesimpulan bahwa penderita HIV mempunyai respon yang baik 
terhadap pengobatan ARV lini pertama berbasis NNRTI, dengan kejadian 
viremia HIV dan mutasi resistensi obat yang rendah. Upaya-upaya lanjutan 
diperlukan untuk meningkatan kepatuhan pengobatan ARV karena penghentian 
obat merupakan faktor risiko utama kegagalan pengobatan. Kami juga 
menyimpulkan bahwa riwayat penasun tidak dapat menjadi alasan penundaan 
pemberian ARV.  
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Melihat ke depan 
Sebagai negara dengan jumlah kasus TB nomor 5 didunia, ko-infeksi TB-HIV 
menyebabkan epidemi ganda di Indonesia. TB adalah ko-infeksi utama pada 
penderita HIV dan menyebabkan kematian pada hampir 25% penderita HIV [4]. 
Kohort kami menunjukkan lebih dari 30% penderita HIV pernah atau sedang 
dalam pengobatan TB pada saat ditemukan. Implementasi program WHO 3I 
untuk TB-HIV - 1. Intensified TB case finding among HIV patients (penemuan 
kasus TB pada penderita HIV), 2. Isoniazid preventive therapy (profilaksis TB 
dengan Isoniazid) dan 3. TB Infection control (kontrol infeksi TB) belum 
sepenuhnya dijalankan [4]. Oleh karena itu masih banyak tantangan yang 
dihadapi untuk meningkatkan mutu pelayanan kesehatan pada TB-HIV. 
Integrasi yang berkualitas untuk pelayanan TB-HIV jelas diperlukan.  
 
Pengguna napza suntik (penasun) merupakan motor utama penggerak epidemi 
HIV di Indonesia. Penasun bukan hanya merupakan faktor risiko infeksi HIV, 
tetapi dapat juga merubah perjalanan alamiah infeksi HIV, meningkatkan risiko 
ko-infeksi dan atau defisiensi nutrisi. Sebagai tambahan, penasun juga dapat 
mempengaruhi kendali perilaku, akses layanan dan sebagai akibatnya dapat 
mempengaruhi hasil pengobatan. Dengan program IMPACT upaya-upaya untuk 
meningkatkan kepatuhan pengobatan telah dilakukan. Diperlukan lebih banyak 
penelitian untuk lebih banyak mengetahui tentang perilaku berisiko penasun dan 
kaitannya dengan infeksi HIV dan ko-infeksi lainnya. Sebagai tambahan, 
penasun, termasuk yang terinfeksi HIV, memerlukan layanan kesehatan yang 
lebih baik. 
 
Seiring dengan perjalanan waktu, proporsi wanita yang terinfeksi HIV terus 
meningkat pada kohort IMPACT di Bandung, termasuk pasangan seksual 
wanita dari pria yang terinfeksi HIV. Kementrian Kesehatan Republik Indonesia 
melaporkan bahwa pada akhir 2009, proporsi wanita penderita HIV adalah 
sebesar 25,8% [5]. Kohort kami memperlihatkan bahwa wanita mempunyai 
status kesehatan yang lebih baik pada saat ditemukan dibanding pria; akan 
tetapi pada saat ditemukan 9,1% diantaranya tengah hamil dan 72,2% telah 
memiliki anak. Wanita yang terinfeksi HIV memerlukan pelayanan kesehatan 
khusus yang saat ini belum tersedia di Indonesia. Diperlukan pemahaman yang 
lebih baik terhadap perubahan epidemi yang pada mulanya dipicu pria penasun 
kearah epidemi yang menempatkan wanita sebagai kelompok berisiko.  
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Berkat program IMPACT, sebuah tim multidisiplin yang kuat telah terbentuk, dan 
dalam beberapa tahun terakhir ini yang berkerja pada berbagai masalah 
pelayanan HIV di Indonesia. Saya berharap tim ini dapat terus bekerja bersama-
sama sehingga kolaborasi penelitian dapat terus berkembang, sehingga 
memperkaya pemahaman kita terhadap HIV dan memperbaiki kualitas 
pelayanan kesehatan komprehensif terhadap penderita HIV di Indonesia dan 
tempat-tempat lainnya. 
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Samenvatting 
In Oost-Europa en Azië is intraveneus drugsgebruik de belangrijkste risico factor 
die bijdraagt tot de HIV-epidemie [1]. Indonesië heeft een van de snelst 
groeiende HIV-epidemieënvan Azië terwijl in de afgelopen jaren de HIV-
prevalentie in landen als Thailand, Cambodja en Myanmar is afgenomen [2].  In 
2011 was het onsterieldrug injecteren verantwoordelijk voor meer dan 72% van 
alle nieuwe HIV-infecties in Indonesia en de HIV prevalentie onder injecterende 
drug gebruikers (IDG) in grote Indonesische steden als Jakarta en Bandung is 
aanzienlijk en varieert van 18% tot meer dan 50%. Zelfs als het aantal IDG 
relatief klein is, kan hun bijdrage aan het verspreiden van HIV aanzienlijk zijn, 
met name door seksueel risico gedrag. In Indonesië zijn IDGmeestal mannen en 
onbeschermde seks komt veel voor, inclusief het hebben van meerdere partners 
(48%) en prostitué bezoek (40%) [3]. De laatste jaren worden echter meer en 
meer vrouwen worden gediagnosticeerd met een HIV infectie met seksueel 
contact als risicofactor. 
Om de verspreiding van HIV in Indonesie tegen te gaan werd een programma 
ontwikkeld en gefinancierd door de EU voor de preventie, bestrijding en 
behandeling van HIV onder drugsgebruikers in West-Java (IMPACT 
programma). Er werd een prospectief cohort ontwikkeldvanaf 2007 van HIV-
seropositievepatiënten die werden gecontroleerd en behandeld in de Teratai 
HIV kliniek van hetUniversitaire HasanSadikin Ziekenhuis in Bandung, het 
belangrijkste referentie ziekenhuis in West-Java. West Java is een van de 
provincies met de hoogste aantalHIV-geïnfecteerde patiënten in Indonesië. Dit 
proefschrift beschrijft de studies uitgevoerd binnen het IMPACT cohort. 
 
In hoofdstuk 2 wordt een overzicht gegeven van de complexiteitvan het leveren 
van HIV-zorg in Indonesië. Vergevorderde ziekte, toegang tot zorg, verlies van 
patiënten tijdens de follow-up en het monitoren van de antiretrovirale 
behandeling zijn voorbeelden van de uitdagingen waar de HIV behandelaar voor 
staat. Stigma en discriminatie ten gevolge van injecterend drugsgebruik 
beperken de toegang tot zorg en veel HIV-geinfecteedepatiënten zijn daarom 
ook niet op HIV getest. Veel patiëntenpresenteren zich daarom in een 
vergevorderd stadium van de ziekte. Co-infecties komen vaak voor bij HIV-
geïnfecteerde patiënten in een vergevorderd stadium, waarbij Mycobacterium 
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tuberculosiseen van de belangrijkste verwekkers is. Inderdaad, bijna de helft 
van de HIV-geïnfecteerde patiënten is in het verleden voor TB behandeld en 
20% werd gelijktijdig behandeld voor HIV en TB. Het IMPACT-programma heeft 
er voor gezorgd dat er aanzienlijke vooruitgang is gemaakt in het leveren van 
HIV-zorg in West-Java, onder andere door optimalisatie van interventies die 
“evidencebased” zijn.  
In hoofdstuk 3 wordt de waarde van de totale lymfocyten (TLC) aantal 
onderzocht als alternatief voor de meting van aantal CD4-cellen, onder andere 
door het gebruik van ROC-curves.Er werden met behulp van TLC ook 
algoritmen gemaakt. We vonden dat de waarde van TLC en CD4-cel metingen 
gelijkwaardig was in het voorspellen van de sterfte in ons cohort. De 
correlatiecoëfficiënt (R) tussen TLC en CD4 was 0,70. Optimale cut-off waarden 
voor TLC om patiënten te identificeren met een CD4-cellen <200 en <350 
cellen/mm3 waren 1500 respectievelijk 1700 cellen / mm3 Een algoritmevoor 
HIV behandeling werd samengesteld op basis van combinaties van TLC, 
geslacht, orale candida infectie, bloedarmoede en body mass index. Dit 
algoritme had een beter  voorspellende waarde dan de WHO stadiering of TLC 
alleen en het systematisch gebruik daarvan in ons cohort  zou 14,05 dollar per 
patiënt hebben bespaard. We concludeerden dat TLC een goede marker is voor 
HIV-geassocieerde mortaliteit en dat eenvoudige algoritmesmet TLC een goede 
indicatie kunnen geven voor start HIV behandeling in geval de financiële 
middelen beperkt zijn 
In hoofdstuk 4, werden verdere studies uitgevoerd om te onderzoeken of TLC 
als alternatief kan functioneren voor CD4-cellen bepalingen tijdens ART. We 
vonden dat TLC niet kan worden gebruikt tijdens het eerste jaar van ART 
behandeling, maar dat TLC na het eerste jaar ART behulpzaam kan zijn bij het 
identificeren van patiënten met immunologische falen en de beslissing om PJP-
profylaxe te stoppen of te continueren. Ook bleek dat er voor mannen en 
vrouwen verschillende TLC drempelwaarden gehanteerd dienen te worden. 
Verdere studies zijn nodig om te onderzoeken of het combineren van TLC met 
klinische indicatoren immunologisch of virologisch falen van ART behandeling 
nauwkeuriger kan voorspellen.  
Anemie bleek een belangrijke factor in de op TLC-gebaseerde 
behandelingsalgoritmen. Inderdaad anemie komt veel voor bij HIV-
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geïnfecteerde patiënten en ijzerdeficiëntie of ijzer redistributiein het lichaam kan 
een belangrijke factorzijn bij de ontwikkeling van anemie. IJzerstapeling is 
geassocieerd met een slechte prognose van een HIV en Hepatitis C virus (HCV) 
infecties terwijl ontsteking en HCV een ijzer herverdeling in het lichaam 
veroorzaken. In hoofdstuk 5 werd de prevalentie van anemie en de relatie met 
sterfte in het IMPACT cohort onderzocht. Verder werd de relatie tussen anemie, 
bepaalde ijzerparameters (sTfR, ferritine) en ontsteking (hsCRP) onderzocht, 
onder invloed van de ernst van HIV, HCV en ART. Anemie werd gevonden in 
49,6% van de ART-naïeve patiënten, met milde anemie (Hb 10,5 tot 12,99 g / dl 
voor mannen en 10,5 tot 11,99 g / dl voor vrouwen) in 62,0% van de gevallen, 
en een matige tot ernstige anemie (Hb<10,5 g / dL) in 38,0%. Anemie was een 
onafhankelijke risico factor voor sterfte, ook na correctie voor het CD4-aantal en 
het gebruik van ART (p = 0,008). Seroprevalentie van HCV verschilden niet in 
patiënten met (56,9%) of zonder anemie (59,6%).  
De serumferritineconcentraties waren verhoogd, vooral bij patiënten met anemie 
(p = 0,07) en / of lage CD4-aantallen (p <0,001), en er was geen relatie wasmet 
hsCRP of HCV. sTfR concentraties waren laag en niet gerelateerd aan Hb, 
CD4, hsCRP of ART. We concludeerden dat anemie veel voorkomt bij 
Indonesische HIV-geïnfecteerde patiënten en dat er een sterke relatie is met 
sterfte. De aanwezigheid van een hoogferritine met een lage concentratie 
vansTfR suggereert een ijzer redistributiein het lichaam waarbij eerder een 
verlaagdeerytropoëtische activiteit daneen ijzer-deficiëntie ten grondslag ligt aan 
de bloedarmoede. Men dient daarom voorzichtig te zijn met het gebruik van 
serumferritine en sTfR om de ijzer status te beoordelen bij patiënten met 
gevorderde HIV-infectie. 
Veranderingen in de distributie van ijzer komen vaak voor bij infectieziekten en 
veel van deze wijzigingen kunnen worden toegeschreven aan hepcidin: de 
centrale ijzer-regulator. Dit hormoon remt de opname van ijzer in de darm en 
vergrendelt ijzer in monocyten / macrofagen en de milt, door afbraak van 
ferroportin: de enige cellulaire ijzer export molecule. Hepcidine-gemedieerde 
ijzerstapeling in macrofagen kan mogelijk bijdragen aan de groei van 
intracellulaire pathogenen, zoals Mycobacterium tuberculosis. Tuberculose is de 
belangrijkste opportunistische HIV-gerelateerdeinfectieziekte in de wereld, en 
een aantal bevindingen wijzen erop dat het ijzer gehalte in macrofagen is 
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gerelateerd aan de ontwikkeling van een actieve tuberculose infectie. In 
hoofdstuk 6 hebben we daarom de relatie tussenhepcidineen de HIV-status 
bestudeerd, alsmede de relatie tussen verschillende ijzerparametersen de 
ontwikkeling van TB in HIV-geinfecteerde patiënten. HIV-patiënten diemeer dan 
1 maand na inclusie in het IMPACT cohort tuberculose ontwikkelden ('cases') 
werden vergeleken met twee groepen van HIV-patiënten die geen 
TBontwikkelden tijdens de follow-up, waarbij 'matchedcontrols' gelijkwaardig 
waren wat betreft leeftijd, geslacht en CD4-aantal, terwijl voor de 
'unmatchedcontrols' de aantal CD4-aantallen duidelijk hoger waren. 
IJzerparameters waaronder hepcidine werden gemeten in de bloedmonsters 
afgenomen bij het eerste Teratai bezoek.  
We vonden dat er een significante associatie is tussen een vergevorderdeHIV-
infectieeneen verhoging vanhepcidinen eenredistributie van ijzer.Deze factoren 
kunnen bijdragen aan de progressie van HIV en de ontwikkeling van anemie. 
Verder vonden we significant hogere serum hepcidine en ferritinewaarden bij 
patiënten die TB ontwikkelden, echter dit effect was vooral aanwezig als actieve 
TB werd gediagnosticeerd 30-60 dagen na het eerste bezoek.  
Behalve ijzerstatus als een risicofactor voor de ontwikkeling van TB bij HIV-
geïnfecteerde patiënten, hebben we ook onderzocht of intraveneus 
drugsgebruik het risico op actieve tuberculose bij HIV-patiënten verhoogd (in 
hoofdstuk 7). Tevens hebben we onderzocht of intraveneus drugsgebruik de 
natuurlijke afname van CD4-cellen van de patiënten in het IMPACT cohort 
versnelt. Inderdaad bleek dat IDG was geassocieerd met een snelle daling van 
CD4-cellen (p = 0,009) in vergelijking met niet-IDG. Ook bleek dat patiënten met 
een voorgeschiedenis van IDG een hogere incidentie van actieve tuberculose te 
hebben (19,5% versus 8% voor patiënten zonder IDG, gecorrigeerde hazard 
ratio: 2,38, p <0,001). Wij concludeerden dat IDG bij HIV-geïnfecteerde 
patiënten in West Java is geassocieerd met een snellere daling van CD4-cellen 
en hoger risico op het ontwikkelen van actieve tuberculose. Deze bevindingen 
zouden moeten meegenomen worden wanneer te starten met ART en over het 
gebruik van tuberculose profylaxe. 
Er is een wijd verspreide overtuiging onder clinici, ook in Indonesië, dat 
antiretrovirale middelen (ARV) bij HIV-geïnfecteerde patiënten die drugs 
gebruiken voorzichtig moeten worden toegepast omdat de kans op een 
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succesvolle behandeling beperkt zou zijn. In het IMPACT cohort vergeleken wij 
daarom het effect van ART bij patiëntenmet en zonder een geschiedenis van 
drugsgebruik (hoofdstuk 8). Een totaal van 773 volwassen HIV-patiënten (81,9% 
IDG's) werden geïncludeerd in het IMPACT cohort tussen januari 1996 en april 
2008. De patiënten met IDG had een mediane hoeveelheid CD4 cellen van 33 
[IQR, 12-111] cellen/mm3 in vergelijking met 84 (IQR, 28 tot 224) CD4 
cellen/mm3 bij de niet-drugs gebruikers.HCV co-infectie (HCV) werd gevonden 
bij 87,7% van de IGDs. Mortaliteit was sterk geassocieerd met CD4-aantallen; 
na 6 maanden van ART was 18,3, 20,3, 7,1 en 0,7% van de patiënten overleden 
met CD4-aantallen van respectievelijk < 25, 25 tot 99, 100-199, > 200/mm3     
(P < 0,0001 ). Sterfte,slechte follow-up en virologisch falen waren niet significant 
verschillend in de twee groepen patiënten. Geconcludeerd werd dat bij eerste 
presentatie HIV-geïnfecteerdeIGD, in vergelijking met non-IGD, in Indonesië 
vaker een meer vergevorderde ziekte hebben, maar dat het effect van 
antiretrovirale therapie gelijkwaardig is. 
Ondanks het op grote schaal beschikbaar komen van ART in Indonesië in de 
afgelopen jaren, is de virologische respons op de eerstelijns behandeling 
grotendeels onbekend. In hoofdstuk 9 bestuderen we het optreden van 
virologisch falen, risicofactoren voor falen, en het optreden van relevante 
mutaties binnen het IMPACT cohort. Tussen september 2007 en maart 2010, 
zijn 595 HIV-patiënten gestart met ART. De meeste patiënten waren mannen 
(72,3%), waarvan 59,7% IDG als risicofactor voor HIV transmissie hadden. Het 
mediane CD4 aantal voor aanvang van ART was 35 cellen/mm3 (IQR 10 tot 
104). Bij 438 HIV-patiënten werden HIV-RNA metingen verricht en 40 (9,1%) 
van deze patiënten hadden een HIV-RNA> 400 kopieën / ml bij mediane follow-
up 16 van (IQR 8-25) maanden. Bij18 (52,9%) patiënten werden resistentie 
mutaties aangetroffen, voornamelijk M184V (35,3%), Y181C (23,5%), K103N 
(11,7%) en TAM's (11,7%). Virologisch falen was significant geassocieerd met 
tijdelijke discontinuering van ART gedurende meer dan 1 maand, hetgeen 
gemeld werd door 3,9% van de patiënten (gecorrigeerde OR 12.64, 95% BI 
4,51-35,41). IDG bleek geen risicofactor te zijn op virologisch falen.  
Wij concludeerden dat virologische response op behandeling over het algemeen 
goed was op eerste lijn ART behandeling, dat het percentage virologisch falen 
laag is en dat resistentie vorming zeer beperkt is. Interventies zijn nodig om het 
Summary | Ringkasan | Samenvatting  
 
 
183 
 10 
tijdelijk staken van behandeling te voorkomen en een geschiedenis van 
injecterend drugsgebruik is geen reden om patiënten ART te onthouden. 
 
Toekomstperspectieven 
Indonesië is het land met heteen op vier na grootste aantal gevallen van 
tuberculose in de wereld en TB-HIV veroorzaakt daarom ook een 'double 
trouble'. TB is inderdaad de belangrijkste HIV-gerelateerde opportunistische 
infectie en verantwoordelijk voor bijna 25% van alle HIV sterfgevallen [4]. Onze 
cohort gegevens tonen aan dat meer dan 30% van de HIV-geïnfecteerde 
patiënten zijn of worden behandeld voor tuberculose. Uitvoering van de drie I’s 
in de context of HIV is echter onvoldoende : 1. Intensievere opsporing van TB bij 
HIV-patiënten, 2. Isoniazide preventieve therapie 3. TB Infectie controle [4] en er 
blijven dus nog steeds grote uitdagingen voor de preventie, bestrijding en 
behandeling van HIV-TB co-infecties bestaan. In ieder geval is er een duidelijke 
behoefte aan kwalitatief hoogwaardige zorg waarbij diensten voor HIV en 
tuberculose zijn geïntegreerd. 
Injecterend drugsgebruik (IDG) is oorspronkelijk de belangrijkste motor die de 
HIV-epidemie heeft aangedreven in grote delen van Indonesië. IDG is niet 
alleen een risicofactor voor HIV-overdracht, maar het kan ook het natuurlijke 
beloop van HIV-infectiebeïnvloeden, het risico van co-infecties en 
voedingstekortenverhogen. Bovendien kan drugsgebruik impulscontrole en 
toegang tot zorg beïnvloeden. In het IMPACT-programma, werden voortdurende 
inspanningen gedaan om de compliantie van de ART behandeling te 
verzekeren. Meer studies zijn echter nodig om het risicogedrag van IDG beter te 
begrijpen. Ook is het nodig dat de toegang tot zorg verder wordt verbeterd, 
zeker gemarginaliseerde groepen zoals IDG. 
In de loop van de tijd werd een aanzienlijke toename van het aantal HIV-
seropositieve vrouwen opgemerkt in de IMPACT cohort in Bandung, inclusief 
vrouwelijke partners van bekende HIV-positieve mannen. Aan het einde van 
2009, waren 25,8% van Indonesische HIV-geinfecteerde personenvrouw [5]. Uit 
de gegevens van onze cohort bleek dat vrouwen over het algemeen in een 
betere gezondheidstoestand verkeerden dan mannen, echter 9,1% was 
zwanger op het moment de HIV test werd afgenomen terwijl 72,2% al kinderen 
had. HIV-geïnfecteerde vrouwen hebben behoefte aan gespecialiseerde 
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gezondheidszorg die op dit moment niet algemeen beschikbaar zijn in 
Indonesië. Er is een beter begrip nodig van hoe een geconcentreerde HIV 
epidemie gedreven door mannelijke IDG langzaam verandert in een meer 
gegeneraliseerde epidemie waar ook vrouwen een duidelijk verhoogd risico 
lopen. 
In de afgelopen jaren is een sterk multidisciplinair team vormgegeven in 
Bandung dat in staat is om veel aspecten van de preventie, controle en 
behandeling van HIV in West Java aan te pakken. Ik hoop dat dit team zal 
blijven samenwerken en dat ons gezamenlijk onderzoek zal doorgaan zodat ons 
begrip van HIV vergroot en daarmee de zorg voor HIV-geïnfecteerde patiënten 
in Indonesië en elders verbetert. 
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